Pharmaceuticals & Biotechnology Sector Financials, Performance and Ratios
-
Sector Score
42.8 /100
Rank 16 out of 27 Sectors -
Advance/Decline
470/249
-
No. of Companies719
-
Avg. Market Cap6,219
-
Price to Earning Ratio4.23
-
Price to Earning Growth Ratio1.32
-
Price to Book Ratio37.74
-
Return on Equity47.98
-
Return on Capital Employed-
-
Return on Assets11.20
-
Dividend yield 1 year %0.80 %
-
Net Profit Growth Annual YoY %-32.55 %
-
Net Profit Growth Qtr YoY %-47.48 %
-
Net Profit Growth Qtr QoQ %-45.69 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Pharmaceuticals & Biotechnology Sector Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Pharmaceuticals & Biotechnology Peer comparison
Compare all stocks in Pharmaceuticals & Biotechnology industry listed on stock exchanges
Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie Inc |
|
373,849.2
|
211.8
|
L
 0.1%
H
208.3
212.8
|
L
 -1.2%
H
208.3
218.7
|
L
 9.8%
H
190.7
218.7
|
L
 22.2%
H
168.1
218.7
|
L
 19.1%
H
153.6
218.7
|
L
 35.9%
H
131.0
218.7
|
L
 148.1%
H
62.6
218.7
|
L
 265.1%
H
45.5
218.7
|
Adc Therapeutics SA |
|
178.9
|
1.9
|
L
 4.5%
H
1.8
1.9
|
L
 0.5%
H
1.6
1.9
|
L
 15.6%
H
1.5
1.9
|
L
 -2.1%
H
1.4
2.2
|
L
 -51.1%
H
1.4
5.4
|
L
 -86.4%
H
0.4
16.0
|
L
H
0.4
56.6
|
L
H
0.4
56.6
|
Amneal Pharmaceuticals Inc... |
|
2,712.2
|
8.8
|
L
 -0.5%
H
8.7
9.0
|
L
 -1.7%
H
8.6
9.1
|
L
 13.2%
H
7.6
9.2
|
L
 11.8%
H
7.6
9.2
|
L
 59.1%
H
5.2
9.5
|
L
 120.4%
H
1.2
9.5
|
L
 188.8%
H
1.2
9.5
|
L
 -80.7%
H
1.2
52.1
|
Annovis Bio Inc |
|
33.3
|
1.7
|
L
 3.6%
H
1.7
1.8
|
L
 -1.7%
H
1.5
1.8
|
L
 -37.4%
H
1.5
2.8
|
L
 -67.8%
H
1.5
5.6
|
L
 -81.2%
H
1.5
20
|
L
 -86.4%
H
1.5
23.9
|
L
 -57.1%
H
1.5
132
|
L
H
1.5
132
|
Bausch Health Companies Inc |
|
2,630.7
|
7.2
|
L
 3.8%
H
6.8
7.2
|
L
H
6.7
7.3
|
L
 16.1%
H
6.1
7.9
|
L
 -8.5%
H
6.1
8.3
|
L
 -22.3%
H
4.0
11.5
|
L
 -67.5%
H
4.0
24.3
|
L
 -62.0%
H
4.0
34.8
|
L
 -96.4%
H
4.0
263.8
|
Bristol-Myers Squibb Co. |
|
119,749.7
|
59.0
|
L
 -2.1%
H
58.7
60.0
|
L
 -3.4%
H
58.7
63.3
|
L
 9.5%
H
53.5
63.3
|
L
 5.8%
H
53.5
63.3
|
L
 12.7%
H
39.4
63.3
|
L
 -15.4%
H
39.4
81.4
|
L
 7.3%
H
39.4
81.4
|
L
 -11.8%
H
39.4
81.4
|
Emergent Biosolutions Inc |
|
310.3
|
5.7
|
L
 3.6%
H
5.6
6.0
|
L
 -1.0%
H
5.3
6.4
|
L
 -41.3%
H
5.0
10.0
|
L
 -32.7%
H
5.0
12.0
|
L
 133.1%
H
1.8
15.1
|
L
 -85.1%
H
1.4
45.1
|
L
 -91.7%
H
1.4
137.6
|
L
 -79.3%
H
1.4
137.6
|
Elanco Animal Health Inc |
|
5,163.8
|
10.4
|
L
 1.3%
H
10.4
10.7
|
L
 -6.3%
H
10.0
11.2
|
L
 -7.2%
H
10.0
11.5
|
L
 -13.7%
H
10.0
12.7
|
L
 -33.6%
H
10.0
18.8
|
L
 -59.0%
H
7.9
27.7
|
L
 -53.5%
H
7.9
37.5
|
L
H
7.9
37.6
|
Enzo Biochem, Inc. |
|
26.1
|
0.5
|
L
 8.7%
H
0.5
0.5
|
L
 8.7%
H
0.4
0.5
|
L
 -7.4%
H
0.4
0.6
|
L
 -51.0%
H
0.4
1.0
|
L
 -58.7%
H
0.4
1.3
|
L
 -83.6%
H
0.4
3.2
|
L
 -80.8%
H
0.4
4.9
|
L
 -84.9%
H
0.4
12.0
|
GSK Plc - ADR |
|
80,417.2
|
39.5
|
L
 0.7%
H
39.1
39.6
|
L
 -1.4%
H
38.8
40.8
|
L
 9.2%
H
36.1
40.8
|
L
 16.3%
H
31.7
40.8
|
L
 -6.4%
H
31.7
45.9
|
L
 -7.0%
H
28.5
47.8
|
L
 2.5%
H
28.5
47.8
|
L
 -16.3%
H
28.5
50.0
|
Johnson & Johnson |
|
392,347.3
|
162.8
|
L
 -0.1%
H
161.1
163.2
|
L
 -2.3%
H
161.1
169.9
|
L
 4.3%
H
153.2
170.0
|
L
 11.0%
H
140.7
170.0
|
L
 2.9%
H
140.7
170.0
|
L
 -7.6%
H
140.7
186.7
|
L
 21.2%
H
109.2
186.7
|
L
 64.1%
H
81.8
186.7
|
Lilly(Eli) & Co |
|
730,643.3
|
813.5
|
L
 1.5%
H
800
815.2
|
L
 -6.5%
H
795.4
863.2
|
L
 -3.7%
H
795.4
935.6
|
L
 3.1%
H
725.0
935.6
|
L
 7.9%
H
711.4
972.5
|
L
 195.3%
H
273.0
972.5
|
L
 483.7%
H
117.1
972.5
|
L
 1063.9%
H
64.2
972.5
|
Merck & Co Inc |
|
238,887.2
|
94.6
|
L
 -0.2%
H
93.5
94.9
|
L
 -0.1%
H
92.9
97
|
L
 13.9%
H
81.0
97.4
|
L
 -7.3%
H
81.0
103.0
|
L
 -22.2%
H
81.0
134.6
|
L
 20.3%
H
77.7
134.6
|
L
 29.1%
H
62.3
134.6
|
L
 76.3%
H
43.6
134.6
|
Nuvation Bio Inc - Ordinar... |
|
724.8
|
2.1
|
L
 -3.2%
H
2.1
2.3
|
L
 5.9%
H
1.8
2.4
|
L
 -5.7%
H
1.7
2.4
|
L
 -18.0%
H
1.7
3.5
|
L
 -6.1%
H
1.7
4.2
|
L
 -59.1%
H
1.0
6.0
|
L
H
1.0
15.2
|
L
H
1.0
15.2
|
Novo Nordisk - ADR |
|
342,472.9
|
77.2
|
L
 1.7%
H
75.2
77.6
|
L
 -11.5%
H
73.8
80.7
|
L
 -0.9%
H
73.8
93.8
|
L
 -27.9%
H
73.8
109.9
|
L
 -41.7%
H
73.8
148.2
|
L
 50.6%
H
47.5
148.2
|
L
 172.0%
H
24.6
148.2
|
L
 224.2%
H
15.5
148.2
|
Novartis AG - ADR |
|
215,403.2
|
109.1
|
L
 -0.1%
H
107.6
109.3
|
L
 -5.6%
H
107.6
116.9
|
L
 3.4%
H
106.1
116.9
|
L
 10.9%
H
96.1
116.9
|
L
 12.1%
H
92.4
120.9
|
L
 28.7%
H
74.1
120.9
|
L
 37.0%
H
69.2
120.9
|
L
 27.1%
H
59.2
120.9
|
Organon & Co. |
|
3,949.2
|
15.3
|
L
 2.3%
H
14.8
15.4
|
L
 -0.8%
H
14.8
16.1
|
L
 0.2%
H
14.1
16.2
|
L
 0.1%
H
13.9
17.2
|
L
 -16.3%
H
13.9
23.1
|
L
 -52.6%
H
10.8
39.1
|
L
H
10.8
39.5
|
L
H
10.8
39.5
|
Prestige Consumer Healthca... |
|
4,145.8
|
83.7
|
L
 1.0%
H
82.6
83.8
|
L
 -6.0%
H
81.8
90.0
|
L
 -2.7%
H
81.8
90.0
|
L
 1.7%
H
72.7
90.0
|
L
 12.1%
H
62.4
90.0
|
L
 48.6%
H
48.5
90.0
|
L
 145.1%
H
27.4
90.0
|
L
 103.7%
H
26.3
90.0
|
Pfizer Inc. |
|
145,869.8
|
25.7
|
L
 0.5%
H
25.5
25.8
|
L
 -3.8%
H
25.5
27.2
|
L
 0.7%
H
25.4
27.2
|
L
 0.6%
H
25.2
27.6
|
L
 -8.0%
H
24.5
31.5
|
L
 -50.7%
H
24.5
56.3
|
L
 -17.0%
H
24.5
61.7
|
L
 -20.1%
H
24.5
61.7
|
Perrigo Company plc |
|
3,719.9
|
27.3
|
L
 1.6%
H
26.6
27.3
|
L
 -1.8%
H
26.6
28.2
|
L
 11.3%
H
23.9
30.9
|
L
 -0.7%
H
23.1
30.9
|
L
 -10.2%
H
23.1
33.5
|
L
 -28.0%
H
23.1
43.9
|
L
 -41.1%
H
23.1
58.8
|
L
 -83.6%
H
23.1
215.7
|
Arcus Biosciences Inc |
|
988.6
|
9.3
|
L
 -2.1%
H
9.3
9.7
|
L
 -2.5%
H
9.0
10.0
|
L
 -28.7%
H
9.0
13.0
|
L
 -41.9%
H
9.0
16.5
|
L
 -50.8%
H
9.0
19.1
|
L
 -70.5%
H
9.0
39.8
|
L
 -43.5%
H
9.0
49.1
|
L
H
6.3
49.1
|
Dr. Reddy`s Laboratories L... |
|
10,564.4
|
12.7
|
L
 0.1%
H
12.6
12.7
|
L
 -1.8%
H
12.5
12.8
|
L
 -6.8%
H
12.5
13.7
|
L
 -12.3%
H
12.5
16.0
|
L
 -15.8%
H
12.5
74.9
|
L
 23.1%
H
9.9
74.9
|
L
 63.2%
H
6.7
74.9
|
L
 18.4%
H
5.6
74.9
|
Takeda Pharmaceutical Co -... |
|
47,425.5
|
15.0
|
L
 -0.1%
H
14.9
15.1
|
L
 -1.1%
H
14.8
15.2
|
L
 10.9%
H
13.7
15.2
|
L
 11.9%
H
12.8
15.2
|
L
 3.7%
H
12.6
15.2
|
L
 3.6%
H
12.3
17.2
|
L
 0.6%
H
12.3
20
|
L
 -43.2%
H
12.3
30.6
|
Teva- Pharmaceutical Indus... |
|
18,711.5
|
16.3
|
L
 -0.8%
H
16.2
16.5
|
L
 6.3%
H
14.4
16.9
|
L
 0.5%
H
14.4
17.6
|
L
 -1.0%
H
14.4
22.8
|
L
 21.6%
H
12.5
22.8
|
L
 117.7%
H
6.8
22.8
|
L
 94.4%
H
6.3
22.8
|
L
 -72.8%
H
6.1
72.3
|
Usana Health Sciences Inc |
|
550.9
|
29.1
|
L
 -4.1%
H
28.7
30.6
|
L
 -11.6%
H
28.7
33.9
|
L
 -8.1%
H
27.7
36.3
|
L
 -20.5%
H
27.7
37.7
|
L
 -41.9%
H
27.7
50.1
|
L
 -64.6%
H
27.7
83.8
|
L
 -53.2%
H
27.7
107.9
|
L
 -41.7%
H
27.7
138.0
|
Zoetis Inc - Ordinary Shar... |
|
72,210.9
|
161.3
|
L
 0.8%
H
158.3
161.4
|
L
 -5.4%
H
158.3
177
|
L
 2.4%
H
154.3
177
|
L
 -9.5%
H
154.3
179.3
|
L
 -6.6%
H
144.8
200.2
|
L
 -14.7%
H
124.2
201.9
|
L
 28.5%
H
90.1
249.3
|
L
 247.2%
H
37.7
249.3
|
Biohaven Ltd |
|
2,974.9
|
29.2
|
L
 3.3%
H
28.5
29.7
|
L
 -2.4%
H
27.0
30.4
|
L
 -29.6%
H
27.0
42.3
|
L
 -26.3%
H
27.0
44.3
|
L
 -48.9%
H
26.8
60.5
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
Aadi Bioscience Inc |
|
91.7
|
2.0
|
L
 2.6%
H
2.0
2.1
|
L
 -6.6%
H
1.9
2.3
|
L
 -23.6%
H
1.9
2.9
|
L
 -17.8%
H
1.9
3.8
|
L
 -8.8%
H
1.2
3.8
|
L
 -88.5%
H
1.2
20.1
|
L
 -76.4%
H
1.2
49.8
|
L
H
1.2
101.3
|
AbCellera Biologics Inc |
|
750.9
|
2.5
|
L
 5%
H
2.5
2.6
|
L
 8.2%
H
2.1
2.6
|
L
 -22.9%
H
2.1
3.6
|
L
 -9.7%
H
2.1
3.7
|
L
 -46.5%
H
2.1
4.8
|
L
 -67.6%
H
2.1
15.0
|
L
H
2.1
71.9
|
L
H
2.1
71.9
|
Abeona Therapeutics Inc |
|
230.6
|
5.3
|
L
 0.2%
H
5.3
5.4
|
L
 2.5%
H
4.9
5.6
|
L
 -12.1%
H
4.9
6.1
|
L
 -10.2%
H
4.9
6.2
|
L
 -38.7%
H
3.1
8.5
|
L
 -18.1%
H
2.2
9.4
|
L
 -87.8%
H
2.2
94.8
|
L
 -93.8%
H
2.2
568.8
|
Oruka Therapeutics Inc. |
|
415.2
|
11.1
|
L
 -0.5%
H
11.0
11.4
|
L
 6.0%
H
10.0
11.8
|
L
 -0.8%
H
9.4
11.8
|
L
 -49.5%
H
9.4
23.5
|
L
 -45.3%
H
2.2
53.9
|
L
 -57.2%
H
2.2
53.9
|
L
 -65.8%
H
2.2
264
|
L
 -99.1%
H
2.2
2343.6
|
Acumen Pharmaceuticals Inc |
|
75.7
|
1.3
|
L
 3.3%
H
1.2
1.3
|
L
 0.8%
H
1.2
1.3
|
L
 -13.1%
H
1.1
1.5
|
L
 -37.9%
H
1.1
2.0
|
L
 -69.9%
H
1.1
4.4
|
L
 -76.9%
H
1.1
11.3
|
L
H
1.1
27.0
|
L
H
1.1
27.0
|
Arbutus Biopharma Corp |
|
625.3
|
3.3
|
L
 -0.6%
H
3.3
3.4
|
L
 -0.3%
H
3.0
3.5
|
L
 0.3%
H
3.0
3.7
|
L
 -5.2%
H
3.0
3.7
|
L
 26.0%
H
2.3
4.7
|
L
 15.4%
H
1.7
4.7
|
L
 55.7%
H
0.9
9.0
|
L
 -81.4%
H
0.8
21.4
|
ABVC BioPharma Inc |
|
15.4
|
0.7
|
L
 -5.8%
H
0.6
0.7
|
L
 1.6%
H
0.6
0.7
|
L
 41.3%
H
0.5
0.9
|
L
 30%
H
0.4
0.9
|
L
 -44.4%
H
0.4
1.7
|
L
 -97.1%
H
0.4
31.3
|
L
 -97.8%
H
0.4
299.5
|
L
 -100.0%
H
0.4
2865.3
|
Acadia Pharmaceuticals Inc |
|
2,918.8
|
17.5
|
L
 4.3%
H
16.7
17.7
|
L
 -0.3%
H
16.6
17.7
|
L
 -12.7%
H
16.6
20.7
|
L
 3.3%
H
16.3
20.7
|
L
 -5.3%
H
14.2
20.7
|
L
 -24.1%
H
12.2
33.9
|
L
 -50.9%
H
12.2
58.7
|
L
 -49.2%
H
12.2
58.7
|
Adicet Bio Inc |
|
64.5
|
0.8
|
L
H
0.8
0.8
|
L
 -2.5%
H
0.7
0.8
|
L
 -21.2%
H
0.7
1.0
|
L
 -18.8%
H
0.7
1.1
|
L
 -61%
H
0.7
2.4
|
L
 -94.0%
H
0.7
21.9
|
L
 -89.6%
H
0.7
21.9
|
L
H
0.7
147.7
|
Achieve Life Sciences Inc. |
|
95.7
|
2.8
|
L
 4.2%
H
2.5
2.8
|
L
 -12.1%
H
2.5
3.1
|
L
 -19.3%
H
2.5
3.5
|
L
 -32.7%
H
2.5
4.2
|
L
 -39.9%
H
2.5
5.6
|
L
 -56.5%
H
2
10.3
|
L
 -55.3%
H
2
18.3
|
L
 -99.9%
H
2
9020
|
AC Immune SA |
|
226.6
|
2.3
|
L
 -0.4%
H
2.3
2.4
|
L
 -5.0%
H
2.2
2.6
|
L
 -16.4%
H
2.2
2.7
|
L
 -22.4%
H
2.2
3.1
|
L
 -34.6%
H
2.2
5.0
|
L
 -38.6%
H
1.7
5.1
|
L
 -51.0%
H
1.7
13
|
L
H
1.7
20.0
|
Arcellx Inc |
|
3,938.4
|
71.7
|
L
 0.1%
H
70.2
73.1
|
L
 1.3%
H
68.0
73.7
|
L
 9.9%
H
57.2
74.7
|
L
 -14.5%
H
57.2
85.3
|
L
 1.5%
H
47.9
107.4
|
L
 321.2%
H
6.0
107.4
|
L
H
6.0
107.4
|
L
H
6.0
107.4
|
Aclaris Therapeutics Inc |
|
168.7
|
1.6
|
L
H
1.5
1.6
|
L
 -14.8%
H
1.5
1.8
|
L
 -33.1%
H
1.5
2.4
|
L
 -51.6%
H
1.5
3.3
|
L
 33.3%
H
1.0
5.2
|
L
 -89.7%
H
0.6
19.0
|
L
 67.7%
H
0.6
30.4
|
L
H
0.6
33.9
|
Acrivon Therapeutics Inc |
|
169.4
|
5.4
|
L
 7.3%
H
5.2
5.5
|
L
 -1.8%
H
5.1
5.5
|
L
 0.4%
H
5
6.1
|
L
 -23.7%
H
4.7
8
|
L
 -12.1%
H
4.7
11.9
|
L
H
3.2
25.5
|
L
H
3.2
25.5
|
L
H
3.2
25.5
|
Grace Therapeutics Inc. |
|
29.9
|
2.2
|
L
 -4.8%
H
2.1
2.3
|
L
 -14.2%
H
2.1
2.5
|
L
 -36.8%
H
2.1
3.5
|
L
 -39.1%
H
2.1
4.7
|
L
 -35.5%
H
2.1
5.0
|
L
 -63.3%
H
1.7
8.1
|
L
 -85.3%
H
1.7
58.6
|
L
 -99.1%
H
1.7
249.6
|
Acurx Pharmaceuticals Inc |
|
9.0
|
0.5
|
L
H
0.5
0.5
|
L
H
0.4
0.5
|
L
 -37.8%
H
0.4
0.9
|
L
 -46.5%
H
0.4
1.3
|
L
 -83.1%
H
0.4
3.3
|
L
 -87.7%
H
0.4
8.8
|
L
H
0.4
8.8
|
L
H
0.4
8.8
|
Adial Pharmaceuticals Inc |
|
4.5
|
0.7
|
L
 3.0%
H
0.7
0.7
|
L
 -8%
H
0.6
0.8
|
L
 -6.8%
H
0.6
1.3
|
L
 -36.7%
H
0.6
1.3
|
L
 -56.3%
H
0.6
3.1
|
L
 -98.5%
H
0.6
56.6
|
L
 -97.8%
H
0.6
127
|
L
H
0.6
236
|
Adma Biologics Inc |
|
4,360.9
|
18.4
|
L
 2.9%
H
17.8
18.6
|
L
 8.3%
H
16.3
18.6
|
L
 15.9%
H
13.5
18.6
|
L
 -0.9%
H
13.5
19.3
|
L
 207.7%
H
5.9
23.6
|
L
 1089.0%
H
1.4
23.6
|
L
 753.2%
H
1.0
23.6
|
L
 137.8%
H
1.0
23.6
|
Adaptive Biotechnologies Corp |
|
1,081.7
|
7.3
|
L
 1.5%
H
7.0
7.5
|
L
 -1.0%
H
6.3
7.9
|
L
 -12.6%
H
6.3
9.0
|
L
 15.6%
H
5.8
9.0
|
L
 124.7%
H
2.3
9.0
|
L
 -32.3%
H
2.3
15.2
|
L
 -63.0%
H
2.3
71.3
|
L
H
2.3
71.3
|
Aditxt Inc |
|
0.0
|
0.0
|
L
 -33.3%
H
0.0
0.0
|
L
 -60%
H
0.0
0.1
|
L
 -71.4%
H
0.0
0.2
|
L
 -94.1%
H
0.0
0.4
|
L
 -100.0%
H
0.0
218
|
L
 -100.0%
H
0.0
45584
|
L
H
0.0
766400
|
L
H
0.0
766400
|
Adverum Biotechnologies Inc |
|
95.9
|
4.6
|
L
 2.4%
H
4.5
4.7
|
L
 0.7%
H
4.2
4.9
|
L
 3.4%
H
3.5
5.1
|
L
 -14.2%
H
3.5
5.5
|
L
 -97.3%
H
3.5
180
|
L
 -96.3%
H
3.5
297
|
L
 -99.6%
H
3.5
2698
|
L
 -99.9%
H
3.5
4518.3
|
Aeterna Zentaris Inc. |
|
10.3
|
3.3
|
L
 5.8%
H
2.7
3.7
|
L
 19.6%
H
2.0
3.7
|
L
 19.2%
H
2.0
3.7
|
L
 13.5%
H
2.0
3.7
|
L
 51.6%
H
2.0
11.1
|
L
 -61.8%
H
1.4
11.1
|
L
 -75.2%
H
1.4
90.5
|
L
 -99.7%
H
1.4
1700
|
Affimed N.V. |
|
14.4
|
0.9
|
L
H
0.9
0.9
|
L
 -11.1%
H
0.9
1.0
|
L
 -17.0%
H
0.9
1.1
|
L
 -58.9%
H
0.9
2.2
|
L
 -80.7%
H
0.9
9.0
|
L
 -98.0%
H
0.6
51
|
L
 -94.8%
H
0.6
117.4
|
L
 -98.6%
H
0.6
242
|
Agenus Inc |
|
43.9
|
1.9
|
L
 10.7%
H
1.7
1.9
|
L
 -20.9%
H
1.7
2.4
|
L
 -47.0%
H
1.7
3.6
|
L
 -38%
H
1.7
4.2
|
L
 -82.8%
H
1.7
196
|
L
 -96.4%
H
1.7
196
|
L
 -96.2%
H
1.7
196
|
L
 -98.3%
H
1.7
199.4
|
Agios Pharmaceuticals Inc |
|
1,772.2
|
30.9
|
L
 -0.5%
H
30.9
31.9
|
L
 -4.5%
H
30.9
33.1
|
L
 -6.9%
H
30.9
36.2
|
L
 -20.6%
H
30.9
44.5
|
L
 3.3%
H
27.1
62.6
|
L
 13.8%
H
16.8
62.6
|
L
 -16.6%
H
16.8
62.6
|
L
 -71.1%
H
16.8
126.4
|
Akebia Therapeutics Inc. |
|
493.1
|
2.3
|
L
 33.7%
H
1.8
2.3
|
L
 19.0%
H
1.5
2.3
|
L
 6.1%
H
1.5
2.3
|
L
 24.9%
H
1.5
2.4
|
L
 32.9%
H
0.8
2.5
|
L
 -1.7%
H
0.2
2.6
|
L
 -61.6%
H
0.2
13.7
|
L
 -82.9%
H
0.2
20.3
|
Akero Therapeutics Inc |
|
3,515.2
|
44.2
|
L
 -1.6%
H
44.0
45.6
|
L
 4.8%
H
41.2
47.1
|
L
 -12.6%
H
41.2
52.7
|
L
 52.8%
H
21.3
58.4
|
L
 60.3%
H
17.9
58.4
|
L
 240.4%
H
7.5
58.4
|
L
 132.4%
H
7.5
58.4
|
L
H
7.5
58.4
|
Akoya Biosciences Inc |
|
74.4
|
1.5
|
L
 1.4%
H
1.5
1.8
|
L
 -5.7%
H
1.5
1.8
|
L
 -35.1%
H
1.4
2.4
|
L
 -33.9%
H
1.4
3.4
|
L
 -69.5%
H
1.4
5.2
|
L
 -86.6%
H
1.4
16.6
|
L
H
1.4
29.0
|
L
H
1.4
29.0
|
Avalon GloboCare Corp |
|
5.4
|
4.9
|
L
 8.7%
H
4.5
5.9
|
L
 -32.4%
H
4.4
6.3
|
L
 32.5%
H
3.6
11.7
|
L
 10.4%
H
2.8
11.7
|
L
 1338.2%
H
0.2
11.7
|
L
 -21.4%
H
0.2
11.7
|
L
 -48.5%
H
0.2
21.9
|
L
H
0.2
135
|
Aldeyra Therapeutics Inc |
|
412.6
|
6.9
|
L
 1.5%
H
6.8
7.1
|
L
 8.8%
H
6.2
7.2
|
L
 6.5%
H
4.8
7.2
|
L
 37.9%
H
4.7
7.2
|
L
 147.7%
H
2.8
7.2
|
L
 79.5%
H
1.4
12.0
|
L
 175.3%
H
1.4
16.0
|
L
 -33.6%
H
1.4
16.7
|
Alector Inc |
|
143.7
|
1.5
|
L
 1.4%
H
1.4
1.5
|
L
 0.7%
H
1.3
1.6
|
L
 -14.7%
H
1.3
2.1
|
L
 -26.4%
H
1.3
2.2
|
L
 -76.3%
H
1.3
6.8
|
L
 -88.9%
H
1.3
15.7
|
L
 -94.1%
H
1.3
43.3
|
L
H
1.3
43.3
|
Aligos Therapeutics Inc |
|
69.9
|
11.4
|
L
 11.3%
H
10.6
11.8
|
L
 -11.6%
H
9.5
12.5
|
L
 -51.7%
H
9.5
24.3
|
L
 -65.1%
H
9.5
46.3
|
L
 -50.4%
H
6.8
46.3
|
L
 -80.6%
H
6.8
74.8
|
L
H
6.8
937.8
|
L
H
6.8
937.8
|
Alkermes plc |
|
5,533.8
|
34.0
|
L
 1.2%
H
33.3
34.5
|
L
 -0.9%
H
33.0
35.6
|
L
 -5.2%
H
33.0
36.5
|
L
 11.5%
H
27.7
36.5
|
L
 18.4%
H
22.9
36.5
|
L
 36.8%
H
21.8
36.5
|
L
 110.8%
H
12.0
36.5
|
L
 -48.7%
H
12.0
80.7
|
Allakos Inc |
|
22.3
|
0.3
|
L
H
0.2
0.3
|
L
 -3.9%
H
0.2
0.3
|
L
 -19.4%
H
0.2
0.3
|
L
 -76.2%
H
0.2
1.4
|
L
 -80.9%
H
0.2
1.6
|
L
 -95.1%
H
0.2
8.7
|
L
 -99.5%
H
0.2
158.0
|
L
H
0.2
158.0
|
Allogene Therapeutics Inc |
|
421.5
|
1.9
|
L
 2.7%
H
1.9
2.1
|
L
 -11.0%
H
1.8
2.2
|
L
 -4.9%
H
1.7
3.8
|
L
 2.7%
H
1.3
3.8
|
L
 -58.4%
H
1.3
4.7
|
L
 -75.1%
H
1.3
17.5
|
L
 -91.2%
H
1.3
55
|
L
H
1.3
55
|
Allarity Therapeutics Inc |
|
4.3
|
1.0
|
L
 6.7%
H
0.9
1.0
|
L
 -9.4%
H
0.9
1.2
|
L
 -2.0%
H
0.7
1.2
|
L
 -5.9%
H
0.7
2.0
|
L
 -86.2%
H
0.1
116
|
L
 -100.0%
H
0.1
94640
|
L
H
0.1
509600
|
L
H
0.1
509600
|
Alnylam Pharmaceuticals Inc |
|
31,297.6
|
241.8
|
L
H
239.5
244.0
|
L
 -1.1%
H
230.9
246.4
|
L
 -5.7%
H
230.9
260.0
|
L
 -0.9%
H
230.9
287.2
|
L
 62.0%
H
142.0
304.4
|
L
 58.1%
H
117.6
304.4
|
L
 138.0%
H
90.6
304.4
|
L
 112.9%
H
31.4
304.4
|
Rein Therapeutics Inc. |
|
43.3
|
2
|
L
 -1.0%
H
1.9
2.1
|
L
 0.5%
H
1.7
2.1
|
L
 -18.0%
H
1.7
3.0
|
L
 -11.5%
H
1.7
3.5
|
L
 -64.2%
H
1.6
7.4
|
L
 -75.2%
H
1.0
15
|
L
 -67.7%
H
1.0
49.4
|
L
H
1.0
309.6
|
Altimmune Inc |
|
455.9
|
5.9
|
L
 13.9%
H
5.4
6.1
|
L
 6.3%
H
5.1
6.1
|
L
 -7.1%
H
5.1
7.1
|
L
 -34.4%
H
5.1
9.6
|
L
 -40.0%
H
5.1
11.2
|
L
 0.3%
H
2.1
23.5
|
L
 104.8%
H
2.1
35.1
|
L
 -98.9%
H
1.5
1050
|
Alvotech |
|
3,406.7
|
11.3
|
L
 1.1%
H
11.2
11.5
|
L
 1.4%
H
10.5
11.7
|
L
 -13.0%
H
10.5
12.9
|
L
 -4.2%
H
10.5
13.7
|
L
 -26.2%
H
9.2
15.8
|
L
H
5.2
18
|
L
H
5.2
18
|
L
H
5.2
18
|
AlloVir Inc |
|
48.7
|
9.7
|
L
 5.8%
H
9.5
9.8
|
L
 -2.2%
H
9
10.1
|
L
 -2.5%
H
9
10.7
|
L
 2044.4%
H
0.4
10.7
|
L
 1137.2%
H
0.4
10.7
|
L
 29.9%
H
0.4
10.7
|
L
H
0.4
49.0
|
L
H
0.4
49.0
|
Alzamend Neuro Inc |
|
4.5
|
0.7
|
L
 -1.5%
H
0.6
0.7
|
L
 -10.5%
H
0.6
0.8
|
L
 -37.6%
H
0.6
1.2
|
L
 -42.9%
H
0.6
1.3
|
L
 -26.9%
H
0.4
15.1
|
L
 -95.0%
H
0.4
22.5
|
L
H
0.4
503.3
|
L
H
0.4
503.3
|
AMGEN Inc. |
|
168,526.6
|
313.7
|
L
 0.3%
H
310.3
314.5
|
L
 -3.4%
H
308.6
335.9
|
L
 7.7%
H
289
335.9
|
L
 15.9%
H
253.3
335.9
|
L
 16.7%
H
253.3
346.9
|
L
 35.5%
H
211.7
346.9
|
L
 55.2%
H
177.1
346.9
|
L
 103.4%
H
130.1
346.9
|
Amylyx Pharmaceuticals Inc |
|
320.7
|
3.6
|
L
 -1.4%
H
3.5
3.8
|
L
 -6.5%
H
3.3
4.1
|
L
 -2.7%
H
2.6
4.1
|
L
 -12.1%
H
2.6
4.4
|
L
 11.7%
H
1.6
7.3
|
L
 -84.4%
H
1.6
41.9
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
Amphastar Pharmaceuticals Inc |
|
1,270.4
|
26.7
|
L
 1.6%
H
26.1
26.8
|
L
 -7.5%
H
25.9
29.3
|
L
 -14.1%
H
25.9
32.7
|
L
 -36.9%
H
25.9
42.5
|
L
 -38.1%
H
25.9
54.0
|
L
 -23.3%
H
25.9
67.7
|
L
 87.9%
H
12.3
67.7
|
L
 71.9%
H
10.5
67.7
|
AnaptysBio Inc |
|
513.1
|
16.7
|
L
 -0.7%
H
16.7
17.7
|
L
 2.4%
H
15.8
18.5
|
L
 -21.2%
H
14.0
21.6
|
L
 7.3%
H
12.2
21.6
|
L
 -28.7%
H
12.2
41.3
|
L
 -36.9%
H
12.2
41.3
|
L
 9.4%
H
12.1
41.3
|
L
H
10
134
|
Anebulo Pharmaceuticals Inc |
|
70.3
|
1.7
|
L
 19.6%
H
1.4
1.7
|
L
 59.8%
H
1.0
1.7
|
L
 28.6%
H
0.9
1.7
|
L
 22.1%
H
0.8
1.9
|
L
 -32.7%
H
0.8
3.3
|
L
 -74.7%
H
0.8
7.7
|
L
H
0.8
9.3
|
L
H
0.8
9.3
|
ANI Pharmaceuticals Inc |
|
1,359.9
|
62.5
|
L
 1.7%
H
61.5
63.6
|
L
 3.1%
H
57.7
64.4
|
L
 6.1%
H
54.1
64.4
|
L
 10.4%
H
52.5
64.4
|
L
 -5.3%
H
52.5
70.8
|
L
 115.4%
H
22.3
70.8
|
L
 73.9%
H
22.3
70.8
|
L
 3.6%
H
22.3
87.0
|
Anixa Biosciences Inc |
|
95.3
|
3.0
|
L
 5.3%
H
2.8
3.1
|
L
 4.2%
H
2.6
3.1
|
L
 -5.7%
H
2.6
3.3
|
L
 3.9%
H
2.1
3.3
|
L
 -19.8%
H
2.1
4.2
|
L
 18.4%
H
2.1
6.5
|
L
 39.6%
H
1.3
8.1
|
L
 48%
H
0.6
9.0
|
Annexon Inc |
|
285.2
|
2.6
|
L
 2.8%
H
2.6
2.7
|
L
 -5.8%
H
2.4
2.8
|
L
 -15.3%
H
2.3
3.2
|
L
 -41.2%
H
2.3
5.7
|
L
 -61.1%
H
2.3
8.4
|
L
 -27.8%
H
1.6
8.4
|
L
H
1.6
38.0
|
L
H
1.6
38.0
|
AN2 Therapeutics Inc |
|
41.8
|
1.4
|
L
 -0.7%
H
1.4
1.4
|
L
 6.9%
H
1.3
1.4
|
L
 25%
H
1.1
1.4
|
L
 -2.1%
H
1.1
1.5
|
L
 -53.3%
H
0.9
3.9
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
Applied Dna Sciences Inc |
|
2.5
|
2.3
|
L
 3666.7%
H
2.0
2.8
|
L
 -65.6%
H
0.1
7.5
|
L
 -73.4%
H
0.1
8.6
|
L
 -72.5%
H
0.1
12.7
|
L
 -99.4%
H
0.1
522
|
L
 -99.9%
H
0.1
7350
|
L
 -99.9%
H
0.1
16390
|
L
 -100.0%
H
0.1
388000
|
Apollomics Inc - Ordinary ... |
|
8.5
|
7.7
|
L
 -3.9%
H
7.6
8.7
|
L
 20.3%
H
6.4
8.7
|
L
 8.2%
H
6.2
8.7
|
L
 -7.8%
H
6.2
12
|
L
 -87.2%
H
0.1
75
|
L
 -99.2%
H
0.1
4900
|
L
H
0.1
4900
|
L
H
0.1
4900
|
Apellis Pharmaceuticals Inc |
|
3,095.2
|
24.7
|
L
 1.2%
H
24.1
24.8
|
L
 -1.5%
H
24.1
25.9
|
L
 -10%
H
23.8
29.0
|
L
 -25.7%
H
23.8
35.7
|
L
 -56.5%
H
23.8
59.9
|
L
 -38.4%
H
19.8
94.8
|
L
 -3.9%
H
16.9
94.8
|
L
H
11.5
94.8
|
Applied Therapeutics Inc |
|
59.3
|
0.5
|
L
 2%
H
0.5
0.6
|
L
 -10.5%
H
0.5
0.6
|
L
 -21.5%
H
0.4
0.7
|
L
 -54.1%
H
0.4
1.2
|
L
 -91.5%
H
0.4
10.6
|
L
 -66.4%
H
0.4
10.6
|
L
 -98.2%
H
0.4
52.0
|
L
H
0.4
57.4
|
Aptorum Group Ltd - Ordina... |
|
6.4
|
0.9
|
L
 -2.2%
H
0.9
1
|
L
 -4.3%
H
0.8
1
|
L
 -24.4%
H
0.8
1.2
|
L
 16.9%
H
0.7
7.5
|
L
 -87.3%
H
0.5
12.0
|
L
 -92.9%
H
0.5
17.8
|
L
 -96.6%
H
0.5
142.3
|
L
H
0.5
332.8
|
Aprea Therapeutics Inc |
|
13.0
|
2.4
|
L
 0.8%
H
2.3
2.5
|
L
 3%
H
2.2
2.8
|
L
 -33.2%
H
2.2
3.7
|
L
 -25%
H
2.2
5
|
L
 -61.2%
H
2.2
6.9
|
L
 -93.1%
H
2.2
40.8
|
L
 -99.7%
H
2.2
822.3
|
L
H
2.2
1062.2
|
Aptose Biosciences Inc |
|
7.9
|
3.7
|
L
 -2.4%
H
3.6
3.9
|
L
 16.4%
H
3.1
3.9
|
L
 -31.7%
H
0.1
7.7
|
L
 -36.3%
H
0.1
11.7
|
L
 -91.9%
H
0.1
51.6
|
L
 -99.2%
H
0.1
697.5
|
L
 -99.8%
H
0.1
4050
|
L
 -99.9%
H
0.1
4163.6
|
Aptevo Therapeutics Inc |
|
3.5
|
2.4
|
L
 1.3%
H
2.4
2.5
|
L
 -5.1%
H
2.4
2.6
|
L
 -27.8%
H
2.4
4
|
L
 -41.1%
H
2.4
5.5
|
L
 -98.8%
H
0.2
207.3
|
L
 -100.0%
H
0.2
11721.6
|
L
 -100.0%
H
0.2
97680
|
L
H
0.2
188945.7
|
AquaBounty Technologies Inc |
|
2.5
|
0.6
|
L
 3.2%
H
0.6
0.6
|
L
 -5.9%
H
0.6
0.7
|
L
 -14.7%
H
0.6
0.8
|
L
 12.3%
H
0.5
1.0
|
L
 -70.4%
H
0.5
2.3
|
L
 -98.0%
H
0.5
47.4
|
L
 -98.3%
H
0.5
266.4
|
L
H
0.5
610
|
Aquestive Therapeutics Inc |
|
280.8
|
2.8
|
L
 4.4%
H
2.8
2.9
|
L
 7.2%
H
2.5
3.1
|
L
 -14.5%
H
2.5
3.4
|
L
 -21.3%
H
2.5
3.9
|
L
 -53.4%
H
2.2
6.2
|
L
 12.7%
H
0.6
6.2
|
L
 69.0%
H
0.6
9.5
|
L
H
0.6
20.7
|
Arcturus Therapeutics Hold... |
|
381.8
|
14.1
|
L
 1.3%
H
13.4
14.3
|
L
 -3.2%
H
12.8
14.8
|
L
 -22.0%
H
12.8
19.3
|
L
 -18.2%
H
12.8
21.3
|
L
 -61.2%
H
12.8
45
|
L
 -24.1%
H
11.7
45
|
L
 51.2%
H
9.8
129.7
|
L
 -68.6%
H
4.1
129.7
|
Ardelyx Inc |
|
1,303.8
|
5.5
|
L
 0.9%
H
5.4
5.5
|
L
 3.2%
H
5.2
5.7
|
L
 -5.5%
H
4.8
6.6
|
L
 6.4%
H
4.4
6.6
|
L
 -32.5%
H
4.3
9.3
|
L
 494.6%
H
0.5
10.1
|
L
 3.4%
H
0.5
10.1
|
L
 -64.7%
H
0.5
22.5
|
Arcutis Biotherapeutics Inc |
|
1,734.5
|
14.6
|
L
 -1.3%
H
14.5
15.4
|
L
 -0.7%
H
14.1
16.1
|
L
 14.4%
H
11.8
16.1
|
L
 15.2%
H
11.1
16.2
|
L
 37.2%
H
7.0
16.2
|
L
 -8.5%
H
1.8
27.4
|
L
 -35.5%
H
1.8
40.9
|
L
H
1.8
40.9
|
Artelo Biosciences Inc |
|
3.1
|
1.0
|
L
 1.1%
H
0.9
1.0
|
L
 -4%
H
0.9
1.0
|
L
 -19.3%
H
0.9
1.3
|
L
 -13.5%
H
0.9
1.6
|
L
 -33.3%
H
0.9
1.7
|
L
 -84%
H
0.9
11.1
|
L
 -92.4%
H
0.9
55.1
|
L
H
0.9
324
|
Arvinas Inc |
|
579.7
|
8.4
|
L
 -1.4%
H
8.4
9.0
|
L
 -53.9%
H
7.9
18.5
|
L
 -54.0%
H
7.9
20.4
|
L
 -56.8%
H
7.9
21
|
L
 -81.2%
H
7.9
45.0
|
L
 -86.0%
H
7.9
75.4
|
L
 -79.2%
H
7.9
108.5
|
L
H
7.9
108.5
|
Arrowhead Pharmaceuticals ... |
|
2,109.2
|
15.4
|
L
 1.9%
H
15.1
15.6
|
L
 -9.5%
H
14.2
16.9
|
L
 -23.0%
H
14.2
21.3
|
L
 -29.7%
H
14.2
22.5
|
L
 -45.7%
H
14.2
30.4
|
L
 -62.3%
H
14.2
51.1
|
L
 -41.6%
H
14.2
93.7
|
L
 104.0%
H
1.2
93.7
|
Assembly Biosciences Inc |
|
69.0
|
10.9
|
L
 2.4%
H
10.8
11.2
|
L
 -2.3%
H
10.6
11.9
|
L
 -16.6%
H
10.6
13.8
|
L
 -29.4%
H
10.6
18.1
|
L
 -10.8%
H
10.6
19.9
|
L
 -38.9%
H
7.7
29.0
|
L
 -93.5%
H
7.7
334.1
|
L
 -93.6%
H
7.7
808.3
|
ASP Isotopes Inc |
|
302.0
|
4.2
|
L
 7.9%
H
3.9
4.3
|
L
 -4.1%
H
3.7
4.4
|
L
 -20.0%
H
3.7
5.4
|
L
 -11.9%
H
3.7
7
|
L
 5.0%
H
1.9
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
Assertio Holdings Inc |
|
68.7
|
0.7
|
L
H
0.7
0.7
|
L
 -7.7%
H
0.7
0.8
|
L
 -14.3%
H
0.7
0.9
|
L
 -21.7%
H
0.7
1.0
|
L
 -35.7%
H
0.7
1.8
|
L
 -69.4%
H
0.7
8.0
|
L
 -77.5%
H
0.7
8.0
|
L
 -99.3%
H
0.7
135.0
|
ATAI Life Sciences N.V. |
|
287.1
|
1.5
|
L
 6.5%
H
1.4
1.5
|
L
 -2.0%
H
1.3
1.5
|
L
 -35.7%
H
1.3
2.4
|
L
 8.8%
H
1.2
2.6
|
L
 -16.4%
H
1.0
2.9
|
L
 -70.0%
H
1.0
5.8
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
Athira Pharma Inc |
|
13.3
|
0.3
|
L
 6.3%
H
0.3
0.3
|
L
H
0.3
0.4
|
L
 -27.7%
H
0.3
0.5
|
L
 -41.4%
H
0.3
0.6
|
L
 -87.0%
H
0.3
3.7
|
L
 -96.5%
H
0.3
14.2
|
L
H
0.3
34.8
|
L
H
0.3
34.8
|
180 Life Sciences Corp |
|
3.4
|
1.1
|
L
 -0.9%
H
1.0
1.1
|
L
 -9.3%
H
1.0
1.2
|
L
 -19.6%
H
1.0
1.4
|
L
 -44.3%
H
1.0
2.8
|
L
 -69.4%
H
1.0
17.8
|
L
 -99.9%
H
1.0
1170.4
|
L
 -100.0%
H
1.0
4957.1
|
L
H
1.0
4957.1
|
Atossa Therapeutics Inc |
|
90.6
|
0.7
|
L
 5.9%
H
0.7
0.7
|
L
 -2.7%
H
0.7
0.8
|
L
 -13.3%
H
0.7
0.9
|
L
 -35.7%
H
0.7
1.2
|
L
 -44.2%
H
0.7
2.3
|
L
 -39.0%
H
0.5
2.3
|
L
 -20.9%
H
0.5
9.8
|
L
 -99.8%
H
0.5
392.4
|
Atara Biotherapeutics Inc |
|
42.5
|
7.3
|
L
 5.7%
H
6.7
7.3
|
L
 5.1%
H
5.9
7.3
|
L
 -15.6%
H
5.9
9.1
|
L
 -29.8%
H
5.4
18.7
|
L
 -53.3%
H
0.4
20.8
|
L
 -96.6%
H
0.4
250.3
|
L
 -96.5%
H
0.4
705
|
L
 -99.1%
H
0.4
1639
|
Avenue Therapeutics Inc |
|
1.6
|
0.8
|
L
 2.6%
H
0.7
0.9
|
L
 -19.4%
H
0.7
1.1
|
L
 -41.9%
H
0.7
1.4
|
L
 -56.1%
H
0.7
2.2
|
L
 -99.9%
H
0.7
956.3
|
L
 -100.0%
H
0.7
93656.3
|
L
 -100.0%
H
0.7
1041170.6
|
L
H
0.7
1041170.6
|
Astria Therapeutics Inc |
|
364.0
|
6.5
|
L
 -2.9%
H
6.3
6.8
|
L
 4.2%
H
5.7
7.3
|
L
 -8.6%
H
5.7
7.3
|
L
 -32.3%
H
5.7
10.0
|
L
 -58.3%
H
5.7
16.9
|
L
 -2.4%
H
2.4
16.9
|
L
 -71.6%
H
2.4
51.5
|
L
H
2.4
1017.6
|
Aurinia Pharmaceuticals Inc |
|
1,120.7
|
8.2
|
L
 0.6%
H
8.1
8.3
|
L
 0.1%
H
7.9
8.4
|
L
 4.8%
H
6.6
8.8
|
L
 -12.9%
H
6.6
9.8
|
L
 57.8%
H
4.7
10.7
|
L
 -22.2%
H
4.1
13.4
|
L
 -37.2%
H
4.1
34.0
|
L
 82.1%
H
1.4
34.0
|
Aura Biosciences Inc |
|
367.1
|
7.4
|
L
 1.2%
H
7.2
7.6
|
L
 -0.7%
H
7.1
7.6
|
L
 -7.6%
H
7.1
8.0
|
L
 -11.8%
H
7.1
9.0
|
L
 2.1%
H
6.6
12.4
|
L
 -65.9%
H
6.0
24.8
|
L
H
6.0
26.2
|
L
H
6.0
26.2
|
Atea Pharmaceuticals Inc |
|
263.4
|
3.1
|
L
 0.7%
H
3.1
3.1
|
L
 3.0%
H
2.8
3.2
|
L
 -2.2%
H
2.8
3.2
|
L
 6.2%
H
2.8
3.6
|
L
 -23.2%
H
2.8
4.1
|
L
 -45.9%
H
2.8
9.8
|
L
H
2.8
94.2
|
L
H
2.8
94.2
|
Tectonic Therapeutic Inc. |
|
472.7
|
25.6
|
L
 9.0%
H
23.8
25.8
|
L
 10.6%
H
21.1
25.8
|
L
 -27.9%
H
21.1
35.4
|
L
 -43.5%
H
15.3
61.1
|
L
 64.3%
H
1.4
61.1
|
L
 53.7%
H
1.4
61.1
|
L
 -85.6%
H
1.4
282
|
L
H
1.4
644.4
|
Aerovate Therapeutics Inc |
|
71.6
|
2.5
|
L
H
2.4
2.6
|
L
 -2.4%
H
2.4
2.6
|
L
 0.8%
H
2.3
2.6
|
L
 -2.4%
H
2.3
2.7
|
L
 -90.8%
H
1.3
32.4
|
L
 -79.4%
H
1.3
32.4
|
L
H
1.3
32.4
|
L
H
1.3
32.4
|
Avalo Therapeutics Inc |
|
77.6
|
7.4
|
L
 -0.4%
H
7.1
7.6
|
L
 -4.8%
H
7.0
8.4
|
L
 0.5%
H
6.4
11.2
|
L
 -19.9%
H
6.0
11.2
|
L
 69.1%
H
4.4
34.5
|
L
 -4.9%
H
0.0
34.5
|
L
 -71.8%
H
0.0
54
|
L
H
0.0
91.8
|
Anavex Life Sciences Corpo... |
|
802.2
|
9.4
|
L
 4.8%
H
9.1
9.5
|
L
 8.8%
H
8.4
9.5
|
L
 10.7%
H
7.7
9.5
|
L
 11.5%
H
7.7
14.4
|
L
 84.5%
H
3.3
14.4
|
L
 -11.5%
H
3.3
15.2
|
L
 255.8%
H
2.2
31.5
|
L
 1266.7%
H
0.7
31.5
|
Aspira Women`s Health Inc |
|
2.5
|
0.1
|
L
 -6.7%
H
0.1
0.2
|
L
 -22.2%
H
0.1
0.4
|
L
 -41.7%
H
0.1
0.4
|
L
 -81.3%
H
0.1
0.9
|
L
 -96.1%
H
0.1
3.8
|
L
 -99.0%
H
0.1
18.9
|
L
 -98.8%
H
0.1
158.1
|
L
 -99.4%
H
0.1
158.1
|
Axsome Therapeutics Inc |
|
5,945.0
|
121.9
|
L
 0.2%
H
120.5
123.5
|
L
 -0.2%
H
116
123.5
|
L
 -7.1%
H
116
139.1
|
L
 35.3%
H
75.6
139.1
|
L
 61.4%
H
64.1
139.1
|
L
 318.5%
H
20.6
139.1
|
L
 99.1%
H
19.4
139.1
|
L
H
1.9
139.1
|
Aytu BioPharma Inc |
|
7.4
|
1.2
|
L
 -1.6%
H
1.2
1.2
|
L
 -4%
H
1.2
1.3
|
L
 -13.0%
H
1.2
1.5
|
L
 -16.7%
H
1.2
1.9
|
L
 -58.2%
H
1.2
3.5
|
L
 -94.5%
H
1.2
23.4
|
L
 -99.5%
H
1.2
444
|
L
 -100.0%
H
1.2
11336448
|
Achilles Therapeutics Plc ... |
|
58.8
|
1.4
|
L
 0.7%
H
1.4
1.4
|
L
 2.9%
H
1.4
1.4
|
L
 3.6%
H
1.4
1.4
|
L
 44.4%
H
0.9
1.4
|
L
 30%
H
0.6
1.4
|
L
 -52.0%
H
0.6
3.5
|
L
H
0.6
19.0
|
L
H
0.6
19.0
|
Adagene Inc - ADR |
|
78.4
|
1.8
|
L
 -10.2%
H
1.8
2.0
|
L
 -12.8%
H
1.8
2.2
|
L
 0.6%
H
1.8
2.3
|
L
 -14.1%
H
1.6
2.3
|
L
 -37.7%
H
1.6
3.6
|
L
 -63.5%
H
0.9
6.1
|
L
H
0.9
31.8
|
L
H
0.9
31.8
|
Adaptimmune Therapeutics P... |
|
115.1
|
0.5
|
L
H
0.4
0.5
|
L
 -6.3%
H
0.4
0.5
|
L
 -22.4%
H
0.4
0.6
|
L
 -22.4%
H
0.4
0.7
|
L
 -69.6%
H
0.4
1.7
|
L
 -74.0%
H
0.4
2.7
|
L
 -83.5%
H
0.4
13.4
|
L
H
0.4
21.6
|
Addex Therapeutics Ltd - ADR |
|
8.1
|
7.5
|
L
 6.2%
H
6.9
7.9
|
L
 -2.1%
H
6.8
8
|
L
 2.5%
H
6.7
9.8
|
L
 -5.8%
H
6.7
9.8
|
L
 -35.6%
H
6.7
27.9
|
L
 -91.7%
H
5
109
|
L
 -95.7%
H
5
750.4
|
L
H
5
750.4
|
Akari Therapeutics Plc - ADR |
|
28.6
|
1.1
|
L
 18.7%
H
0.9
1.1
|
L
 17.4%
H
0.9
1.1
|
L
H
0.9
1.1
|
L
 11.3%
H
0.9
1.5
|
L
 -45.2%
H
0.9
4.4
|
L
 -95.1%
H
0.9
32.2
|
L
 -95.7%
H
0.9
84.2
|
L
 -99.4%
H
0.9
934
|
Amarin Corp - ADR |
|
169.8
|
0.4
|
L
H
0.4
0.4
|
L
 -22.6%
H
0.4
0.5
|
L
 -32.8%
H
0.4
0.6
|
L
 -8.9%
H
0.4
0.7
|
L
 -52.3%
H
0.4
1.1
|
L
 -85.7%
H
0.4
3.7
|
L
 -96.7%
H
0.4
13.9
|
L
 -85.9%
H
0.4
26.1
|
Argen X SE - ADR |
|
36,758.0
|
605.0
|
L
 4.1%
H
582.4
605.4
|
L
 1.8%
H
563.0
605.4
|
L
 -5.4%
H
563.0
650.8
|
L
 -0.4%
H
563.0
678.2
|
L
 62.9%
H
349.9
678.2
|
L
 111.2%
H
267.3
678.2
|
L
 390.5%
H
103.8
678.2
|
L
H
17.3
678.2
|
Ascendis Pharma A/S - ADR |
|
9,192.6
|
153.0
|
L
 0.4%
H
151.2
155.4
|
L
 5.0%
H
136.6
155.4
|
L
 6.2%
H
136.6
158
|
L
 17.8%
H
118.0
158
|
L
 2.9%
H
111.1
158
|
L
 39.8%
H
61.6
161
|
L
 39.9%
H
61.6
184.0
|
L
 759.4%
H
11.9
184.0
|
Alterity Therapeutics Ltd ... |
|
42.1
|
3.9
|
L
 4.2%
H
3.8
4.0
|
L
 5.9%
H
3.6
4.0
|
L
 -10.9%
H
3.5
4.5
|
L
 76.7%
H
2.1
5.9
|
L
 123.9%
H
1
5.9
|
L
 -44.7%
H
1
8.7
|
L
 -26.1%
H
1
51.5
|
L
 -94.3%
H
1
111
|
Autolus Therapeutics plc -... |
|
497.6
|
1.9
|
L
 -1.1%
H
1.9
2.0
|
L
 -7.0%
H
1.8
2.0
|
L
 -8.3%
H
1.7
2.2
|
L
 -24.9%
H
1.7
2.8
|
L
 -67.9%
H
1.7
6.6
|
L
 -52.2%
H
1.6
7.5
|
L
 -66.3%
H
1.6
17.2
|
L
H
1.6
53.2
|
Avadel Pharmaceuticals plc... |
|
804.9
|
8.3
|
L
 -0.7%
H
8.3
8.5
|
L
 5.3%
H
7.5
8.5
|
L
 -3.3%
H
7.5
8.8
|
L
 -19.8%
H
7.4
11.5
|
L
 -47.7%
H
7.4
19.1
|
L
 20.9%
H
1.1
19.1
|
L
 38.6%
H
1.1
19.1
|
L
 -51.7%
H
1.0
26.1
|
Astrazeneca plc - ADR |
|
240,585.6
|
77.6
|
L
 1.4%
H
76.7
77.7
|
L
 0.1%
H
74.2
77.7
|
L
 5.5%
H
73.5
78.4
|
L
 16.6%
H
63.8
78.4
|
L
 17.0%
H
62.8
87.7
|
L
 26.4%
H
52.7
87.7
|
L
 83.5%
H
36.2
87.7
|
L
 130.4%
H
25.6
87.7
|
BridgeBio Pharma Inc |
|
6,270.5
|
33.0
|
L
 2.0%
H
32.4
33.5
|
L
 4.4%
H
30.5
33.5
|
L
 -5.5%
H
30.5
39.5
|
L
 19.9%
H
25.3
39.5
|
L
 19.6%
H
21.6
39.5
|
L
 287.4%
H
5.0
44.3
|
L
 43.0%
H
5.0
73.5
|
L
H
5.0
73.5
|
BioAtla Inc |
|
19.7
|
0.3
|
L
 6.3%
H
0.3
0.4
|
L
H
0.3
0.4
|
L
 -26.1%
H
0.2
0.5
|
L
 -76.4%
H
0.2
1.5
|
L
 -86.1%
H
0.2
4.0
|
L
 -93.2%
H
0.2
12.2
|
L
H
0.2
76.6
|
L
H
0.2
76.6
|
BioCardia Inc. |
|
11.9
|
2.6
|
L
 1.2%
H
2.6
2.7
|
L
 -0.8%
H
2.5
2.7
|
L
 -8.5%
H
1.9
2.9
|
L
 25%
H
1.6
3.0
|
L
 -55.6%
H
1.6
6.4
|
L
 -91.1%
H
1.6
43.8
|
L
 -95.0%
H
1.6
129
|
L
 -98.6%
H
1.6
2073.6
|
Brainstorm Cell Therapeuti... |
|
9.1
|
1.6
|
L
 1.9%
H
1.6
1.6
|
L
 -0.6%
H
1.6
1.7
|
L
 -14.5%
H
1.5
1.9
|
L
 9.7%
H
1.4
2.5
|
L
 381.8%
H
0.2
3.7
|
L
 -49.5%
H
0.1
4.7
|
L
 -71.4%
H
0.1
18.0
|
L
 -61.5%
H
0.1
18.0
|
Biocryst Pharmaceuticals Inc. |
|
1,609.0
|
7.7
|
L
 2.1%
H
7.6
7.7
|
L
 0.1%
H
7.2
8.0
|
L
 -14.9%
H
7.2
9.5
|
L
 2.3%
H
7.0
9.5
|
L
 54%
H
4.0
9.5
|
L
 -49.2%
H
4.0
18
|
L
 248.4%
H
1.6
20.0
|
L
 -23.2%
H
1.4
20.0
|
BriaCell Therapeutics Corp |
|
14.2
|
3.8
|
L
 11.3%
H
3.5
3.9
|
L
 8.8%
H
3.3
3.9
|
L
 -11.7%
H
3
5.4
|
L
 481.8%
H
0.4
7.9
|
L
 30.2%
H
0.4
7.9
|
L
 -51.8%
H
0.4
12.0
|
L
 -59.5%
H
0.4
12.8
|
L
 -90.2%
H
0.4
95.1
|
Black Diamond Therapeutics... |
|
97.5
|
1.7
|
L
 4.2%
H
1.7
1.8
|
L
 -8.5%
H
1.6
1.9
|
L
 -27.4%
H
1.6
2.5
|
L
 -32.8%
H
1.6
2.8
|
L
 -64.1%
H
1.6
7.7
|
L
 -37.7%
H
1.2
7.7
|
L
 -92.8%
H
1.2
46.3
|
L
H
1.2
46.3
|
Beam Therapeutics Inc |
|
2,419.1
|
24.2
|
L
 -3.3%
H
23.9
25.8
|
L
 -14.9%
H
23.9
28.5
|
L
 -25.2%
H
23.6
35.3
|
L
 -13.3%
H
22.5
35.3
|
L
 -31.6%
H
20.8
36.8
|
L
 -56.1%
H
17.0
73.3
|
L
 39.4%
H
13
138.5
|
L
H
13
138.5
|
Biofrontera Inc |
|
8.3
|
0.9
|
L
 -1.1%
H
0.9
1.0
|
L
 1.1%
H
0.9
1.0
|
L
 -21.2%
H
0.8
1.2
|
L
 -12.3%
H
0.8
1.9
|
L
 -40%
H
0.7
2.4
|
L
 -98.1%
H
0.6
122.4
|
L
H
0.6
292.6
|
L
H
0.6
292.6
|
Biogen Inc |
|
20,410.5
|
139.4
|
L
 -0.4%
H
138.6
140.8
|
L
 -7.3%
H
138.6
157.1
|
L
 1.5%
H
135.0
157.1
|
L
 -7.1%
H
128.5
157.1
|
L
 -36.4%
H
128.5
238.0
|
L
 -29.3%
H
128.5
319.8
|
L
 -54.3%
H
128.5
468.6
|
L
 -63.4%
H
128.5
468.6
|
BioVie Inc |
|
19.9
|
1.1
|
L
 5.9%
H
1.0
1.1
|
L
 -9.2%
H
1.0
1.2
|
L
 -41.0%
H
1.0
1.9
|
L
 -59.1%
H
1.0
2.7
|
L
 54.3%
H
0.3
7.5
|
L
 -61.6%
H
0.3
14.4
|
L
 -58.5%
H
0.3
46.1
|
L
 -96.7%
H
0.3
56.3
|
Bluebird bio Inc |
|
36.5
|
3.8
|
L
 0.5%
H
3.7
3.8
|
L
 -6.3%
H
3.7
4.1
|
L
 -48.4%
H
3.6
7.6
|
L
 -40.9%
H
3.6
10.3
|
L
 164.1%
H
0.3
10.3
|
L
 -16.1%
H
0.3
10.3
|
L
 -88.5%
H
0.3
46.9
|
L
 -95.2%
H
0.3
152.9
|
Biomea Fusion Inc |
|
92.0
|
2.5
|
L
 -4.5%
H
2.5
2.8
|
L
 -6.3%
H
2.3
2.8
|
L
 -31.9%
H
2.3
4.0
|
L
 -55.0%
H
2.3
6.1
|
L
 -85.8%
H
2.3
17.9
|
L
 -56.5%
H
2.3
43.7
|
L
H
2.3
43.7
|
L
H
2.3
43.7
|
Biomarin Pharmaceutical In... |
|
13,247.6
|
69.4
|
L
 -1.6%
H
68.4
70.4
|
L
 -3.9%
H
68.4
73.0
|
L
 7.1%
H
64.4
73.5
|
L
 5.2%
H
60.6
73.5
|
L
 -17.2%
H
60.6
94.9
|
L
 -11.3%
H
60.6
117.8
|
L
 -17.8%
H
60.6
131.9
|
L
 -43.8%
H
60.6
151.8
|
Bionano Genomics Inc |
|
9.5
|
3.5
|
L
 4.5%
H
3.3
3.6
|
L
 -15.0%
H
3.3
4.2
|
L
 -39.8%
H
3.3
6.1
|
L
 1345.8%
H
0.1
11.6
|
L
 243.6%
H
0.1
11.6
|
L
 -80.2%
H
0.1
43.5
|
L
 -27.7%
H
0.1
156.9
|
L
H
0.1
156.9
|
Benitec Biopharma Inc |
|
351.1
|
15.0
|
L
 1.2%
H
14.5
15.3
|
L
 15.2%
H
12.0
15.3
|
L
 33.1%
H
9.8
15.3
|
L
 27.2%
H
9.7
15.3
|
L
 193.5%
H
4.8
15.3
|
L
 -57.5%
H
1.9
40.8
|
L
 -82.8%
H
1.9
295.6
|
L
 -99.6%
H
1.9
3547.1
|
Bolt Biotherapeutics Inc |
|
15.7
|
0.4
|
L
 -2.4%
H
0.4
0.4
|
L
 -6.8%
H
0.4
0.5
|
L
 -18%
H
0.4
0.5
|
L
 -22.6%
H
0.4
0.6
|
L
 -63.1%
H
0.4
1.6
|
L
 -85.7%
H
0.4
3.2
|
L
H
0.4
43.1
|
L
H
0.4
43.1
|
Bon Natural Life Ltd |
|
6.0
|
1.4
|
L
 94.6%
H
1.1
3.0
|
L
 51.6%
H
0.7
3.0
|
L
 9.1%
H
0.7
3.0
|
L
 -15.3%
H
0.7
3.0
|
L
 213.0%
H
0.4
5.3
|
L
 -51.2%
H
0.4
6.5
|
L
 -98.3%
H
0.4
17.6
|
L
 -98.3%
H
0.4
107.2
|
Blueprint Medicines Corp |
|
5,724.7
|
89.6
|
L
 -0.3%
H
88
90.8
|
L
 2.8%
H
84.6
91.0
|
L
 -4.6%
H
84.6
96.8
|
L
 -3.9%
H
84.6
118.3
|
L
 -1.0%
H
80.7
121.9
|
L
 53.0%
H
37.8
121.9
|
L
 79.0%
H
37.8
125.6
|
L
H
13.0
125.6
|
Bio-Path Holdings Inc |
|
1.4
|
0.2
|
L
 -5.6%
H
0.2
0.2
|
L
 -5.6%
H
0.1
0.2
|
L
 -73.0%
H
0.1
0.4
|
L
 -74.2%
H
0.1
3.4
|
L
 -96.3%
H
0.1
7.7
|
L
 -94.3%
H
0.1
7.7
|
L
 -95.3%
H
0.1
24.3
|
L
 -100.0%
H
0.1
638
|
BioXcel Therapeutics Inc |
|
7.2
|
2.1
|
L
 -4.9%
H
2.0
2.4
|
L
 -36.8%
H
2.0
3.9
|
L
 -7.8%
H
1.7
6.8
|
L
 419.5%
H
0.2
6.8
|
L
 -20.5%
H
0.2
6.8
|
L
 -85.9%
H
0.2
34.1
|
L
 -89.3%
H
0.2
71.5
|
L
H
0.2
71.5
|
BeyondSpring Inc |
|
70.1
|
1.7
|
L
 -1.1%
H
1.7
1.8
|
L
 4.2%
H
1.6
1.8
|
L
 1.8%
H
1.6
1.9
|
L
 6.1%
H
1.4
1.9
|
L
 -40.8%
H
1.4
3.8
|
L
 0.6%
H
0.5
4
|
L
 -83.2%
H
0.5
33
|
L
H
0.5
48.5
|
Bicycle Therapeutics Plc -... |
|
670.6
|
9.7
|
L
 0.6%
H
9.4
10.3
|
L
 -5.3%
H
9.4
10.8
|
L
 -22.8%
H
9.4
13.1
|
L
 -28.6%
H
9.4
17.0
|
L
 -59.2%
H
9.4
28.7
|
L
 -77.0%
H
9.4
50.5
|
L
 -35.7%
H
9.4
62.1
|
L
H
6.2
62.1
|
Biodexa Pharmaceuticals Pl... |
|
1.3
|
1.9
|
L
 -4.5%
H
1.9
2.1
|
L
 -37.7%
H
1.8
4.4
|
L
 -55.5%
H
1.8
4.7
|
L
 -54.8%
H
1.8
9.2
|
L
 -99.7%
H
1.8
1849.9
|
L
 -100.0%
H
1.8
1050000
|
L
 -100.0%
H
1.8
7070000
|
L
H
1.8
398544219.1
|
Bioline Rx Ltd - ADR |
|
11.2
|
3.2
|
L
 3.6%
H
3.0
3.2
|
L
 -0.6%
H
3.0
3.3
|
L
 -14.8%
H
2.9
4.2
|
L
 -64.9%
H
0.1
14.7
|
L
 -93.1%
H
0.1
56
|
L
 -94.8%
H
0.1
101.2
|
L
 -94.2%
H
0.1
253.6
|
L
 -99.7%
H
0.1
1680
|
Belite Bio Inc - ADR |
|
2,147.3
|
67.4
|
L
 -2.9%
H
66.3
69.4
|
L
 6.7%
H
63.1
71.0
|
L
 20.4%
H
54.3
71.0
|
L
 8.2%
H
52.0
71.0
|
L
 75.3%
H
31
86.5
|
L
H
6
86.5
|
L
H
6
86.5
|
L
H
6
86.5
|
Neuphoria Therapeutics Inc. |
|
8.3
|
4.7
|
L
 -2.5%
H
4.3
5.0
|
L
 -14.2%
H
4.3
5.4
|
L
 -4.5%
H
4.3
5.8
|
L
 1375%
H
0.2
12.6
|
L
 358.3%
H
0.2
12.6
|
L
 -44.3%
H
0.2
12.6
|
L
H
0.2
22
|
L
H
0.2
22
|
BioNTech SE - ADR |
|
23,869.9
|
99.5
|
L
 2.1%
H
97.9
99.7
|
L
 -8.6%
H
97.4
107.5
|
L
 -17.0%
H
97.4
124.5
|
L
 -17.4%
H
97.4
129.3
|
L
 7.6%
H
76.5
131.5
|
L
 -31.4%
H
76.5
189.1
|
L
 221.6%
H
37
464
|
L
H
12.5
464
|
Cabaletta Bio Inc |
|
89.0
|
1.8
|
L
 2.3%
H
1.8
1.9
|
L
 -1.6%
H
1.7
2.0
|
L
 -32.8%
H
1.6
2.9
|
L
 -35.5%
H
1.6
2.9
|
L
 -90.3%
H
1.6
19.1
|
L
 8.3%
H
0.6
26.4
|
L
 -77.3%
H
0.6
26.4
|
L
H
0.6
26.4
|
CalciMedica Inc |
|
26.7
|
2.0
|
L
 4.2%
H
1.9
2
|
L
 -11.6%
H
1.8
2.3
|
L
 -21.1%
H
1.8
2.7
|
L
 -27.5%
H
1.8
3.7
|
L
 -49.8%
H
1.8
6.3
|
L
 -87.8%
H
1
22.1
|
L
H
1
530.3
|
L
H
1
530.3
|
Capricor Therapeutics Inc |
|
601.6
|
13.2
|
L
 3.4%
H
12.8
13.4
|
L
 3.3%
H
11.8
13.4
|
L
 -17.1%
H
11.8
16.5
|
L
 -0.2%
H
11.8
16.5
|
L
 107.0%
H
3.5
23.4
|
L
 219.6%
H
2.7
23.4
|
L
 1136.4%
H
0.9
23.4
|
L
 -81.6%
H
0.9
106.8
|
Cara Therapeutics Inc |
|
23.5
|
5.1
|
L
 1.4%
H
5
5.1
|
L
 4.3%
H
4.8
5.2
|
L
 -1.4%
H
4.3
5.3
|
L
 63.4%
H
0.3
6.4
|
L
 -51.3%
H
0.3
11.5
|
L
 -96.3%
H
0.3
167.6
|
L
 -96.3%
H
0.3
355.8
|
L
 -95.6%
H
0.3
355.8
|
Carisma Therapeutics Inc |
|
17.1
|
0.4
|
L
 2.5%
H
0.4
0.4
|
L
 -8.9%
H
0.4
0.5
|
L
 -16.3%
H
0.4
0.5
|
L
 2.5%
H
0.4
0.6
|
L
 -82.3%
H
0.4
2.7
|
L
 -96.7%
H
0.4
19.3
|
L
 -96.8%
H
0.4
120.8
|
L
 -99.8%
H
0.4
275.5
|
CASI Pharmaceuticals Inc |
|
34.4
|
2.2
|
L
 7.3%
H
2.0
2.4
|
L
 0.9%
H
2.0
2.4
|
L
 -11.2%
H
2.0
2.6
|
L
 -34.5%
H
2.0
3.5
|
L
 -30.2%
H
2.0
7.7
|
L
 -72.2%
H
1.5
10.3
|
L
 -85.9%
H
1.5
39
|
L
 -85.1%
H
1.5
88.9
|
C4 Therapeutics Inc |
|
144.1
|
2.0
|
L
 0.5%
H
2.0
2.1
|
L
 -14.0%
H
2.0
2.3
|
L
 -36.2%
H
2.0
3.2
|
L
 -53.7%
H
2.0
4.5
|
L
 -77.3%
H
2.0
9.2
|
L
 -90.6%
H
1.1
26.8
|
L
H
1.1
51.2
|
L
H
1.1
51.2
|
Cidara Therapeutics Inc |
|
241.5
|
22.1
|
L
 -1.4%
H
22.0
22.7
|
L
 -6.8%
H
20.2
24.1
|
L
 -7.9%
H
20.0
25.8
|
L
 -3.6%
H
17.2
28.4
|
L
 -92.0%
H
10
488
|
L
 -92.1%
H
10
840
|
L
 -97.6%
H
10
1780
|
L
H
10
7652
|
Chromadex Corp |
|
609.6
|
7.8
|
L
 1.6%
H
7.6
7.9
|
L
 1.8%
H
7.3
8.2
|
L
 33.6%
H
5.3
9.2
|
L
 28.1%
H
5.2
9.2
|
L
 226.7%
H
2.3
9.2
|
L
 288.1%
H
1.2
9.2
|
L
 134.7%
H
1.2
23.7
|
L
 90.8%
H
1.2
23.7
|
Cullinan Oncology Inc |
|
514.3
|
8.8
|
L
 -1.5%
H
8.6
9.0
|
L
 0.9%
H
8.0
9.4
|
L
 -7.8%
H
7.9
9.8
|
L
 -25.2%
H
7.9
13.0
|
L
 -44.8%
H
7.9
30.2
|
L
 -31.0%
H
7.3
30.2
|
L
H
7.3
59.9
|
L
H
7.3
59.9
|
Compugen Ltd |
|
154.3
|
1.7
|
L
 2.5%
H
1.6
1.7
|
L
 -0.6%
H
1.6
1.7
|
L
 -25.7%
H
1.6
2.3
|
L
 2.5%
H
1.4
2.7
|
L
 -39.6%
H
1.4
2.8
|
L
 -43.5%
H
0.5
3.6
|
L
 -80%
H
0.5
19.9
|
L
 -77.8%
H
0.5
19.9
|
Cognition Therapeutics Inc |
|
18.7
|
0.5
|
L
 7.1%
H
0.4
0.5
|
L
 4.7%
H
0.4
0.5
|
L
 -23.7%
H
0.4
0.7
|
L
 -6.3%
H
0.4
1.3
|
L
 -75.3%
H
0.3
3.0
|
L
 -82.1%
H
0.3
6.3
|
L
H
0.3
13.8
|
L
H
0.3
13.8
|
Coherus Biosciences Inc |
|
106.6
|
0.9
|
L
 3.4%
H
0.9
1
|
L
 -11.5%
H
0.9
1.2
|
L
 -22.0%
H
0.9
1.2
|
L
 -42.5%
H
0.9
1.8
|
L
 -58.6%
H
0.7
2.6
|
L
 -92.7%
H
0.7
14.1
|
L
 -93.8%
H
0.7
22.2
|
L
 -96.8%
H
0.7
38.1
|
Cingulate Inc |
|
13.1
|
3.6
|
L
 -1.1%
H
3.6
3.7
|
L
 -7.0%
H
3.5
3.9
|
L
 -20.4%
H
3.5
4.6
|
L
 -14.7%
H
3.5
5.6
|
L
 217.7%
H
0.2
20.8
|
L
 151.0%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
Checkpoint Therapeutics Inc |
|
219.4
|
4.0
|
L
 -0.5%
H
4.0
4
|
L
 60.7%
H
4.0
4.1
|
L
 19.9%
H
2.4
4.1
|
L
 8.2%
H
2.4
4.4
|
L
 106.8%
H
1.4
4.5
|
L
 -76.5%
H
1.3
19.3
|
L
 -66.1%
H
1.3
53.8
|
L
H
1.3
150
|
Clene Inc |
|
36.9
|
4.4
|
L
 1.4%
H
4.4
4.6
|
L
 -3.3%
H
4.3
4.6
|
L
 -7.9%
H
4.1
5.0
|
L
 -15.5%
H
4.1
6.2
|
L
 -44.6%
H
3.8
9.2
|
L
 -90.8%
H
3.8
102.6
|
L
 751.9%
H
0.5
356.4
|
L
H
0.5
356.4
|
Cellectar Biosciences Inc |
|
14.7
|
0.3
|
L
 6.7%
H
0.3
0.3
|
L
H
0.3
0.3
|
L
 10.3%
H
0.3
0.4
|
L
 23.1%
H
0.2
0.4
|
L
 -90.8%
H
0.2
4.2
|
L
 -93.2%
H
0.2
7.9
|
L
 -98.1%
H
0.2
29.8
|
L
 -100.0%
H
0.2
3889
|
Clearside Biomedical Inc |
|
67.5
|
0.9
|
L
 3.5%
H
0.8
0.9
|
L
 -4.3%
H
0.8
0.9
|
L
 -16.8%
H
0.8
1.1
|
L
 -12.8%
H
0.8
1.1
|
L
 -48.0%
H
0.8
1.8
|
L
 -64.3%
H
0.7
2.9
|
L
 -55.7%
H
0.7
7.7
|
L
H
0.6
25.1
|
Clearmind Medicine Inc |
|
5.4
|
1.1
|
L
 0.9%
H
1.1
1.1
|
L
 7.6%
H
1.1
1.2
|
L
 -19.2%
H
1.1
1.4
|
L
 -22.5%
H
1.1
2.2
|
L
 -10.2%
H
1.0
2.3
|
L
 -88.3%
H
0.1
17.1
|
L
 -4.2%
H
0.1
21.9
|
L
H
0.1
21.9
|
Compass Therapeutics Inc |
|
340.2
|
2.5
|
L
 -0.4%
H
2.5
2.7
|
L
 -8.6%
H
2.3
2.7
|
L
 -27.2%
H
2.3
3.6
|
L
 68.5%
H
1.3
4.1
|
L
 7.4%
H
0.8
4.1
|
L
 59.7%
H
0.8
5.7
|
L
H
0.8
11
|
L
H
0.8
11
|
Chimerix Inc |
|
787.2
|
8.5
|
L
 -0.1%
H
8.5
8.5
|
L
 0.4%
H
8.4
8.5
|
L
 93.2%
H
4.5
8.5
|
L
 186.8%
H
2.7
8.5
|
L
 635.7%
H
0.8
8.5
|
L
 65.9%
H
0.8
8.5
|
L
 467.8%
H
0.8
11.6
|
L
 -79.7%
H
0.8
58.0
|
Cns Pharmaceuticals Inc |
|
4.7
|
3.1
|
L
 15.1%
H
2.7
3.4
|
L
 17.7%
H
2.4
3.4
|
L
 -55.4%
H
2
8.4
|
L
 -39.4%
H
2
9.5
|
L
 -99.7%
H
2
1100
|
L
 -100.0%
H
2
33600
|
L
 -100.0%
H
2
421500
|
L
H
2
426750
|
Context Therapeutics Inc |
|
53.2
|
0.7
|
L
 9.2%
H
0.6
0.7
|
L
 -11.3%
H
0.6
0.8
|
L
 -13.4%
H
0.6
0.9
|
L
 -48.9%
H
0.6
1.4
|
L
 -34.9%
H
0.6
2.8
|
L
 -60.3%
H
0.5
2.8
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
Cocrystal Pharma Inc |
|
16.7
|
1.6
|
L
 -1.8%
H
1.6
1.7
|
L
 -3.5%
H
1.6
1.8
|
L
 -11.4%
H
1.6
2.1
|
L
 -14.1%
H
1.6
3.3
|
L
 7.9%
H
1.4
3.3
|
L
 -71.5%
H
1.3
7.4
|
L
 -83.2%
H
1.3
41.5
|
L
 -99.5%
H
1.3
550.8
|
Co-Diagnostics Inc |
|
15.3
|
0.5
|
L
H
0.5
0.5
|
L
 -14.3%
H
0.5
0.6
|
L
 -30.4%
H
0.5
0.7
|
L
 -42.2%
H
0.5
1.1
|
L
 -55.1%
H
0.5
2.2
|
L
 -91.6%
H
0.5
7.1
|
L
 -95.1%
H
0.5
31.0
|
L
H
0.5
31.0
|
Coeptis Therapeutics Holdi... |
|
35.9
|
11.1
|
L
 5.8%
H
10.5
11.4
|
L
 4.4%
H
10.0
11.8
|
L
 -11.2%
H
9.2
13.5
|
L
 210.7%
H
2.3
13.7
|
L
 53.8%
H
2.3
13.7
|
L
 10.0%
H
2.3
242.6
|
L
H
2.3
242.6
|
L
H
2.3
242.6
|
Cogent Biosciences Inc |
|
812.9
|
7.1
|
L
 -2.1%
H
7.1
7.5
|
L
 1.9%
H
6.6
7.9
|
L
 -11.1%
H
6.6
8.3
|
L
 -12.5%
H
6.6
10.2
|
L
 1.3%
H
5.7
12.6
|
L
 28.9%
H
3.7
18.1
|
L
 453.5%
H
1.2
18.1
|
L
H
1.2
70.6
|
Collegium Pharmaceutical Inc |
|
927.6
|
29.5
|
L
 1.2%
H
29.0
30.0
|
L
 1.9%
H
28.4
30.0
|
L
 -0.7%
H
27.3
31.4
|
L
 -2.1%
H
27.3
34.1
|
L
 -24.6%
H
27.3
42.3
|
L
 62.4%
H
14.0
42.3
|
L
 69.7%
H
13
42.3
|
L
H
7.4
42.3
|
Corcept Therapeutics Inc |
|
5,909.2
|
56.0
|
L
 2.1%
H
54.1
56.8
|
L
 1.1%
H
53.0
58.0
|
L
 -23.0%
H
52.5
75
|
L
 1.1%
H
49
75
|
L
 141.1%
H
20.8
75
|
L
 133.4%
H
17.2
75
|
L
 418.6%
H
9.7
75
|
L
 1300.3%
H
3.2
75
|
Cosmos Health Inc |
|
11.2
|
0.5
|
L
 -2.0%
H
0.5
0.5
|
L
 -5.9%
H
0.5
0.5
|
L
 -22.6%
H
0.4
0.7
|
L
 -33.3%
H
0.4
1.1
|
L
 -35.1%
H
0.4
1.6
|
L
 -99.3%
H
0.4
75
|
L
 -99.2%
H
0.4
225
|
L
 -99.7%
H
0.4
312.5
|
Cumberland Pharmaceuticals... |
|
76.3
|
5.5
|
L
 -0.6%
H
5.2
5.6
|
L
 -14.3%
H
4.6
6.4
|
L
 6.0%
H
4.6
7.3
|
L
 129.4%
H
2.1
7.3
|
L
 203.3%
H
1.0
7.3
|
L
 113.3%
H
1.0
7.3
|
L
 43.3%
H
1.0
7.5
|
L
 -19.5%
H
1.0
8.0
|
Catalyst Pharmaceuticals Inc |
|
2,552.9
|
21.0
|
L
 0.7%
H
20.8
21.2
|
L
 -4.3%
H
20.2
21.7
|
L
 -9.7%
H
20.2
23.6
|
L
 0.2%
H
19.2
24.6
|
L
 30.8%
H
14.5
24.6
|
L
 178.8%
H
6.2
24.6
|
L
 516.4%
H
2.6
24.6
|
L
 402.9%
H
0.5
24.6
|
Corbus Pharmaceuticals Hol... |
|
83.1
|
6.8
|
L
 5.8%
H
6.5
6.9
|
L
H
6.4
7.2
|
L
 -20.2%
H
6.4
8.8
|
L
 -55.0%
H
6.4
15
|
L
 -84.5%
H
6.4
61.9
|
L
 -40.4%
H
2.1
61.9
|
L
 -94.4%
H
2.1
293.4
|
L
 -92.7%
H
2.1
323.4
|
Caribou Biosciences Inc |
|
93.9
|
1.0
|
L
 2.0%
H
1
1.0
|
L
 -12.9%
H
1.0
1.2
|
L
 -25.2%
H
1.0
1.5
|
L
 -47.1%
H
1.0
2.0
|
L
 -81.2%
H
1.0
5.8
|
L
 -88.2%
H
1.0
13.2
|
L
H
1.0
32.6
|
L
H
1.0
32.6
|
Cardiol Therapeutics Inc -... |
|
92.2
|
1.1
|
L
 -1.7%
H
1.1
1.2
|
L
 -2.6%
H
1.0
1.2
|
L
 -7.4%
H
1.0
1.3
|
L
 -15.0%
H
1.0
1.5
|
L
 -25.7%
H
1.0
3.1
|
L
 -19.9%
H
0.5
3.1
|
L
 -59.8%
H
0.5
5.3
|
L
H
0.5
8.5
|
Curis Inc |
|
24.0
|
2.8
|
L
H
2.8
3.0
|
L
 -2.4%
H
2.6
3.1
|
L
 -11.8%
H
2.6
3.4
|
L
 -20.5%
H
2.6
4.5
|
L
 -72.4%
H
2.6
17.5
|
L
 -94.7%
H
2.6
58
|
L
 -83.5%
H
2.6
348
|
L
 -99.1%
H
2.6
375
|
CorMedix Inc |
|
635.3
|
10.5
|
L
 0.9%
H
10.3
10.6
|
L
 -2.2%
H
10.0
11
|
L
 -0.1%
H
9.3
11.3
|
L
 21.5%
H
7.8
13.1
|
L
 174.8%
H
3.6
13.9
|
L
 117.2%
H
2.6
13.9
|
L
 164.4%
H
2.2
18.8
|
L
 -75.1%
H
0.9
52
|
Crinetics Pharmaceuticals Inc |
|
3,207.4
|
34.5
|
L
 -1.6%
H
34.4
35.6
|
L
 3.6%
H
32.7
36
|
L
 -2.1%
H
31.8
37.7
|
L
 -35.8%
H
31.8
56.2
|
L
 -11.5%
H
31.8
62.5
|
L
 80.7%
H
15.2
62.5
|
L
 163.3%
H
10.6
62.5
|
L
H
10.6
62.5
|
Cronos Group Inc |
|
723.0
|
1.9
|
L
 1.6%
H
1.9
1.9
|
L
 -5.0%
H
1.9
2.0
|
L
 -4.1%
H
1.9
2.1
|
L
 -2.1%
H
1.8
2.1
|
L
 -10%
H
1.8
3.1
|
L
 -39.0%
H
1.6
4.3
|
L
 -64.1%
H
1.6
15.8
|
L
H
0.2
25.1
|
CRISPR Therapeutics AG |
|
3,612.8
|
42.1
|
L
 0.3%
H
41.9
43.5
|
L
 -7.5%
H
40.8
46.1
|
L
 -15.3%
H
40.5
55.9
|
L
 -3.8%
H
36.5
55.9
|
L
 -42.3%
H
36.5
75.9
|
L
 -29.8%
H
36.5
91.1
|
L
 11.9%
H
32.3
220.2
|
L
H
11.6
220.2
|
Corvus Pharmaceuticals Inc |
|
290.4
|
4.5
|
L
 0.4%
H
4.4
4.8
|
L
 -2.2%
H
4.1
4.8
|
L
 -7.4%
H
3.8
5.0
|
L
 -38.8%
H
3.8
7.4
|
L
 137.9%
H
1.3
10
|
L
 209.6%
H
0.6
10
|
L
 88.3%
H
0.6
10
|
L
H
0.6
22.1
|
Champions Oncology Inc |
|
126.4
|
9.2
|
L
 3.8%
H
9.0
9.4
|
L
 -7.1%
H
8.6
10.2
|
L
 -16.6%
H
8.6
11.2
|
L
 45.8%
H
6.1
12.0
|
L
 68.7%
H
3.6
12.0
|
L
 21.6%
H
3.6
12.0
|
L
 61.1%
H
3.6
14.7
|
L
 87.2%
H
1.1
17.9
|
CytomX Therapeutics Inc |
|
52.1
|
0.7
|
L
 10.2%
H
0.6
0.7
|
L
 -1.5%
H
0.6
0.7
|
L
 -18.8%
H
0.6
0.8
|
L
 -41.4%
H
0.6
1.2
|
L
 -68.6%
H
0.6
5.9
|
L
 -78.2%
H
0.6
5.9
|
L
 -87.4%
H
0.6
15.4
|
L
H
0.6
35
|
Cue Biopharma Inc |
|
60.8
|
1.0
|
L
 -1.0%
H
0.9
1.1
|
L
 -12.7%
H
0.9
1.1
|
L
 -35.6%
H
0.9
1.5
|
L
 2.1%
H
0.9
1.8
|
L
 -53.6%
H
0.5
2.3
|
L
 -78.2%
H
0.5
6.3
|
L
 -92.7%
H
0.5
31.7
|
L
H
0.5
31.7
|
CureVac N.V. |
|
675.3
|
3.0
|
L
 -0.7%
H
3.0
3.1
|
L
 -1.0%
H
2.9
3.2
|
L
 -17.5%
H
2.9
3.6
|
L
 -3.8%
H
2.7
5
|
L
 -8.8%
H
2.2
5.3
|
L
 -81.8%
H
2.2
20.5
|
L
H
2.2
151.8
|
L
H
2.2
151.8
|
Cadrenal Therapeutics Inc |
|
34.0
|
19.1
|
L
 9.4%
H
17.2
19.1
|
L
 13.3%
H
14.6
19.9
|
L
 0.1%
H
14.6
22.9
|
L
 68.5%
H
10.7
22.9
|
L
 3135.6%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
Cyanotech Corp. |
|
2.7
|
0.4
|
L
 -9.5%
H
0.4
0.4
|
L
 5.6%
H
0.4
0.4
|
L
 -5%
H
0.3
0.4
|
L
 31.0%
H
0.3
0.5
|
L
 31.0%
H
0.3
0.9
|
L
 -87.7%
H
0.1
3.6
|
L
 -81%
H
0.1
6.3
|
L
 -95.8%
H
0.1
10.9
|
Cyclacel Pharmaceuticals Inc |
|
61.8
|
0.3
|
L
H
0.3
0.3
|
L
 -6.3%
H
0.3
0.3
|
L
 -18.9%
H
0.3
0.4
|
L
 -16.7%
H
0.3
0.9
|
L
 -87.7%
H
0.3
4
|
L
 -88.9%
H
0.2
4.4
|
L
 -96.9%
H
0.2
19.3
|
L
 -99.9%
H
0.2
264
|
Cyclerion Therapeutics Inc |
|
6.4
|
2.5
|
L
 2.4%
H
2.5
2.7
|
L
 -9.6%
H
2.5
2.8
|
L
 -18.9%
H
2.3
3.2
|
L
 -23.3%
H
2.3
6.3
|
L
 -22.2%
H
1.3
8.4
|
L
 -87.4%
H
1.3
28
|
L
 -95.3%
H
1.3
179.2
|
L
H
1.3
457
|
Cyclo Therapeutics Inc - O... |
|
22.9
|
0.7
|
L
H
0.7
0.8
|
L
 -5.4%
H
0.7
0.8
|
L
 -28.6%
H
0.7
1
|
L
 18.6%
H
0.6
1.5
|
L
 -57.6%
H
0.6
1.8
|
L
 -73.3%
H
0.6
3.4
|
L
 -93.6%
H
0.6
30
|
L
 -98.9%
H
0.6
118
|
Cytokinetics Inc |
|
5,252.7
|
44.4
|
L
 -0.1%
H
43.5
45
|
L
 2.1%
H
42.0
45.1
|
L
 -3.9%
H
41.9
51.7
|
L
 -8.8%
H
40.5
52.8
|
L
 -32.0%
H
40.5
75.7
|
L
 30.7%
H
26.0
110
|
L
 315.4%
H
8
110
|
L
 455.9%
H
5.5
110
|
Cellectis - ADR |
|
124.1
|
1.2
|
L
 -3.9%
H
1.1
1.4
|
L
 -1.6%
H
1.1
1.4
|
L
 -20%
H
1.1
1.6
|
L
 -29.6%
H
1.1
2.2
|
L
 -51.2%
H
1.1
3.4
|
L
 -70.8%
H
1.0
5.0
|
L
 -87.9%
H
1.0
34.7
|
L
H
1.0
50
|
Chemomab Therapeutics Ltd ... |
|
26.6
|
1.4
|
L
 1.4%
H
1.3
1.4
|
L
 12.8%
H
1.2
1.5
|
L
 -28.1%
H
1.2
2.1
|
L
 -10.8%
H
1.2
2.5
|
L
 76.3%
H
0.6
2.6
|
L
 -64.5%
H
0.4
5.6
|
L
 -99.4%
H
0.4
2700.8
|
L
H
0.4
2944
|
Compass Pathways Plc - ADR |
|
322.5
|
3.5
|
L
 -0.3%
H
3.5
3.7
|
L
 -7.0%
H
3.4
3.9
|
L
 -23.9%
H
3.4
4.9
|
L
 -17.5%
H
3.2
5.2
|
L
 -64.9%
H
3.2
10.3
|
L
 -69.7%
H
3.2
21.5
|
L
H
3.2
61.7
|
L
H
3.2
61.7
|
Centessa Pharmaceuticals p... |
|
2,259.8
|
17.1
|
L
 1.6%
H
16.3
17.5
|
L
 5.6%
H
15.3
18.0
|
L
 0.4%
H
14.6
18.0
|
L
 3.4%
H
14.4
19.1
|
L
 59.4%
H
7.8
19.1
|
L
 118.6%
H
2.9
19.1
|
L
H
2.9
26.9
|
L
H
2.9
26.9
|
Connect Biopharma Holdings... |
|
47.5
|
0.9
|
L
 1.2%
H
0.9
0.9
|
L
 1.2%
H
0.8
0.9
|
L
 -6.5%
H
0.8
1.0
|
L
 -23.2%
H
0.8
1.4
|
L
 -33.9%
H
0.8
2.7
|
L
 -65.0%
H
0.5
5.0
|
L
H
0.5
29.3
|
L
H
0.5
29.3
|
Dare Bioscience Inc |
|
25.1
|
2.9
|
L
 -1.4%
H
2.9
3.1
|
L
 -2.4%
H
2.9
3.1
|
L
 -5.3%
H
2.9
3.3
|
L
 -9.4%
H
2.7
3.4
|
L
 -48.8%
H
0.3
7.6
|
L
 -83.6%
H
0.3
22.6
|
L
 -73.9%
H
0.3
46.2
|
L
 -99.7%
H
0.3
1304.4
|
Day One Biopharmaceuticals... |
|
823.0
|
8.1
|
L
 -6.7%
H
8.1
8.9
|
L
 -6.3%
H
7.9
9.0
|
L
 -33.8%
H
7.9
12.6
|
L
 -36.3%
H
7.9
13.5
|
L
 -43.6%
H
7.9
18.1
|
L
 -22.5%
H
5.4
28.4
|
L
H
5.4
28.7
|
L
H
5.4
28.7
|
Journey Medical Corp |
|
109.7
|
5.3
|
L
 -1.7%
H
5.1
5.4
|
L
 2.1%
H
5.0
5.5
|
L
 0.2%
H
4.9
5.8
|
L
 3.1%
H
3.5
5.8
|
L
 54.4%
H
2.9
6.9
|
L
 25.6%
H
1.0
8.1
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
DiaMedica Therapeutics Inc |
|
246.7
|
5.8
|
L
 1.8%
H
5.5
5.9
|
L
H
5.3
5.9
|
L
 -8.3%
H
5.3
6.8
|
L
 7.3%
H
4.5
6.8
|
L
 90.4%
H
2.1
6.8
|
L
 150.9%
H
1.1
6.8
|
L
 60.3%
H
1.1
10.9
|
L
 260.6%
H
1
13.8
|
Denali Therapeutics Inc |
|
2,200.0
|
15.2
|
L
 1.8%
H
15.0
15.7
|
L
 -9.2%
H
14.2
16.5
|
L
 -29.1%
H
14.0
22.8
|
L
 -34.0%
H
14.0
24.3
|
L
 -24.7%
H
14.0
33.3
|
L
 -48.8%
H
14.0
39.4
|
L
 -6.6%
H
13.2
93.9
|
L
H
12.3
93.9
|
Dominari Holdings Inc |
|
67.8
|
4.7
|
L
 -10.3%
H
4.5
5.0
|
L
 -23.7%
H
4.5
6.3
|
L
 -60.6%
H
4.5
12
|
L
 205.8%
H
0.8
13.6
|
L
 126.4%
H
0.8
13.6
|
L
 -26.5%
H
0.8
13.6
|
L
 -77.5%
H
0.8
46.6
|
L
 -99.5%
H
0.8
1258.1
|
DarioHealth Corp |
|
27.8
|
0.7
|
L
 3.1%
H
0.6
0.7
|
L
 -8.2%
H
0.6
0.8
|
L
 -4.3%
H
0.6
0.8
|
L
 -8.2%
H
0.6
1.6
|
L
 -55.9%
H
0.6
1.9
|
L
 -88.5%
H
0.6
7.7
|
L
 -88.2%
H
0.6
31.9
|
L
 -99.1%
H
0.6
233.5
|
Dermata Therapeutics Inc |
|
6.4
|
1.2
|
L
 0.9%
H
1.1
1.2
|
L
 -1.7%
H
1.1
1.3
|
L
H
1.1
1.3
|
L
 9.2%
H
1
1.7
|
L
 197.5%
H
0.2
5.8
|
L
 -92.0%
H
0.2
23.5
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
Durect Corp |
|
26.7
|
0.9
|
L
 6.2%
H
0.8
0.9
|
L
 13.2%
H
0.7
0.9
|
L
 11.7%
H
0.7
0.9
|
L
 14.7%
H
0.7
1.0
|
L
 -33.3%
H
0.7
1.9
|
L
 -84.3%
H
0.5
9.7
|
L
 -94.3%
H
0.5
29.6
|
L
 -94.8%
H
0.5
39.5
|
Bright Minds Biosciences Inc |
|
252.0
|
35.8
|
L
 -0.8%
H
35.6
36.8
|
L
 3.7%
H
31.6
36.8
|
L
 -14.4%
H
31.1
42.1
|
L
 -13.3%
H
28.2
47.4
|
L
 2652.3%
H
0.9
79.0
|
L
 361.7%
H
0.9
79.0
|
L
H
0.9
79.0
|
L
H
0.9
79.0
|
Design Therapeutics Inc |
|
266.8
|
4.7
|
L
 -0.4%
H
4.7
5.0
|
L
 -4.5%
H
4.6
5.6
|
L
 15.2%
H
4.0
5.6
|
L
 -16.1%
H
3.6
6.8
|
L
 82.2%
H
2.5
7.8
|
L
 -73.0%
H
1.9
26.3
|
L
H
1.9
50.5
|
L
H
1.9
50.5
|
Precision Biosciences Inc |
|
38.7
|
5.0
|
L
 -0.2%
H
5.0
5.2
|
L
 -2.7%
H
4.9
5.3
|
L
 -4.4%
H
4.7
6.1
|
L
 -16.6%
H
3.6
7.4
|
L
 -55.3%
H
3.6
16.0
|
L
 70.3%
H
0.3
19.4
|
L
 -18.4%
H
0.3
19.4
|
L
H
0.3
23.7
|
Dynavax Technologies Corp. |
|
1,720.9
|
13.9
|
L
 1.3%
H
13.7
14.0
|
L
 -3.7%
H
13.6
14.6
|
L
 8.2%
H
12.7
14.6
|
L
 7.0%
H
11.8
14.6
|
L
 15.1%
H
9.7
14.6
|
L
 32.9%
H
7.3
17.5
|
L
 475.5%
H
1.8
21.4
|
L
 -38.2%
H
1.8
32.5
|
Dyne Therapeutics Inc |
|
1,363.1
|
12.1
|
L
 1.4%
H
11.9
12.3
|
L
 -2.8%
H
11.2
12.6
|
L
 -13.4%
H
11.2
14.5
|
L
 -53.2%
H
11.2
26.7
|
L
 -57.0%
H
11.2
47.5
|
L
 39.6%
H
4.3
47.5
|
L
H
4.3
47.5
|
L
H
4.3
47.5
|
DBV Technologies - ADR |
|
99.9
|
4.9
|
L
 -6.5%
H
4.8
5.1
|
L
 16.5%
H
4.2
5.3
|
L
 10.7%
H
3.8
5.3
|
L
 36.4%
H
2.7
5.4
|
L
 -38.4%
H
0.5
8.3
|
L
 -65.0%
H
0.5
34.3
|
L
 -91.7%
H
0.5
73.8
|
L
 -97.6%
H
0.5
505.7
|
Editas Medicine Inc |
|
121.1
|
1.5
|
L
 6.6%
H
1.4
1.5
|
L
 -15.1%
H
1.4
1.7
|
L
 5.8%
H
1.4
3.3
|
L
 1.4%
H
1.1
3.3
|
L
 -82.0%
H
1.1
8.4
|
L
 -90.2%
H
1.1
21.6
|
L
 -92.5%
H
1.1
100.0
|
L
H
1.1
100.0
|
Edesa Biotech Inc |
|
16.7
|
2.4
|
L
 0.4%
H
2.4
2.5
|
L
 2.6%
H
2.2
2.6
|
L
 -11.2%
H
2
2.7
|
L
 23.2%
H
1.6
4.5
|
L
 -45.6%
H
1.6
5.6
|
L
 -89.0%
H
1.6
28.3
|
L
 -82.4%
H
1.6
133.7
|
L
 -99.9%
H
1.6
3228.1
|
Eagle Pharmaceuticals Inc |
|
16.8
|
1.3
|
L
H
1.0
1.3
|
L
 52.9%
H
1.0
1.4
|
L
 11.1%
H
0.8
1.6
|
L
 73.3%
H
0.0
1.6
|
L
 -78.5%
H
0
6.4
|
L
 -97.4%
H
0
52.2
|
L
 -96.7%
H
0
58.3
|
L
 -97.2%
H
0
104.2
|
Eledon Pharmaceuticals Inc |
|
218.0
|
3.7
|
L
 1.4%
H
3.5
3.7
|
L
 -3.7%
H
3.5
3.8
|
L
 -19.4%
H
3.5
4.7
|
L
 -18.2%
H
3.5
5.0
|
L
 137.0%
H
1.5
5.4
|
L
 19.3%
H
1.1
5.4
|
L
 -41.4%
H
1.1
27.3
|
L
 -99.8%
H
1.1
2386.3
|
Elevation Oncology Inc |
|
31.4
|
0.5
|
L
 6%
H
0.5
0.5
|
L
 3.9%
H
0.5
0.5
|
L
 -20.9%
H
0.4
0.7
|
L
 -17.2%
H
0.4
1.0
|
L
 -87.9%
H
0.4
5.8
|
L
 -78.9%
H
0.4
5.9
|
L
H
0.4
16.2
|
L
H
0.4
16.2
|
Elicio Therapeutics Inc. |
|
122.9
|
7.8
|
L
 -1.9%
H
7.6
8
|
L
 -1.8%
H
7.4
8.1
|
L
 -5.1%
H
7.4
9.0
|
L
 52.9%
H
4.7
10.0
|
L
 55%
H
3.3
11.5
|
L
 -56.0%
H
3.0
26.3
|
L
H
3.0
263
|
L
H
3.0
263
|
Enliven Therapeutics Inc |
|
1,016.4
|
20.7
|
L
 2.2%
H
20.6
22.2
|
L
 -1.2%
H
19.5
22.2
|
L
 -4.3%
H
18.7
22.5
|
L
 -10.4%
H
18.7
25.4
|
L
 73.3%
H
11.7
30.0
|
L
 228.2%
H
3.9
30.0
|
L
 -67.6%
H
3.9
250.8
|
L
H
3.9
250.8
|
Climb Bio Inc. |
|
90.9
|
1.4
|
L
 1.5%
H
1.3
1.4
|
L
 -8.2%
H
1.2
1.5
|
L
 -11.2%
H
1.2
1.6
|
L
 -48.1%
H
1.2
2.6
|
L
 -50%
H
1.2
11.6
|
L
 -85.4%
H
1.2
11.6
|
L
H
1.2
29.7
|
L
H
1.2
29.7
|
Enlivex Therapeutics Ltd |
|
26.8
|
1.2
|
L
 11.9%
H
1.1
1.3
|
L
 2.5%
H
1.0
1.3
|
L
 16.2%
H
0.9
1.3
|
L
 5.2%
H
0.9
1.3
|
L
 -70.3%
H
0.8
4.6
|
L
 -75.9%
H
0.8
8.6
|
L
 -74.3%
H
0.8
29.4
|
L
 -99.5%
H
0.8
339.9
|
Ensysce Biosciences Inc |
|
5.5
|
3.9
|
L
 -0.3%
H
3.8
4.2
|
L
 -22.5%
H
3.8
4.9
|
L
 -32.9%
H
3.8
6.1
|
L
 -30.8%
H
3.8
9.9
|
L
 392.4%
H
0.1
9.9
|
L
 -98.5%
H
0.1
396
|
L
 -99.8%
H
0.1
5757.6
|
L
H
0.1
5757.6
|
Enanta Pharmaceuticals Inc |
|
141.9
|
6.7
|
L
 -2.6%
H
6.6
7.0
|
L
 -7.9%
H
6.4
7.4
|
L
 -6.9%
H
6.4
8.8
|
L
 7.6%
H
4.7
8.8
|
L
 -53.2%
H
4.7
17.8
|
L
 -89.9%
H
4.7
79.5
|
L
 -87.7%
H
4.7
102
|
L
 -80.6%
H
4.7
127.8
|
Entera Bio Ltd |
|
69.2
|
1.9
|
L
 1.6%
H
1.9
2
|
L
 -0.5%
H
1.8
2.1
|
L
 -22.6%
H
1.8
2.5
|
L
 -13.0%
H
1.8
2.8
|
L
 37.2%
H
1.3
3.4
|
L
 -14.2%
H
0.5
3.4
|
L
 -24.5%
H
0.5
10.2
|
L
H
0.5
10.2
|
Enveric Biosciences Inc |
|
3.3
|
1.7
|
L
 5.5%
H
1.6
1.8
|
L
 -5.0%
H
1.6
1.8
|
L
 8.1%
H
1.1
4.5
|
L
 380.6%
H
0.3
4.8
|
L
 60.2%
H
0.3
4.8
|
L
 -87.6%
H
0.3
20
|
L
 -99.0%
H
0.3
1060
|
L
 -99.9%
H
0.3
67500
|
Evolus Inc |
|
839.3
|
13.2
|
L
 1.9%
H
12.8
13.2
|
L
 -2.8%
H
11.9
13.6
|
L
 -10.5%
H
11.9
15.1
|
L
 14.7%
H
9.3
17.1
|
L
 -5.0%
H
9.3
17.8
|
L
 32.7%
H
6.5
17.8
|
L
 166.1%
H
2.9
17.8
|
L
H
2.9
39.5
|
Essa Pharma Inc |
|
71.9
|
1.6
|
L
 -0.6%
H
1.6
1.7
|
L
 -1.2%
H
1.6
1.7
|
L
 -6.4%
H
1.6
1.8
|
L
 -1.2%
H
1.6
2.0
|
L
 -82%
H
1.4
9.6
|
L
 -74.3%
H
1.4
11.7
|
L
 -63.8%
H
1.4
36
|
L
 -98.2%
H
1.4
245
|
Equillium Inc |
|
26.9
|
0.8
|
L
 -2.6%
H
0.8
0.8
|
L
 -5%
H
0.7
0.8
|
L
 -19.2%
H
0.7
1.0
|
L
 8.6%
H
0.5
1.0
|
L
 -70.1%
H
0.5
3.0
|
L
 -76.8%
H
0.5
3.5
|
L
 -74.5%
H
0.5
27.1
|
L
H
0.5
27.1
|
Erasca Inc |
|
407.1
|
1.4
|
L
 -2.0%
H
1.4
1.5
|
L
 -5.9%
H
1.4
1.6
|
L
 -8.3%
H
1.2
1.6
|
L
 -43.8%
H
1.2
2.8
|
L
 -32.7%
H
1.2
3.5
|
L
 -86.5%
H
1.2
11.8
|
L
H
1.2
24.5
|
L
H
1.2
24.5
|
Esperion Therapeutics Inc. |
|
296.8
|
1.5
|
L
H
1.5
1.6
|
L
 -11.2%
H
1.5
1.7
|
L
 -19.4%
H
1.5
1.9
|
L
 -33.3%
H
1.5
2.5
|
L
 -27.5%
H
1.5
3.9
|
L
 -67.4%
H
0.7
8.9
|
L
 -95.6%
H
0.7
53.7
|
L
 -98.0%
H
0.7
121.0
|
89bio Inc |
|
1,236.5
|
8.5
|
L
 3.6%
H
8
8.6
|
L
 7.9%
H
6.9
8.7
|
L
 -19.9%
H
6.9
11.3
|
L
 10.1%
H
6.0
11.8
|
L
 -37.4%
H
6.0
13.7
|
L
 136.6%
H
2
22.9
|
L
 -63.2%
H
2
42.4
|
L
H
2
47.3
|
Eton Pharmaceuticals Inc |
|
405.9
|
15.6
|
L
 6.7%
H
14.7
15.6
|
L
 6.8%
H
12.9
15.6
|
L
 -5.1%
H
12.9
17.1
|
L
 26.2%
H
11.6
18.4
|
L
 304.7%
H
3.0
18.4
|
L
 296.4%
H
2.0
18.4
|
L
 299.5%
H
2.0
18.4
|
L
H
2.0
18.4
|
Evoke Pharma Inc |
|
5.7
|
3.8
|
L
 -0.5%
H
3.5
3.8
|
L
 -1.6%
H
3.5
4.0
|
L
 -28.9%
H
3.4
5.3
|
L
 -18.9%
H
3.4
5.8
|
L
 -48.7%
H
0.4
12.3
|
L
 -94.2%
H
0.4
201.6
|
L
 -97.2%
H
0.4
873.0
|
L
 -99.6%
H
0.4
1599.8
|
Edgewise Therapeutics Inc |
|
2,443.9
|
25.7
|
L
 1.5%
H
23.9
26.1
|
L
 -8.4%
H
23.8
28.5
|
L
 1.1%
H
23.5
30.0
|
L
 -7.1%
H
23.1
35.5
|
L
 51.7%
H
14.9
38.1
|
L
 150.9%
H
5.1
38.1
|
L
H
5.1
40.5
|
L
H
5.1
40.5
|
Exelixis Inc |
|
10,257.7
|
36.7
|
L
 -0.4%
H
36.4
37.4
|
L
 -5%
H
36.4
40.0
|
L
 4.7%
H
34
40.0
|
L
 4.6%
H
31.9
40.0
|
L
 59.5%
H
20.1
40.0
|
L
 80.5%
H
14.9
40.0
|
L
 118.5%
H
13.7
40.0
|
L
 1288.3%
H
2.5
40.0
|
Eyenovia Inc |
|
3.5
|
1.7
|
L
 1.9%
H
1.6
1.7
|
L
 3.8%
H
1.5
1.7
|
L
 -14.1%
H
1.4
2.0
|
L
 -75.3%
H
0.0
18.0
|
L
 -98.7%
H
0.0
131.1
|
L
 -99.2%
H
0.0
468
|
L
 -99.1%
H
0.0
617.6
|
L
H
0.0
859.2
|
EyePoint Pharmaceuticals Inc |
|
448.1
|
6.5
|
L
 -4.5%
H
6.4
7.1
|
L
 -8.6%
H
6.4
7.6
|
L
 0.3%
H
5.5
7.6
|
L
 -12.6%
H
5.5
9.5
|
L
 -69.7%
H
5.5
24.0
|
L
 -45.9%
H
2.2
31.0
|
L
 -39.1%
H
2.2
31.0
|
L
 -84.8%
H
2.2
58.1
|
Evaxion Biotech A/S - ADR |
|
11.2
|
1.8
|
L
 -0.6%
H
1.8
1.8
|
L
 -5.3%
H
1.8
2.0
|
L
 -28.5%
H
1.7
2.7
|
L
 56.1%
H
0.8
9.8
|
L
 -40.5%
H
0.8
9.8
|
L
 -93.3%
H
0.8
35.2
|
L
H
0.8
250.4
|
L
H
0.8
250.4
|
Evotec SE - ADR |
|
1,246.4
|
3.5
|
L
 3.5%
H
3.5
3.5
|
L
 -3.6%
H
3.4
3.6
|
L
 -23.4%
H
3.4
4.7
|
L
 -21.7%
H
3.4
5.1
|
L
 -49.1%
H
2.9
8.0
|
L
 -74.8%
H
2.9
16.5
|
L
 -67.7%
H
2.9
26.6
|
L
 77.3%
H
1.6
26.6
|
Fate Therapeutics Inc |
|
107.7
|
0.9
|
L
H
0.9
1.0
|
L
 -6.9%
H
0.9
1.0
|
L
 -33.8%
H
0.9
1.8
|
L
 -48.6%
H
0.9
2.1
|
L
 -87.5%
H
0.9
7.7
|
L
 -97.0%
H
0.9
43.1
|
L
 -95.5%
H
0.9
121.2
|
L
 -81.4%
H
0.9
121.2
|
Fortress Biotech Inc |
|
46.1
|
1.7
|
L
 3.1%
H
1.6
1.7
|
L
 8.4%
H
1.6
1.8
|
L
 -2.3%
H
1.5
1.8
|
L
 -13.9%
H
1.5
2.4
|
L
 -13.9%
H
1.4
2.9
|
L
 -91.2%
H
1.2
23.0
|
L
 -91.6%
H
1.2
91.5
|
L
 -96.3%
H
1.2
91.5
|
Forte Biosciences Inc |
|
37.1
|
5.8
|
L
 -3.3%
H
5.7
6.0
|
L
 -10.8%
H
5.7
6.6
|
L
 -51.7%
H
5.7
12.6
|
L
 -75.0%
H
5.7
26.0
|
L
 -62.6%
H
4.1
28
|
L
 -83.4%
H
4.1
39.8
|
L
 251.5%
H
0.9
1349.8
|
L
H
0.0
1349.8
|
4D Molecular Therapeutics Inc |
|
190.3
|
4.1
|
L
 -4.0%
H
4.1
4.4
|
L
 1.0%
H
3.7
4.4
|
L
 -15.8%
H
3.7
5.1
|
L
 -38.1%
H
3.7
6.9
|
L
 -87.0%
H
3.7
36.3
|
L
 -70.8%
H
3.7
36.3
|
L
H
3.7
55.1
|
L
H
3.7
55.1
|
Fennec Pharmaceuticals Inc |
|
177.7
|
6.5
|
L
 6.2%
H
5.9
6.6
|
L
 -5.4%
H
5.8
6.9
|
L
 -2.5%
H
5.8
7.1
|
L
 7.6%
H
5.5
7.1
|
L
 -34.5%
H
4.0
11.5
|
L
 25.2%
H
4.0
11.9
|
L
 11.5%
H
3.8
11.9
|
L
 150.4%
H
0.3
15.0
|
FibroGen Inc |
|
44.3
|
0.4
|
L
 2.3%
H
0.4
0.5
|
L
 18.9%
H
0.4
0.5
|
L
 -21.4%
H
0.3
0.9
|
L
 33.3%
H
0.3
0.9
|
L
 -79.0%
H
0.2
2.8
|
L
 -96.4%
H
0.2
25.7
|
L
 -98.6%
H
0.2
57.2
|
L
 -98.4%
H
0.2
68.6
|
Foghorn Therapeutics Inc |
|
246.4
|
4.4
|
L
 -1.1%
H
4.4
4.7
|
L
 -2.0%
H
4.1
4.9
|
L
 -27.7%
H
4.1
6.7
|
L
 -17.0%
H
3.9
6.7
|
L
 -25.0%
H
3.9
10.2
|
L
 -60.5%
H
2.7
18.1
|
L
H
2.7
28.3
|
L
H
2.7
28.3
|
Q32 Bio Inc. |
|
24.4
|
2
|
L
 8.7%
H
1.9
2.0
|
L
 -9.9%
H
1.8
2.2
|
L
 -25.1%
H
1.8
2.8
|
L
 -46.0%
H
1.8
4.2
|
L
 -87.9%
H
1.8
53.8
|
L
 -96.2%
H
1.8
64.3
|
L
 -99.3%
H
1.8
349.1
|
L
H
1.8
572.4
|
Flora Growth Corp |
|
12.1
|
0.6
|
L
 -4.6%
H
0.6
0.6
|
L
 -4.6%
H
0.6
0.7
|
L
 -24.4%
H
0.6
1.0
|
L
 -52.3%
H
0.6
1.3
|
L
 -43.6%
H
0.6
2.9
|
L
 -98.1%
H
0.6
47.6
|
L
H
0.6
429
|
L
H
0.6
429
|
Amicus Therapeutics Inc |
|
2,734.4
|
8.9
|
L
 1.0%
H
8.8
9
|
L
 0.5%
H
8.5
9
|
L
 -8.9%
H
8.5
10
|
L
 -4.9%
H
8.5
10
|
L
 -22.5%
H
8.5
12.7
|
L
 -0.6%
H
5.9
14.6
|
L
 7.6%
H
5.9
25.4
|
L
 -3.8%
H
4.4
25.4
|
Fulcrum Therapeutics Inc |
|
168.4
|
3.1
|
L
 7.6%
H
2.9
3.2
|
L
 -0.6%
H
2.8
3.2
|
L
 -15.5%
H
2.8
3.9
|
L
 -21.2%
H
2.8
5.2
|
L
 -72.5%
H
2.8
11.5
|
L
 -80.2%
H
2.3
24.8
|
L
 -80.5%
H
2.3
33.1
|
L
H
2.3
33.1
|
Galectin Therapeutics Inc |
|
105.4
|
1.7
|
L
 -4.6%
H
1.6
1.8
|
L
 3.7%
H
1.6
1.8
|
L
 19.2%
H
1.4
1.8
|
L
 -20.4%
H
0.7
2.4
|
L
 -18.5%
H
0.7
4.3
|
L
 -3.4%
H
0.7
4.3
|
L
 -16.4%
H
0.7
5.7
|
L
 -52%
H
0.5
9.5
|
Gain Therapeutics Inc |
|
56.0
|
2.1
|
L
 -4.1%
H
2.1
2.3
|
L
 11.6%
H
1.8
2.3
|
L
 -22.7%
H
1.5
2.8
|
L
 29.5%
H
1.5
2.8
|
L
 -50.8%
H
0.9
4.6
|
L
 -37.0%
H
0.9
6.7
|
L
H
0.9
17.9
|
L
H
0.9
17.9
|
Generation Bio Co |
|
32.2
|
0.5
|
L
 -5.9%
H
0.5
0.5
|
L
 -9.4%
H
0.5
0.6
|
L
 -29.4%
H
0.5
0.8
|
L
 -57.9%
H
0.5
1.3
|
L
 -84.5%
H
0.5
4.7
|
L
 -89.5%
H
0.5
9.6
|
L
H
0.5
55.7
|
L
H
0.5
55.7
|
CytoMed Therapeutics Ltd |
|
28.6
|
2.5
|
L
 -7.1%
H
2.5
2.6
|
L
 -8.5%
H
2.4
2.8
|
L
 -3.1%
H
2.4
2.8
|
L
 -8.8%
H
2.1
4.1
|
L
 16.4%
H
1.2
4.1
|
L
H
1.2
9.3
|
L
H
1.2
9.3
|
L
H
1.2
9.3
|
Geron Corp. |
|
1,044.5
|
1.6
|
L
 -1.8%
H
1.6
1.7
|
L
 -5.2%
H
1.6
1.8
|
L
 -35.9%
H
1.5
2.7
|
L
 -57.5%
H
1.5
4
|
L
 -51.2%
H
1.5
5.3
|
L
 57.7%
H
1.0
5.3
|
L
 70.8%
H
0.8
5.3
|
L
 -62.2%
H
0.8
7.0
|
GH Research PLC |
|
682.3
|
11
|
L
 1.1%
H
10.9
11.7
|
L
 4.8%
H
10.2
11.8
|
L
 -23.1%
H
8.6
14.6
|
L
 42.1%
H
6.7
20.5
|
L
 0.9%
H
6
20.5
|
L
 -29.4%
H
5.1
20.5
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
Gilead Sciences, Inc. |
|
138,781.4
|
111.4
|
L
 -1.7%
H
110.9
113.4
|
L
 -5.1%
H
110.9
120.0
|
L
 7.1%
H
104
120.0
|
L
 21.8%
H
88.6
120.0
|
L
 51.2%
H
62.1
120.0
|
L
 91.1%
H
57.2
120.0
|
L
 57.5%
H
56.6
120.0
|
L
 11.9%
H
56.6
123.4
|
Galmed Pharmaceuticals Ltd |
|
2.9
|
1.7
|
L
 3.0%
H
1.7
2.0
|
L
 -8.5%
H
1.7
2.1
|
L
 -34.0%
H
1.7
2.9
|
L
 -41.8%
H
1.7
3.6
|
L
 -52.7%
H
0.2
13.6
|
L
 -99.2%
H
0.2
330.9
|
L
 -99.7%
H
0.2
1132.2
|
L
 -99.9%
H
0.2
4870.8
|
Greenwich LifeSciences Inc |
|
157.7
|
12
|
L
 1.9%
H
11.8
12.1
|
L
 -0.8%
H
11.3
12.2
|
L
 -3.1%
H
11.3
12.8
|
L
 -10.4%
H
10.8
14.5
|
L
 -31.4%
H
10.8
21.4
|
L
 -43.7%
H
6.8
24.5
|
L
H
3.3
158.1
|
L
H
3.3
158.1
|
Galecto Inc |
|
5.3
|
4.1
|
L
 2.0%
H
4.0
4.2
|
L
 -0.3%
H
3.8
4.2
|
L
 -15.3%
H
3.8
5
|
L
 -20.7%
H
3.8
6.0
|
L
 393.9%
H
0.5
14.8
|
L
 121.3%
H
0.5
14.8
|
L
H
0.5
18.0
|
L
H
0.5
18.0
|
Monte Rosa Therapeutics Inc |
|
385.2
|
6.3
|
L
 1.0%
H
6.1
6.4
|
L
 -1.9%
H
5.8
6.7
|
L
 -7.5%
H
5.3
7.2
|
L
 -17.1%
H
5.2
8.0
|
L
 -2.2%
H
3.2
12.4
|
L
 -55.1%
H
2.4
15.5
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
GlycoMimetics Inc |
|
16.8
|
0.3
|
L
H
0.3
0.3
|
L
 -3.7%
H
0.2
0.3
|
L
 -10.3%
H
0.2
0.4
|
L
 8.3%
H
0.2
0.4
|
L
 -89.8%
H
0.1
3.2
|
L
 -74.8%
H
0.1
4.2
|
L
 -89.8%
H
0.1
5.2
|
L
 -96.8%
H
0.1
26.1
|
Genelux Corp |
|
117.4
|
3.4
|
L
 -5.0%
H
3.3
3.7
|
L
 -19.1%
H
3.3
4.4
|
L
 -36.3%
H
3.3
5.4
|
L
 45.9%
H
2.2
5.9
|
L
 -45.7%
H
1.6
6.5
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
Genprex Inc |
|
3.1
|
0.4
|
L
H
0.4
0.4
|
L
 5.9%
H
0.3
0.4
|
L
 -18.2%
H
0.3
0.4
|
L
 -69.0%
H
0.3
1.3
|
L
 -91.1%
H
0.3
4.5
|
L
 -82.2%
H
0.2
8.0
|
L
 -81.0%
H
0.2
8.0
|
L
H
0.2
19.5
|
Gossamer Bio Inc |
|
328.6
|
1.5
|
L
 11.5%
H
1.3
1.5
|
L
 19.8%
H
1.1
1.5
|
L
 10.7%
H
1.1
1.6
|
L
 55.9%
H
0.8
1.6
|
L
 -0.7%
H
0.5
1.6
|
L
 -82.8%
H
0.5
15.2
|
L
 -86.5%
H
0.5
16.8
|
L
H
0.5
27.2
|
Geovax Labs Inc |
|
14.5
|
1.5
|
L
H
1.5
1.6
|
L
 -9.9%
H
1.5
1.9
|
L
 -11.0%
H
1.4
1.9
|
L
 -34.5%
H
1.4
2.8
|
L
 -17.2%
H
1.1
11.1
|
L
 10.8%
H
0.3
11.1
|
L
 -68.0%
H
0.3
35
|
L
 -100.0%
H
0.3
1000000
|
Galera Therapeutics Inc |
|
2.3
|
0.0
|
L
 -25%
H
0.0
0.0
|
L
 -25%
H
0.0
0.0
|
L
 -25%
H
0.0
0.0
|
L
H
0.0
0.1
|
L
 -85.7%
H
0.0
0.3
|
L
 -98.6%
H
0.0
3.6
|
L
 -99.7%
H
0.0
15
|
L
H
0.0
19.5
|
GT Biopharma Inc |
|
6.5
|
2.6
|
L
 3.2%
H
2.3
2.6
|
L
 4.9%
H
2.3
2.7
|
L
 19.6%
H
2.0
3.1
|
L
 -6.9%
H
1.7
4.1
|
L
 -44.7%
H
1.7
10.7
|
L
 -5.2%
H
0.2
10.7
|
L
 -16.3%
H
0.2
19.7
|
L
 -100.0%
H
0.2
89250
|
Galapagos NV - ADR |
|
1,714.0
|
26.0
|
L
 0.1%
H
26.0
26.3
|
L
 -2.1%
H
25.4
27.0
|
L
 2.2%
H
25.4
27.5
|
L
 -3.0%
H
22.4
29.7
|
L
 -23.4%
H
22.4
34.0
|
L
 -56.8%
H
22.4
72.1
|
L
 -85.2%
H
22.4
233.1
|
L
 8.3%
H
22.3
274.0
|
Genmab - ADR |
|
13,034.2
|
20.5
|
L
 2.8%
H
20.4
21.1
|
L
 -15.0%
H
19.8
24.1
|
L
 -3.7%
H
19.8
24.3
|
L
 1.7%
H
18.6
24.3
|
L
 -31.5%
H
18.6
31.0
|
L
 -38.8%
H
18.6
47.5
|
L
 3.3%
H
16.2
49.1
|
L
 166.0%
H
6.8
49.1
|
Genfit - ADR |
|
175.2
|
3.5
|
L
 0.3%
H
3.5
3.7
|
L
 -3.8%
H
3.5
3.7
|
L
 -15.0%
H
3.1
4.0
|
L
 -8.1%
H
3.1
4.3
|
L
 -0.3%
H
3.1
6.4
|
L
 -5.1%
H
2.9
6.4
|
L
 -72.9%
H
2.9
22.5
|
L
H
2.9
26.3
|
Genenta Science SpA - ADR |
|
70.1
|
3.8
|
L
 -2.8%
H
3.8
3.8
|
L
 0.8%
H
3.6
4.2
|
L
 -12.4%
H
3.6
4.8
|
L
 -25.3%
H
3.5
5.7
|
L
 -1.8%
H
2.2
7.3
|
L
 -33.4%
H
2.2
9.3
|
L
H
2.2
13.1
|
L
H
2.2
13.1
|
Grifols SA - ADR - Level III |
|
5,429.7
|
8.0
|
L
 3.4%
H
7.9
8.0
|
L
 -5.3%
H
7.4
8.3
|
L
 9.0%
H
7.0
8.8
|
L
 8.9%
H
6.6
8.8
|
L
 30.2%
H
5.8
10.0
|
L
 -25.6%
H
5.3
13.3
|
L
 -59.0%
H
5.3
21.9
|
L
 -51.0%
H
5.3
25.7
|
Halozyme Therapeutics Inc. |
|
7,668.7
|
62.3
|
L
 2.0%
H
61.1
62.7
|
L
 2.1%
H
60.1
63.1
|
L
 6.8%
H
56.1
63.1
|
L
 30.4%
H
46.3
63.1
|
L
 52.4%
H
37.7
65.5
|
L
 76.1%
H
29.9
65.5
|
L
 260.8%
H
12.7
65.5
|
L
 290.9%
H
7.0
65.5
|
HCW Biologics Inc |
|
15.1
|
0.3
|
L
 3.0%
H
0.3
0.4
|
L
 -5.6%
H
0.3
0.4
|
L
 -15%
H
0.3
0.4
|
L
 -5.6%
H
0.2
1.0
|
L
 -77.8%
H
0.2
2.5
|
L
 -83.5%
H
0.2
3.3
|
L
H
0.2
7.8
|
L
H
0.2
7.8
|
Hepion Pharmaceuticals Inc |
|
0.7
|
0.0
|
L
 -50%
H
0.0
0.0
|
L
 -75%
H
0.0
0.1
|
L
 -88.9%
H
0.0
0.2
|
L
 -96.6%
H
0.0
0.7
|
L
 -99.1%
H
0.0
2.9
|
L
 -99.9%
H
0.0
26.6
|
L
 -99.9%
H
0.0
96.6
|
L
 -100.0%
H
0.0
70336
|
HilleVax Inc |
|
87.2
|
1.8
|
L
 1.2%
H
1.7
1.8
|
L
 -4.9%
H
1.7
1.9
|
L
 -5.9%
H
1.7
2.0
|
L
 -10.7%
H
1.7
2.2
|
L
 -90.3%
H
1.6
18
|
L
H
1.6
24.4
|
L
H
1.6
24.4
|
L
H
1.6
24.4
|
Hookipa Pharma Inc |
|
14.1
|
1.2
|
L
H
1.2
1.2
|
L
 -7.9%
H
1.1
1.4
|
L
 -38.1%
H
1.1
2.0
|
L
 -45.1%
H
1.1
2.8
|
L
 -83.7%
H
1.1
10.5
|
L
 -92.3%
H
1.1
23.9
|
L
 -98.4%
H
1.1
200
|
L
H
1.1
200
|
Hoth Therapeutics Inc |
|
14.6
|
1.1
|
L
 1.8%
H
1.1
1.1
|
L
 1.8%
H
1.0
1.2
|
L
 -1.8%
H
0.8
1.3
|
L
 37.0%
H
0.7
3.8
|
L
 -4.3%
H
0.6
3.8
|
L
 -91.8%
H
0.6
40.7
|
L
 -98.8%
H
0.6
175
|
L
H
0.6
347
|
Werewolf Therapeutics Inc |
|
53.8
|
1.2
|
L
 -0.8%
H
1.2
1.3
|
L
 -2.4%
H
1.2
1.3
|
L
 -19.5%
H
1.0
1.6
|
L
 -27.3%
H
1.0
1.7
|
L
 -80.5%
H
1.0
6.9
|
L
 -73.9%
H
1.0
8.2
|
L
H
1.0
24.0
|
L
H
1.0
24.0
|
Harmony Biosciences Holdin... |
|
1,876.3
|
32.7
|
L
H
32.1
33.1
|
L
 -2.8%
H
32.1
35.1
|
L
 -16.1%
H
31.7
39.5
|
L
 2.7%
H
31.7
40.9
|
L
 2.3%
H
28.1
41.6
|
L
 -25.3%
H
18.6
62.1
|
L
H
18.6
62.1
|
L
H
18.6
62.1
|
Harrow Health Inc |
|
819.5
|
23.0
|
L
 3.5%
H
22.5
23.6
|
L
 -5.6%
H
21.1
24.0
|
L
 -24.4%
H
21.1
31.5
|
L
 -35.2%
H
21.1
37.5
|
L
 119.4%
H
9.3
59.2
|
L
 228.7%
H
5.4
59.2
|
L
 362.0%
H
3.3
59.2
|
L
 187.6%
H
1.4
59.2
|
Heron Therapeutics Inc |
|
353.4
|
2.3
|
L
H
2.3
2.5
|
L
 -2.9%
H
2.1
2.5
|
L
 30.3%
H
1.6
2.7
|
L
 45%
H
1.5
2.7
|
L
 -24.2%
H
1.0
3.9
|
L
 -52.1%
H
0.5
6.4
|
L
 -82.8%
H
0.5
22.4
|
L
 -84.1%
H
0.5
42.9
|
Quantum BioPharma Ltd. - O... |
|
9.4
|
4.9
|
L
 8.4%
H
4.6
5.2
|
L
 5.8%
H
4.2
5.2
|
L
 -45.8%
H
4.1
10.0
|
L
 20.4%
H
2.7
18
|
L
 -89.5%
H
2.7
49.0
|
L
 -91.0%
H
2.7
136.5
|
L
 -97.7%
H
2.7
910
|
L
H
2.7
11431.9
|
Humacyte Inc |
|
391.2
|
3.0
|
L
 9.8%
H
2.8
3.1
|
L
 -1.6%
H
2.8
3.1
|
L
 -22.3%
H
2.8
4.0
|
L
 -25.9%
H
2.8
6.8
|
L
 -6.2%
H
2.8
10.0
|
L
 -46.4%
H
2.0
10.0
|
L
H
2.0
17.5
|
L
H
2.0
17.5
|
HUTCHMED (China) Limited -... |
|
2,682.0
|
15.7
|
L
 2.1%
H
15.5
15.7
|
L
 -5.1%
H
15.1
15.8
|
L
 13.7%
H
13.6
17.1
|
L
 0.7%
H
12.8
17.1
|
L
 -10.9%
H
12.8
21.9
|
L
 -1.3%
H
7.4
21.9
|
L
 -21.8%
H
7.4
43.9
|
L
H
7.4
43.9
|
ImmunityBio Inc |
|
2,449.4
|
2.9
|
L
 -1.0%
H
2.8
3.0
|
L
 -4.3%
H
2.7
3.1
|
L
 -20.7%
H
2.7
4.3
|
L
H
2.3
4.3
|
L
 -44.1%
H
2.3
10.5
|
L
 -46.6%
H
1.2
10.5
|
L
H
1.2
40.8
|
L
H
1.2
40.8
|
Immucell Corp. |
|
44.5
|
5.0
|
L
 2.0%
H
4.9
5
|
L
 -2.4%
H
4.3
5.2
|
L
 -1.2%
H
4.3
5.6
|
L
 1.4%
H
4.3
5.6
|
L
 -5.0%
H
3.3
5.8
|
L
 -42.4%
H
3.3
11.0
|
L
 24.8%
H
3.3
13.2
|
L
 -27.2%
H
3.3
13.2
|
Ideaya Biosciences Inc |
|
1,626.4
|
18.6
|
L
 -2%
H
18.5
19.5
|
L
 0.7%
H
17.0
19.6
|
L
 -11.5%
H
17.0
22.4
|
L
 -27.2%
H
17.0
27.2
|
L
 -58.1%
H
17.0
46.4
|
L
 56.3%
H
8.1
47.7
|
L
 361.0%
H
3.0
47.7
|
L
H
3.0
47.7
|
InflaRx N.V. |
|
79.9
|
1.2
|
L
 3.5%
H
1.1
1.2
|
L
 -1.7%
H
1.1
1.3
|
L
 -40.5%
H
1.1
2.0
|
L
 -49.6%
H
1.1
2.8
|
L
 -24.7%
H
1.1
2.8
|
L
 -43.1%
H
0.8
7.3
|
L
 -61.6%
H
0.8
9.7
|
L
H
0.8
53.1
|
IGM Biosciences Inc |
|
74.1
|
1.2
|
L
 -3.9%
H
1.2
1.3
|
L
 -6.1%
H
1.2
1.4
|
L
 -13.3%
H
1.2
1.6
|
L
 -82.7%
H
1.2
7.9
|
L
 -88.4%
H
1.2
22.5
|
L
 -90.8%
H
1.2
36.0
|
L
 -96.6%
H
1.2
133
|
L
H
1.2
133
|
Ikena Oncology Inc |
|
64.7
|
1.3
|
L
 -1.5%
H
1.3
1.4
|
L
 -6.9%
H
1.3
1.5
|
L
 -10.1%
H
1.3
1.5
|
L
 -18.8%
H
1.3
1.9
|
L
 -14.7%
H
1.2
1.9
|
L
 -76.4%
H
1.0
9.0
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
Inhibikase Therapeutics Inc |
|
163.5
|
2.3
|
L
 2.3%
H
2.1
2.3
|
L
 14.8%
H
1.9
2.3
|
L
 -4.3%
H
1.9
3.3
|
L
 -34.6%
H
1.9
4.2
|
L
 6.6%
H
1.1
4.2
|
L
 -70.2%
H
0.8
9.1
|
L
H
0.8
70.8
|
L
H
0.8
70.8
|
Illumina Inc |
|
13,559.0
|
85.6
|
L
 1.8%
H
83.8
86.1
|
L
 -1.2%
H
81.5
92.7
|
L
 -14.6%
H
80.2
105.7
|
L
 -40.5%
H
80.2
153.1
|
L
 -33.0%
H
80.2
156.7
|
L
 -72.6%
H
80.2
371.2
|
L
 -63.3%
H
80.2
555.8
|
L
 -54.5%
H
80.2
555.8
|
IM Cannabis Corp |
|
5.5
|
1.8
|
L
 -2.2%
H
1.7
2.0
|
L
 -7.3%
H
1.7
2.0
|
L
 -20.9%
H
1.7
2.3
|
L
 -27.9%
H
1.7
2.9
|
L
 -19.8%
H
0.4
8.1
|
L
 -98.2%
H
0.4
155.4
|
L
H
0.4
697.8
|
L
H
0.4
697.8
|
Immix Biopharma Inc |
|
45.4
|
1.7
|
L
 4.4%
H
1.6
1.7
|
L
 8.6%
H
1.5
1.7
|
L
 -16.7%
H
1.5
2
|
L
 -23.6%
H
1.5
2.5
|
L
 -37.5%
H
1.3
3.4
|
L
 -19.1%
H
0.7
7.8
|
L
H
0.7
8.7
|
L
H
0.7
8.7
|
Immunome Inc |
|
742.6
|
8.8
|
L
 -1.8%
H
8.8
9.2
|
L
 -6.1%
H
8.4
9.5
|
L
 -15.7%
H
8.4
10.7
|
L
 -30.0%
H
8.4
12.9
|
L
 -61.0%
H
8.4
26.7
|
L
 124.3%
H
2.1
31.0
|
L
H
2.1
63.8
|
L
H
2.1
63.8
|
Imunon Inc |
|
12.6
|
0.9
|
L
 -2.3%
H
0.9
0.9
|
L
 -4.4%
H
0.9
0.9
|
L
 -4.4%
H
0.8
0.9
|
L
 3.6%
H
0.8
1.1
|
L
H
0.6
3.7
|
L
 -82.4%
H
0.5
7.7
|
L
 -93.2%
H
0.5
97.5
|
L
 -99.8%
H
0.5
749.7
|
Immuneering Corp - Ordinar... |
|
49.7
|
1.6
|
L
 3.9%
H
1.6
1.7
|
L
 5.3%
H
1.4
1.7
|
L
 -14.0%
H
1.4
1.9
|
L
 -2.4%
H
1.4
3.8
|
L
 -16.2%
H
1
3.8
|
L
 -75.6%
H
1
16.2
|
L
H
1
34.0
|
L
H
1
34.0
|
Immatics N.V |
|
553.1
|
4.6
|
L
 0.7%
H
4.5
4.6
|
L
 -2.4%
H
4.4
4.7
|
L
 -9.9%
H
4.1
5.2
|
L
 -36.1%
H
4.1
7.6
|
L
 -62.1%
H
4.1
13.8
|
L
 -32.7%
H
4.1
13.8
|
L
H
4.1
18.4
|
L
H
4.1
18.4
|
Immunic Inc |
|
103.6
|
1.2
|
L
 2.7%
H
1.1
1.2
|
L
H
1.1
1.2
|
L
 15%
H
1
1.4
|
L
 0.9%
H
0.9
1.4
|
L
 -12.2%
H
0.9
2.1
|
L
 -88.9%
H
0.9
12.6
|
L
 -81.7%
H
0.9
28.2
|
L
 -99.9%
H
0.9
1186.8
|
Immunovant Inc |
|
3,315.7
|
19.5
|
L
 3.9%
H
18.7
19.5
|
L
 -2.5%
H
18.6
20.7
|
L
 -4.0%
H
17.7
21.7
|
L
 -25.7%
H
17.7
28
|
L
 -36.1%
H
17.7
36.0
|
L
 270.4%
H
3.1
45.6
|
L
 32.8%
H
3.1
53.8
|
L
H
3.1
53.8
|
IN8bio Inc |
|
15.9
|
0.2
|
L
 -4.4%
H
0.2
0.2
|
L
 -12%
H
0.2
0.3
|
L
 -24.1%
H
0.2
0.3
|
L
 -24.1%
H
0.2
0.4
|
L
 -80.7%
H
0.2
1.7
|
L
 -92.7%
H
0.2
5.0
|
L
H
0.2
10.3
|
L
H
0.2
10.3
|
Inhibrx Inc |
|
668.0
|
14.1
|
L
 -0.4%
H
13.7
14.5
|
L
 3.8%
H
12.3
15.3
|
L
 5.3%
H
11.7
15.3
|
L
 -3.4%
H
11.7
16.8
|
L
 -59.7%
H
10.8
35.4
|
L
 -30.1%
H
7.7
39.8
|
L
H
7.7
51.0
|
L
H
7.7
51.0
|
Incyte Corp. |
|
13,132.6
|
67.9
|
L
 0.2%
H
67.2
68.1
|
L
 -4.1%
H
66.4
71.9
|
L
 -3.6%
H
66.4
76.2
|
L
 -1.0%
H
65.6
77.0
|
L
 16.3%
H
50.4
84.0
|
L
 -7.4%
H
50.3
86.3
|
L
 -8.1%
H
50.3
110.4
|
L
 -24.0%
H
50.3
153.2
|
Indaptus Therapeutics Inc |
|
11.3
|
0.8
|
L
 -1.2%
H
0.8
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
H
0.7
0.9
|
L
 -20%
H
0.7
1.1
|
L
 -57.2%
H
0.7
3.1
|
L
 -74.9%
H
0.7
4.3
|
L
 -95.3%
H
0.7
63.3
|
L
 -97.5%
H
0.7
8800
|
Indivior Plc |
|
1,206.7
|
9.7
|
L
 0.9%
H
9.6
9.9
|
L
 -0.2%
H
9.0
10.1
|
L
 -1.5%
H
7.6
11.3
|
L
 -16.3%
H
7.6
12.8
|
L
 -53.3%
H
7.3
22.5
|
L
 172.7%
H
3
26.5
|
L
 1436.5%
H
0.4
26.5
|
L
 284.1%
H
0.4
26.5
|
MiNK Therapeutics Inc |
|
33.6
|
8.5
|
L
 6.4%
H
8.2
8.5
|
L
 3.5%
H
7.5
8.5
|
L
 -10.6%
H
7.5
12
|
L
 37.8%
H
0.9
13.8
|
L
 -5.0%
H
0.9
19
|
L
 -62.6%
H
0.9
43.2
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
InMed Pharmaceuticals Inc |
|
3.4
|
2.8
|
L
 4.8%
H
2.7
2.9
|
L
 3.3%
H
2.5
2.9
|
L
 -10.8%
H
2.5
3.5
|
L
 -46.4%
H
2.5
8.3
|
L
 -60.8%
H
2.4
15.7
|
L
 -99.2%
H
2.4
710
|
L
 -99.9%
H
2.4
5214
|
L
 -99.9%
H
2.4
32175
|
INmune Bio Inc |
|
180.4
|
8.0
|
L
 -1.1%
H
7.8
8.4
|
L
 -0.9%
H
7.8
8.8
|
L
 -13.4%
H
7.3
9.6
|
L
 67.4%
H
4.3
10.5
|
L
 -28.1%
H
4.3
12.7
|
L
 23.8%
H
4.3
14.7
|
L
 156.5%
H
2.2
30.4
|
L
H
2.2
30.4
|
Inovio Pharmaceuticals Inc |
|
73.3
|
2.0
|
L
 5.2%
H
2.0
2.0
|
L
 4.1%
H
1.9
2.1
|
L
 -5.6%
H
1.8
2.3
|
L
 -12.5%
H
1.7
2.4
|
L
 -81.1%
H
1.7
14.8
|
L
 -35.4%
H
0.3
14.8
|
L
 -71.8%
H
0.3
33.8
|
L
 -71.2%
H
0.3
33.8
|
Insmed Inc |
|
13,855.5
|
76.6
|
L
 2.0%
H
75.7
77.4
|
L
 2.2%
H
71.6
77.4
|
L
 -3.5%
H
71.6
84.9
|
L
 6.9%
H
61.5
84.9
|
L
 197.6%
H
21.9
84.9
|
L
 251.3%
H
16.0
84.9
|
L
 274.5%
H
12.1
84.9
|
L
 257.7%
H
9.0
84.9
|
Innoviva Inc |
|
1,089.9
|
17.4
|
L
H
17.3
17.5
|
L
 -1.4%
H
17
17.9
|
L
 -3.8%
H
17
18.6
|
L
 -6.4%
H
17
19.4
|
L
 17.0%
H
14.3
21.3
|
L
 -5.6%
H
10.6
21.3
|
L
 59.7%
H
7.6
21.3
|
L
 -1.0%
H
6.4
21.3
|
Inozyme Pharma Inc |
|
64.2
|
1
|
L
H
1.0
1.0
|
L
 -13.0%
H
1.0
1.2
|
L
 -27.0%
H
1.0
1.4
|
L
 -64.8%
H
1.0
3.3
|
L
 -83.0%
H
1.0
7.8
|
L
 -75.2%
H
1.0
7.8
|
L
H
1.0
31.7
|
L
H
1.0
31.7
|
IO Biotech Inc |
|
58.0
|
0.9
|
L
 -1.1%
H
0.9
0.9
|
L
 -2.2%
H
0.8
0.9
|
L
 -5.4%
H
0.8
1.2
|
L
 11.4%
H
0.7
1.2
|
L
 -46.7%
H
0.7
1.8
|
L
 -76.8%
H
0.7
9.8
|
L
H
0.7
17.9
|
L
H
0.7
17.9
|
Ionis Pharmaceuticals Inc |
|
5,239.5
|
33.0
|
L
 0.2%
H
32.7
33.3
|
L
 -2.5%
H
31.5
34.3
|
L
 6.2%
H
30.9
35
|
L
 -10.0%
H
30.2
38.9
|
L
 -22.5%
H
30.2
52.3
|
L
 0.8%
H
30.2
54.4
|
L
 -31.9%
H
25.0
64.4
|
L
 -53.4%
H
19.6
86.6
|
Iovance Biotherapeutics Inc |
|
1,177.1
|
3.6
|
L
 2.0%
H
3.5
3.6
|
L
 -4.3%
H
3.5
4.0
|
L
 -35.6%
H
3.5
6.1
|
L
 -54.2%
H
3.5
8.2
|
L
 -74.2%
H
3.5
15.9
|
L
 -71.3%
H
3.2
18.7
|
L
 -85.7%
H
3.2
54.2
|
L
 -72.6%
H
3.2
54.2
|
Century Therapeutics Inc |
|
51.0
|
0.6
|
L
 7.1%
H
0.6
0.6
|
L
 -9.1%
H
0.6
0.7
|
L
 -23.1%
H
0.6
0.8
|
L
 -50.8%
H
0.6
1.3
|
L
 -88%
H
0.6
5.2
|
L
 -95.5%
H
0.6
14.1
|
L
H
0.6
32.9
|
L
H
0.6
32.9
|
Disc Medicine Inc |
|
1,763.7
|
51.0
|
L
 -2.7%
H
50.7
53.6
|
L
 -8.4%
H
50.7
56.3
|
L
 -5.7%
H
50.7
57.2
|
L
 -21.1%
H
50.7
67.9
|
L
 -17.4%
H
25.6
68.9
|
L
 256.8%
H
11.8
77.6
|
L
H
11.6
190.9
|
L
H
11.6
190.9
|
Ironwood Pharmaceuticals I... |
|
238.4
|
1.5
|
L
 -1.3%
H
1.5
1.5
|
L
 -0.7%
H
1.3
1.6
|
L
 -22.4%
H
1.3
2.1
|
L
 -57.8%
H
1.3
5.1
|
L
 -83.5%
H
1.3
9.2
|
L
 -87.5%
H
1.3
15.7
|
L
 -85.4%
H
1.3
15.7
|
L
 -88.2%
H
1.3
17.7
|
Intra-Cellular Therapies Inc |
|
13,956.6
|
131.3
|
L
 -0.1%
H
131.2
131.4
|
L
 0.0%
H
131.2
131.4
|
L
 2.7%
H
127.9
131.4
|
L
 58.1%
H
80.8
131.4
|
L
 102.6%
H
63.9
131.4
|
L
 124.9%
H
42.0
131.4
|
L
 733.9%
H
10.9
131.4
|
L
 459.0%
H
6.8
131.4
|
ITeos Therapeutics Inc |
|
279.6
|
7.3
|
L
 1.8%
H
7.2
7.5
|
L
 3.8%
H
6.7
7.7
|
L
 -1.1%
H
6.7
7.7
|
L
 -4.7%
H
6.7
8.3
|
L
 -32.3%
H
6.7
18.8
|
L
 -79.6%
H
6.7
37.3
|
L
H
6.7
52.4
|
L
H
6.7
52.4
|
Iterum Therapeutics Plc |
|
47.7
|
1.4
|
L
 3.0%
H
1.3
1.4
|
L
H
1.3
1.4
|
L
 -10.4%
H
1.3
1.6
|
L
 -23.3%
H
1.3
2.1
|
L
 -5.5%
H
0.8
3.0
|
L
 -73.4%
H
0.6
7.1
|
L
 -95.2%
H
0.6
90.3
|
L
H
0.6
195
|
Invivyd Inc |
|
95.7
|
0.8
|
L
 -1.2%
H
0.8
0.9
|
L
 -20.8%
H
0.8
1.0
|
L
 -50.3%
H
0.8
2.1
|
L
 42.9%
H
0.4
2.7
|
L
 -77.8%
H
0.4
4.7
|
L
 -83.1%
H
0.4
6.1
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
I-Mab - ADR |
|
68.5
|
0.8
|
L
H
0.8
0.9
|
L
 -2.3%
H
0.8
0.9
|
L
 -12.5%
H
0.8
1
|
L
 -16%
H
0.8
1.4
|
L
 -54.8%
H
0.8
2
|
L
 -93.8%
H
0.8
21.4
|
L
 -93.9%
H
0.8
85.4
|
L
H
0.8
85.4
|
Immunocore Holdings plc - ADR |
|
1,442.0
|
28.8
|
L
 1.9%
H
28.4
29.8
|
L
 -3.4%
H
27.2
30.4
|
L
 -2.7%
H
27.2
31.4
|
L
 -1.8%
H
27.2
33.9
|
L
 -52.7%
H
27.2
66
|
L
 16.6%
H
24.9
77.0
|
L
H
18.4
77.0
|
L
H
18.4
77.0
|
Immutep Limited - ADR |
|
259.1
|
1.8
|
L
 1.7%
H
1.7
1.8
|
L
 1.1%
H
1.7
1.9
|
L
 -9.2%
H
1.7
2.1
|
L
 -18.4%
H
1.7
2.3
|
L
 -25.5%
H
1.7
3.3
|
L
 -28.5%
H
1.5
3.9
|
L
 -6.8%
H
0.5
8.0
|
L
 -36.4%
H
0.5
21.6
|
Immuron Limited - ADR |
|
10.4
|
1.8
|
L
H
1.8
1.9
|
L
 3.4%
H
1.8
2.1
|
L
 -10.8%
H
1.7
2.1
|
L
 -14.2%
H
1.7
2.5
|
L
 -36.6%
H
1.7
3.1
|
L
 -36.8%
H
1.4
6.0
|
L
 -13.3%
H
1.4
29.0
|
L
H
1.4
29.0
|
Innate Pharma - ADR |
|
167.6
|
2
|
L
H
1.9
2
|
L
 -6.1%
H
1.9
2.2
|
L
 3.1%
H
1.9
2.6
|
L
 -33.8%
H
1.6
2.7
|
L
 -20.6%
H
1.3
3.5
|
L
 -36.7%
H
1.3
4.0
|
L
 -58.3%
H
1.3
12.0
|
L
H
1.3
12.0
|
Inventiva - ADR |
|
156.0
|
3.0
|
L
 -0.7%
H
2.7
3
|
L
 -4.2%
H
2.7
3.1
|
L
 18.7%
H
2.5
3.3
|
L
 21.6%
H
2.1
3.3
|
L
 -29.1%
H
1.5
4.5
|
L
 -71.6%
H
1.5
12.2
|
L
H
1.5
19.1
|
L
H
1.5
19.1
|
Jaguar Health Inc |
|
7.2
|
0.4
|
L
 -2.2%
H
0.4
0.5
|
L
 -24.1%
H
0.4
0.6
|
L
 -51.1%
H
0.4
1.0
|
L
 -54.6%
H
0.4
1.3
|
L
 -99.8%
H
0.4
1296
|
L
 -100.0%
H
0.4
220050
|
L
 -100.0%
H
0.4
3620696.0
|
L
H
0.4
400302000
|
Janux Therapeutics Inc |
|
1,813.3
|
30.7
|
L
 -2.1%
H
30.6
32.3
|
L
 0.1%
H
28.9
32.3
|
L
 -15.6%
H
28.9
38.4
|
L
 -49.8%
H
28.9
63
|
L
 -22.2%
H
28.9
71.7
|
L
 80.8%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
Jazz Pharmaceuticals plc |
|
8,378.7
|
138.0
|
L
 1.4%
H
135.3
138.2
|
L
 -0.6%
H
134.0
140.3
|
L
 3.0%
H
132.6
148.1
|
L
 12.6%
H
118.7
148.1
|
L
 14.1%
H
99.1
148.1
|
L
 -10.8%
H
99.1
170.0
|
L
 23.9%
H
86.9
189
|
L
 -21.2%
H
86.9
194.7
|
Jasper Therapeutics Inc |
|
82.5
|
5.5
|
L
 2.0%
H
5.4
5.6
|
L
 2.2%
H
5.0
5.6
|
L
 -9.7%
H
4.9
6.6
|
L
 -73.4%
H
4.6
23.0
|
L
 -78.1%
H
4.6
31.0
|
L
 78.2%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
Kineta Inc |
|
4.0
|
0.3
|
L
 6.5%
H
0.3
0.4
|
L
 -8.3%
H
0.3
0.4
|
L
 -34%
H
0.3
0.5
|
L
 -57.1%
H
0.3
0.8
|
L
 -38.9%
H
0.3
1.2
|
L
 -95.6%
H
0.3
17.4
|
L
 -99.8%
H
0.3
273
|
L
H
0.3
2888.2
|
Kala Pharmaceuticals Inc |
|
39.9
|
6.6
|
L
 -3.0%
H
6.5
6.9
|
L
 -7.1%
H
6.5
7.1
|
L
 -21.8%
H
6.4
8.4
|
L
 6.0%
H
5.7
11.2
|
L
 -13.0%
H
4.2
11.2
|
L
 -92.8%
H
3.5
97
|
L
 -98.0%
H
3.5
734
|
L
H
3.5
1337.5
|
KalVista Pharmaceuticals Inc |
|
622.7
|
12.6
|
L
 2.9%
H
12.0
12.6
|
L
 5.7%
H
11.5
12.9
|
L
 29.1%
H
9.6
12.9
|
L
 45.0%
H
7.3
12.9
|
L
 5.6%
H
7.3
15.5
|
L
 -13.1%
H
4.1
17.1
|
L
 78.2%
H
4.1
45
|
L
H
4.1
129.1
|
Kamada Ltd |
|
412.9
|
7.2
|
L
 -0.7%
H
7.1
7.3
|
L
 -3.1%
H
6.9
7.4
|
L
 -7.7%
H
6.5
8.0
|
L
 22.3%
H
5.7
9.2
|
L
 28.2%
H
4.7
9.2
|
L
 28.2%
H
3.7
9.2
|
L
 52.8%
H
3.7
13.3
|
L
 76.0%
H
3.1
13.3
|
Kiniksa Pharmaceuticals Lt... |
|
1,642.5
|
22.6
|
L
 2.0%
H
22.0
22.9
|
L
 5.1%
H
20.4
22.9
|
L
 14.5%
H
19.2
22.9
|
L
 11.9%
H
17.8
22.9
|
L
 13.1%
H
16.6
28.2
|
L
 138%
H
7.4
28.2
|
L
 45.7%
H
7.4
28.7
|
L
H
5.0
32.9
|
Kodiak Sciences Inc |
|
191.6
|
3.6
|
L
 5.5%
H
3.5
3.7
|
L
 0.6%
H
3.4
3.9
|
L
 -30.8%
H
3.4
5.5
|
L
 -57.0%
H
3.4
11.4
|
L
 -37.9%
H
2.2
11.6
|
L
 -50%
H
1.4
12.8
|
L
 -93.2%
H
1.4
171.2
|
L
H
1.4
171.2
|
Kiora Pharmaceuticals Inc |
|
9.7
|
3.2
|
L
 -0.3%
H
3.2
3.3
|
L
 -0.3%
H
3.1
3.3
|
L
 -10.5%
H
2.9
3.8
|
L
 -5.5%
H
2.9
4.1
|
L
 406.3%
H
0.4
5.6
|
L
 -86.2%
H
0.4
39.2
|
L
 -98.1%
H
0.4
327.2
|
L
 -99.9%
H
0.4
21000
|
Karyopharm Therapeutics Inc |
|
56.8
|
6.8
|
L
 -2.7%
H
6.8
7.2
|
L
 -2.0%
H
6.8
8.5
|
L
 -27.0%
H
0.6
10.4
|
L
 -35.7%
H
0.6
12.5
|
L
 -70.2%
H
0.6
24.8
|
L
 -92.8%
H
0.6
129.5
|
L
 -97.6%
H
0.6
389.7
|
L
 -98.4%
H
0.6
534.8
|
Kiromic BioPharma Inc |
|
3.1
|
1.2
|
L
 -2.5%
H
1.2
1.2
|
L
 7.3%
H
1.1
1.3
|
L
 -22%
H
1.1
1.9
|
L
 23.2%
H
0.8
1.9
|
L
 -21.0%
H
0.8
3.7
|
L
 -94.5%
H
0.2
27.1
|
L
H
0.2
555
|
L
H
0.2
555
|
Kronos Bio Inc |
|
56.7
|
0.9
|
L
 2.2%
H
0.9
1.0
|
L
 -2.1%
H
0.9
1.0
|
L
 -7.8%
H
0.9
1.0
|
L
 -4.1%
H
0.9
1.1
|
L
 -19.0%
H
0.7
1.6
|
L
 -86.8%
H
0.7
8.4
|
L
H
0.7
39.6
|
L
H
0.7
39.6
|
Keros Therapeutics Inc |
|
469.7
|
11.6
|
L
 1.0%
H
11.5
11.8
|
L
 1.8%
H
10.6
11.9
|
L
 12.2%
H
10.3
12.3
|
L
 -38.6%
H
9.8
19.7
|
L
 -82.8%
H
9.8
72.4
|
L
 -77.2%
H
9.8
73
|
L
H
9.8
88.8
|
L
H
9.8
88.8
|
Krystal Biotech Inc |
|
5,167.2
|
179.4
|
L
 1.1%
H
175.2
180.3
|
L
 -0.3%
H
175.0
187.1
|
L
 17.1%
H
148
190
|
L
 9.6%
H
141.7
190
|
L
 3.7%
H
141.7
219.3
|
L
 189.2%
H
47.7
219.3
|
L
 305.7%
H
33.1
219.3
|
L
H
8.0
219.3
|
TuHURA Biosciences Inc. |
|
96.5
|
2.3
|
L
 15.2%
H
2
2.3
|
L
 9.1%
H
1.8
2.3
|
L
 -45.6%
H
1.8
4.2
|
L
 -53.8%
H
1.8
5.5
|
L
 -30.7%
H
0.2
14.6
|
L
 -99.6%
H
0.2
1470
|
L
 -99.7%
H
0.2
5862.5
|
L
 -100.0%
H
0.2
190225
|
Pasithea Therapeutics Corp |
|
1.4
|
1.1
|
L
 6.7%
H
1.0
1.1
|
L
 -6.7%
H
1.0
1.2
|
L
 -23.5%
H
0.9
1.5
|
L
 -58.1%
H
0.9
3.9
|
L
 -84.1%
H
0.9
9.3
|
L
 -10.5%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
Kura Oncology Inc |
|
576.6
|
7.1
|
L
 -1.9%
H
7.0
7.5
|
L
 -5.2%
H
6.8
7.9
|
L
 -13.8%
H
6.8
8.6
|
L
 -25.9%
H
6.8
10.0
|
L
 -68.0%
H
6.8
23.5
|
L
 -52.7%
H
6.8
24.2
|
L
 -20.3%
H
6.4
43
|
L
H
2.5
43
|
Kymera Therapeutics Inc |
|
2,232.1
|
34.4
|
L
 2.8%
H
33.6
35.0
|
L
 4.5%
H
31.5
35.5
|
L
 -6.8%
H
29.1
38.9
|
L
 -16.5%
H
29.1
45.3
|
L
 -15.3%
H
29.1
53.3
|
L
 -3.6%
H
9.6
53.3
|
L
H
9.6
91.9
|
L
H
9.6
91.9
|
Kezar Life Sciences Inc |
|
42.8
|
5.9
|
L
 0.7%
H
5.8
6.1
|
L
 -3.8%
H
5.7
6.2
|
L
 -0.3%
H
5.5
6.6
|
L
 -13.0%
H
5.5
7.0
|
L
 -33.3%
H
0.7
10.4
|
L
 -95.8%
H
0.7
185.5
|
L
 -82.0%
H
0.7
185.5
|
L
H
0.7
363.3
|
Kazia Therapeutics Limited... |
|
5.6
|
1
|
L
 4.2%
H
0.9
1.0
|
L
 -15.3%
H
0.9
1.2
|
L
 12.4%
H
0.8
1.4
|
L
 -71.8%
H
0.8
4.2
|
L
 -55.4%
H
0.5
15.8
|
L
 -98.3%
H
0.5
86.1
|
L
 -97.4%
H
0.5
158.5
|
L
 -99.2%
H
0.5
378.5
|
Lexaria Bioscience Corp |
|
23.7
|
1.4
|
L
 2.3%
H
1.3
1.4
|
L
 -6.9%
H
1.3
1.5
|
L
 -15.6%
H
1.2
1.7
|
L
 -40.8%
H
1.2
2.4
|
L
 -65.4%
H
1.2
4.4
|
L
 -57.0%
H
0.7
6.9
|
L
 -85.5%
H
0.7
15.6
|
L
 -42.6%
H
0.7
76.2
|
Lifecore Biomedical Inc |
|
239.6
|
6.5
|
L
 1.7%
H
6.2
6.5
|
L
 4.7%
H
6
6.6
|
L
 6.2%
H
5.4
6.6
|
L
 -11.9%
H
5.4
7.8
|
L
 -12.3%
H
3.7
8.0
|
L
 -44.1%
H
1.5
12.0
|
L
 -32.8%
H
1.5
12.9
|
L
 -54.0%
H
1.5
15.6
|
Lifevantage Corporation |
|
213.7
|
17.0
|
L
 0.7%
H
16.5
17.4
|
L
 10.6%
H
15.1
17.4
|
L
 -8.2%
H
14.9
19.3
|
L
 12.3%
H
14.9
27.4
|
L
 143.3%
H
5.2
27.4
|
L
 253.3%
H
3.0
27.4
|
L
 76.8%
H
3.0
27.4
|
L
 208.0%
H
1.4
27.4
|
Ligand Pharmaceuticals, In... |
|
2,044.7
|
106.2
|
L
 0.5%
H
105.2
109.3
|
L
 -7.5%
H
103.4
112.8
|
L
 -11.5%
H
103.4
123.5
|
L
 -9.2%
H
102.8
124.0
|
L
 49.4%
H
67.7
129.9
|
L
 57.4%
H
46.8
129.9
|
L
 102.1%
H
36.9
141.8
|
L
 119.4%
H
36.9
179.8
|
Longeveron Inc - Ordinary ... |
|
25.2
|
1.7
|
L
 3.1%
H
1.6
1.7
|
L
 11.9%
H
1.4
1.8
|
L
 1.2%
H
1.2
1.9
|
L
 -7.7%
H
1.2
2.2
|
L
 -62.4%
H
0.8
43.0
|
L
 -97.2%
H
0.8
167.7
|
L
H
0.8
450
|
L
H
0.8
450
|
Atyr Pharma Inc |
|
333.3
|
4.0
|
L
 -0.5%
H
3.7
4.3
|
L
 16.4%
H
3.0
4.3
|
L
 16.4%
H
2.7
4.7
|
L
 29.7%
H
2.7
4.7
|
L
 99.5%
H
1.4
4.7
|
L
 -16.4%
H
1.1
6.6
|
L
 48.1%
H
1.1
13.1
|
L
H
1.1
396.1
|
Lipella Pharmaceuticals Inc |
|
2.6
|
2.2
|
L
 -1.8%
H
2.0
2.3
|
L
 -6.1%
H
2.0
2.4
|
L
 -44.6%
H
2.0
3.9
|
L
 -17.6%
H
2.0
7.3
|
L
 -65.5%
H
2.0
12
|
L
H
0
61.8
|
L
H
0
61.8
|
L
H
0
61.8
|
Lixte Biotechnology Holdin... |
|
3.2
|
1.2
|
L
 0.8%
H
1.1
1.3
|
L
 0.8%
H
1.0
1.3
|
L
 -16.6%
H
1.0
1.6
|
L
 -38.9%
H
1.0
3
|
L
 -47.6%
H
1.0
4.4
|
L
 -89%
H
1.0
49.5
|
L
 -97.7%
H
1.0
78.6
|
L
 -91.9%
H
1.0
110.4
|
Lipocine Inc |
|
17.9
|
3.4
|
L
 1.5%
H
3.2
3.4
|
L
 -2.6%
H
3.0
3.4
|
L
 -7.7%
H
2.9
3.7
|
L
 -33.3%
H
2.9
5.5
|
L
 -27.2%
H
2.9
11.8
|
L
 -86.5%
H
2.3
32.1
|
L
 -46.1%
H
2.3
41.1
|
L
 -97.0%
H
2.3
326.9
|
Leap Therapeutics Inc |
|
15.3
|
0.4
|
L
 2.6%
H
0.4
0.4
|
L
 -9.1%
H
0.4
0.5
|
L
 -20%
H
0.4
0.5
|
L
 -86.4%
H
0.4
3.6
|
L
 -81.9%
H
0.4
4.8
|
L
 -97.6%
H
0.4
19.5
|
L
 -97.3%
H
0.4
41.7
|
L
H
0.4
102.5
|
Liquidia Corp |
|
1,221.3
|
14.4
|
L
 2.9%
H
14.1
14.5
|
L
 -2.6%
H
13.5
14.6
|
L
 -10.9%
H
13.5
16.8
|
L
 32.1%
H
10.4
16.8
|
L
 -9.3%
H
8.3
17.0
|
L
 133.9%
H
3.3
17.0
|
L
 260.8%
H
2.3
17.0
|
L
H
2.3
38.5
|
Larimar Therapeutics Inc |
|
165.3
|
2.6
|
L
 -0.8%
H
2.6
2.7
|
L
 -14.5%
H
2.5
3.1
|
L
 -22.5%
H
2.5
3.5
|
L
 -57.5%
H
2.5
5.2
|
L
 -70.2%
H
2.5
11.2
|
L
 -38.3%
H
1.5
13.7
|
L
 -74.3%
H
1.5
25.9
|
L
 -99.5%
H
1.5
664.3
|
Lisata Therapeutics Inc |
|
20.6
|
2.4
|
L
 3.0%
H
2.4
2.4
|
L
 1.3%
H
2.1
2.6
|
L
 -4.8%
H
2.1
2.7
|
L
 -7.4%
H
2.1
4.2
|
L
 -22.4%
H
2.1
4.2
|
L
 -74.9%
H
2.0
11.9
|
L
 -91.3%
H
2.0
73.4
|
L
 -99.6%
H
2.0
637.5
|
Lantern Pharma Inc |
|
41.0
|
3.8
|
L
 1.6%
H
3.6
3.9
|
L
 3.8%
H
3.4
3.9
|
L
 -24.2%
H
3.4
5.2
|
L
 15.2%
H
3.0
6.1
|
L
 -56.3%
H
2.8
12.0
|
L
 -37.7%
H
2.4
12.0
|
L
H
2.4
24.8
|
L
H
2.4
24.8
|
LAVA Therapeutics NV |
|
34.2
|
1.3
|
L
 -2.3%
H
1.3
1.4
|
L
 -9.7%
H
1.3
1.4
|
L
 38.3%
H
0.9
1.5
|
L
 17.1%
H
0.9
1.5
|
L
 -55.9%
H
0.9
4.2
|
L
 -70.2%
H
0.9
7.4
|
L
H
0.9
17.2
|
L
H
0.9
17.2
|
Lexicon Pharmaceuticals Inc |
|
133.8
|
0.4
|
L
 2.8%
H
0.4
0.4
|
L
 -5.1%
H
0.3
0.4
|
L
 -52.6%
H
0.3
1.0
|
L
 -54.3%
H
0.3
1.1
|
L
 -85.8%
H
0.3
2.6
|
L
 -81.0%
H
0.3
3.8
|
L
 -81.8%
H
0.3
9.7
|
L
 -95.2%
H
0.3
19.6
|
Lyell Immunopharma Inc |
|
171.2
|
0.6
|
L
 -4.9%
H
0.6
0.6
|
L
 -21.6%
H
0.6
0.7
|
L
 -4.9%
H
0.6
0.8
|
L
 -13.4%
H
0.5
0.8
|
L
 -73.2%
H
0.5
3.1
|
L
 -90.3%
H
0.5
8.7
|
L
H
0.5
19.8
|
L
H
0.5
19.8
|
Lyra Therapeutics Inc |
|
11.1
|
0.2
|
L
 -5.6%
H
0.2
0.2
|
L
 -10.5%
H
0.2
0.2
|
L
 -19.1%
H
0.2
0.2
|
L
 -5.6%
H
0.2
0.2
|
L
 -97.1%
H
0.2
6.8
|
L
 -95.8%
H
0.2
8.2
|
L
H
0.2
22
|
L
H
0.2
22
|
Legend Biotech Corp - ADR |
|
6,831.7
|
37.2
|
L
 -2.2%
H
36.5
38.7
|
L
 5.5%
H
33.8
38.8
|
L
 2.1%
H
32.8
40
|
L
 5.5%
H
30.2
40
|
L
 -41.9%
H
30.2
65.5
|
L
 4.4%
H
30.2
77.3
|
L
H
23.4
77.3
|
L
H
23.4
77.3
|
LianBio - ADR |
|
20.5
|
0.2
|
L
 -5%
H
0.2
0.2
|
L
 -5%
H
0.2
0.2
|
L
H
0.2
0.3
|
L
 -29.6%
H
0.2
0.3
|
L
 -45.7%
H
0.2
0.4
|
L
 -93.2%
H
0.2
6.2
|
L
H
0.2
16.4
|
L
H
0.2
16.4
|
Mustang Bio Inc |
|
3.9
|
1.4
|
L
 0.7%
H
1.4
1.5
|
L
 -4.7%
H
1.4
1.6
|
L
 -49.6%
H
1.4
3.1
|
L
 -85.4%
H
0.1
21.9
|
L
 -97.0%
H
0.1
67
|
L
 -99.8%
H
0.1
877.5
|
L
 -99.9%
H
0.1
3915
|
L
H
0.1
10012.5
|
Microbot Medical Inc |
|
53.5
|
1.5
|
L
 6.9%
H
1.5
1.6
|
L
 6.2%
H
1.3
1.6
|
L
 -22.6%
H
1.3
2.1
|
L
 54%
H
0.9
3.4
|
L
 38.7%
H
0.8
3.4
|
L
 -68.8%
H
0.8
6.8
|
L
 -69.1%
H
0.8
12.2
|
L
 -99.9%
H
0.8
2041.2
|
Moleculin Biotech Inc |
|
13.6
|
1.1
|
L
 -2.6%
H
1.1
1.2
|
L
 0.9%
H
1.1
1.3
|
L
 -48.2%
H
0.9
2.2
|
L
 -51.3%
H
0.4
3.7
|
L
 -84.8%
H
0.4
132.8
|
L
 -94.1%
H
0.4
132.8
|
L
 -97.2%
H
0.4
177.3
|
L
H
0.4
862.2
|
Seres Therapeutics Inc |
|
117.8
|
0.7
|
L
 7.8%
H
0.6
0.7
|
L
 -10.4%
H
0.6
0.8
|
L
 -16.9%
H
0.6
0.9
|
L
 -21.6%
H
0.6
1
|
L
 -12.7%
H
0.5
1.5
|
L
 -90.0%
H
0.5
9.5
|
L
 -78.6%
H
0.5
38.5
|
L
H
0.5
52
|
Madrigal Pharmaceuticals Inc |
|
7,691.7
|
348.4
|
L
 7.8%
H
326.7
348.4
|
L
 5.1%
H
315.0
348.4
|
L
 3.3%
H
299.6
377.5
|
L
 14.4%
H
266.4
377.5
|
L
 28.8%
H
189
377.5
|
L
 287.1%
H
57.2
377.5
|
L
 323.9%
H
52.3
377.5
|
L
 329.0%
H
5.3
377.5
|
MediWound Ltd |
|
200.0
|
18.5
|
L
 1.7%
H
18.2
18.6
|
L
 9.5%
H
16
18.6
|
L
 -1.2%
H
15.8
19.1
|
L
 7.2%
H
15.8
20.6
|
L
 15.9%
H
12.8
24
|
L
 37.9%
H
7.1
24
|
L
 25.5%
H
7.1
43.5
|
L
 -65.9%
H
7.1
73.3
|
23andMe Holding Co - Ordin... |
|
51.5
|
1.9
|
L
 5.5%
H
1.8
2
|
L
 28.9%
H
1.4
2
|
L
 -24.7%
H
1.3
3.0
|
L
 -42.7%
H
1.3
4.2
|
L
 -78.4%
H
0.3
12.8
|
L
 -97.2%
H
0.3
126.2
|
L
H
0.3
363.2
|
L
H
0.3
363.2
|
MEI Pharma Inc |
|
15.4
|
2.3
|
L
 0.4%
H
2.3
2.3
|
L
 -3.8%
H
2.3
2.5
|
L
 -14.1%
H
2.3
2.8
|
L
 -14.4%
H
2.3
2.9
|
L
 -39.7%
H
2.3
4.2
|
L
 -93.2%
H
2.3
38.8
|
L
 -88.8%
H
2.3
91.5
|
L
 -98.1%
H
2.3
130
|
Macrogenics Inc |
|
139.3
|
2.2
|
L
 0.9%
H
2.2
2.3
|
L
 -2.2%
H
2.2
2.5
|
L
 -13.3%
H
2.2
3.0
|
L
 -30.6%
H
2.2
3.6
|
L
 -86.1%
H
2.2
19.5
|
L
 -73.0%
H
2.1
21.9
|
L
 -64.5%
H
2.1
36.5
|
L
 -93.6%
H
2.1
39.9
|
Mangoceuticals Inc |
|
19.4
|
3.9
|
L
 -3.2%
H
3.9
4.0
|
L
 -26.0%
H
3.9
5.2
|
L
 -19.2%
H
3.6
6.2
|
L
 49.8%
H
2.1
6.2
|
L
 2072.2%
H
0.2
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
MeiraGTx Holdings plc |
|
614.3
|
7.8
|
L
 -5.6%
H
7.7
8.8
|
L
 22.1%
H
5.8
8.8
|
L
 16.3%
H
5.8
8.8
|
L
 27.3%
H
5.6
8.8
|
L
 22.7%
H
3.9
8.8
|
L
 -42.8%
H
3.5
15.2
|
L
 -39.8%
H
3.5
24.9
|
L
H
3.5
30.2
|
Mirum Pharmaceuticals Inc |
|
2,170.3
|
44.3
|
L
 -0.6%
H
43.8
45.9
|
L
 1.9%
H
42.0
46.0
|
L
 -11.5%
H
42.0
54.2
|
L
 4.3%
H
40.0
54.2
|
L
 65.4%
H
23.1
54.2
|
L
 104.5%
H
17.3
54.2
|
L
 249.2%
H
9.1
54.2
|
L
H
6.5
54.2
|
Milestone Pharmaceuticals Inc |
|
115.7
|
2.2
|
L
 6.9%
H
2.1
2.2
|
L
 17.9%
H
1.8
2.2
|
L
 -4.4%
H
1.5
2.3
|
L
 22.6%
H
1.5
2.5
|
L
 49.7%
H
1.1
2.5
|
L
 -57.8%
H
1.1
9.9
|
L
 -86.2%
H
1.1
17.0
|
L
H
1.1
28.0
|
MoonLake Immunotherapeutic... |
|
2,439.5
|
38.6
|
L
 1.9%
H
37.8
39.2
|
L
 1.3%
H
36.5
39.8
|
L
 -10.8%
H
36.5
44.6
|
L
 -24.9%
H
36.5
56.9
|
L
 -18.4%
H
36.5
56.9
|
L
 288.2%
H
4.3
65.0
|
L
H
4.3
65.0
|
L
H
4.3
65.0
|
Mineralys Therapeutics Inc |
|
894.9
|
14.3
|
L
 5.6%
H
13.5
14.4
|
L
 35.5%
H
12.6
18.3
|
L
 39.2%
H
8.2
18.3
|
L
 19.8%
H
8.2
18.3
|
L
 12.3%
H
8.2
18.3
|
L
H
5.9
22.0
|
L
H
5.9
22.0
|
L
H
5.9
22.0
|
Mannkind Corp |
|
1,578.7
|
5.2
|
L
 1.0%
H
5.2
5.3
|
L
 4.4%
H
4.8
5.3
|
L
 -4.1%
H
4.8
5.9
|
L
 -20.5%
H
4.8
7.1
|
L
 16.3%
H
4.0
7.6
|
L
 54.3%
H
2.6
7.6
|
L
 447.4%
H
0.8
7.6
|
L
 -81.1%
H
0.7
36.6
|
Mind Medicine Inc |
|
478.6
|
6.4
|
L
 0.6%
H
6.2
6.7
|
L
 -7.0%
H
6.0
6.8
|
L
 -35.8%
H
5.8
10.4
|
L
 -9.5%
H
5.8
10.4
|
L
 -30.8%
H
5.0
12.2
|
L
 -58.9%
H
2.1
20.0
|
L
 56.0%
H
2.1
86.6
|
L
H
0.0
154.8
|
Medicinova Inc |
|
76.0
|
1.6
|
L
 5.4%
H
1.5
1.6
|
L
 -2.5%
H
1.5
1.6
|
L
 -21.3%
H
1.5
2
|
L
 -26.2%
H
1.5
2.2
|
L
 19.2%
H
1.1
2.6
|
L
 -32.6%
H
1.1
3.2
|
L
 -61.5%
H
1.1
13.3
|
L
 -53.9%
H
1.1
14.5
|
Monopar Therapeutics Inc |
|
181.6
|
29.8
|
L
 0.9%
H
29.8
31.0
|
L
 4.6%
H
27.2
34.1
|
L
 -31.0%
H
27.2
45.6
|
L
 17.2%
H
21
54.1
|
L
 812.6%
H
1.7
54.1
|
L
 119.6%
H
1.4
54.1
|
L
 -7.2%
H
1.4
85.1
|
L
H
1.4
240
|
Marker Therapeutics Inc |
|
13.3
|
1.2
|
L
 5.1%
H
1.2
1.3
|
L
 -17.3%
H
1.1
2.0
|
L
 -27.9%
H
1.1
2.1
|
L
 -69.5%
H
1.1
6.0
|
L
 -72.0%
H
1.1
6.0
|
L
 -69%
H
0.7
9.7
|
L
 -92.4%
H
0.7
37.7
|
L
 -95.0%
H
0.7
205.2
|
Moderna Inc |
|
13,384.9
|
34.6
|
L
 0.9%
H
34.2
35.8
|
L
 -2.8%
H
32.6
38.1
|
L
 4.9%
H
29.4
38.1
|
L
 -17.2%
H
29.3
48.1
|
L
 -66.7%
H
29.3
170.5
|
L
 -76.6%
H
29.3
217.3
|
L
 62.5%
H
22.2
497.5
|
L
H
11.5
497.5
|
Mersana Therapeutics Inc |
|
57.3
|
0.5
|
L
 2.2%
H
0.5
0.5
|
L
 -14.8%
H
0.5
0.5
|
L
 -20.7%
H
0.5
0.6
|
L
 -78.6%
H
0.5
2.2
|
L
 -90.9%
H
0.5
5.1
|
L
 -88.2%
H
0.5
9.6
|
L
 -92.6%
H
0.5
29.1
|
L
H
0.5
29.1
|
Merus N.V |
|
3,254.2
|
47.1
|
L
 -1.1%
H
46.7
49.3
|
L
 2.2%
H
45.0
49.9
|
L
 17.2%
H
40.5
49.9
|
L
 10.0%
H
37.8
49.9
|
L
 7.3%
H
37.8
61.6
|
L
 79.8%
H
12.0
61.6
|
L
 189.5%
H
10.2
61.6
|
L
H
7.3
61.6
|
Maravai LifeSciences Holdi... |
|
347.5
|
2.5
|
L
 1.2%
H
2.4
2.5
|
L
 -17.2%
H
2.4
3.0
|
L
 -41.7%
H
2.4
4.4
|
L
 -56.4%
H
2.4
6.2
|
L
 -68.2%
H
2.4
11.6
|
L
 -93.6%
H
2.4
41.8
|
L
H
2.4
63.6
|
L
H
2.4
63.6
|
Mannatech Inc |
|
19.3
|
10.2
|
L
 -2.1%
H
10
10.5
|
L
 -12.0%
H
10
12.1
|
L
 -13.3%
H
10
12.3
|
L
 -1.9%
H
9.7
16.5
|
L
 13.5%
H
6.8
16.5
|
L
 -68.5%
H
6.8
38.3
|
L
 2.2%
H
6.5
49.1
|
L
 -43.4%
H
6.5
49.1
|
MaxCyte Inc |
|
348.8
|
3.3
|
L
 7.5%
H
3.0
3.3
|
L
 -6.3%
H
2.8
3.5
|
L
 -21.1%
H
2.8
4.2
|
L
 -23.1%
H
2.8
5.2
|
L
 -23.7%
H
2.8
5.3
|
L
 -37.5%
H
2.5
7.8
|
L
 101.8%
H
2.5
17.4
|
L
H
1.6
17.4
|
TNF Pharmaceuticals Inc. |
|
1.0
|
0.4
|
L
 5.7%
H
0.3
0.4
|
L
H
0.3
0.4
|
L
 -35.1%
H
0.3
0.7
|
L
 -67.8%
H
0.3
1.6
|
L
 -87.2%
H
0.3
3.5
|
L
 -88.9%
H
0.1
6.2
|
L
 -90.5%
H
0.1
17.7
|
L
 -100.0%
H
0.1
2027.5
|
Mainz Biomed N.V. |
|
9.7
|
4.4
|
L
 -7.8%
H
4.2
4.8
|
L
 -22.3%
H
4.1
5.5
|
L
 -27.8%
H
4.1
6.3
|
L
 -16.2%
H
3.7
8.2
|
L
 -89.5%
H
3.7
45.2
|
L
 -99.2%
H
3.7
712.4
|
L
H
3.7
1200
|
L
H
3.7
1200
|
Mesoblast Ltd - ADR |
|
1,720.8
|
13.6
|
L
 2.0%
H
13.1
13.6
|
L
 0.6%
H
12.4
14.0
|
L
 -24.3%
H
12.4
18.5
|
L
 15.2%
H
11.6
22
|
L
 457.6%
H
2.1
22
|
L
 210.1%
H
1.0
22
|
L
 158.1%
H
1.0
22
|
L
 -7.6%
H
1.0
22
|
Molecular Partners AG - ADR |
|
159.7
|
4.3
|
L
 -1.4%
H
4.3
4.4
|
L
 -13.6%
H
4.3
4.8
|
L
 -9.8%
H
4.3
5.1
|
L
 -20.3%
H
4.3
5.9
|
L
 9.3%
H
3.3
12.7
|
L
 -78.9%
H
3.3
22.0
|
L
 -69.7%
H
3.3
32.0
|
L
 -81.2%
H
3.3
38.8
|
Mereo Biopharma Group Plc ... |
|
406.5
|
2.6
|
L
 4.8%
H
2.5
2.7
|
L
 5.2%
H
2.4
2.7
|
L
 -8.7%
H
2.3
3.0
|
L
 -30.0%
H
2.3
3.8
|
L
 -15.8%
H
2.3
5.0
|
L
 101.5%
H
0.3
5.0
|
L
 138.2%
H
0.3
5.0
|
L
H
0.3
8.5
|
Natural Alternatives Inter... |
|
21.7
|
3.5
|
L
 -2.2%
H
3.5
3.5
|
L
 -8.9%
H
3.3
3.8
|
L
 -15.7%
H
3.3
4.2
|
L
 -18.6%
H
3.3
4.4
|
L
 -38.2%
H
3.3
7.3
|
L
 -67.2%
H
3.3
12.6
|
L
 -42.9%
H
3.3
19.9
|
L
 -36.6%
H
3.3
19.9
|
NewAmsterdam Pharma Compan... |
|
2,566.4
|
23.4
|
L
 -0.9%
H
22.8
24
|
L
 -1.8%
H
22.2
24
|
L
 17.4%
H
17.2
24.2
|
L
 -6.5%
H
17.2
26.9
|
L
 6.1%
H
15.2
27.3
|
L
 138.2%
H
5.6
32.9
|
L
H
5.6
32.9
|
L
H
5.6
32.9
|
Nature`s Sunshine Products... |
|
240.5
|
13.0
|
L
 -3.3%
H
12.9
13.5
|
L
 -10.7%
H
12.9
15.3
|
L
 -10.3%
H
12.9
15.3
|
L
 -16.7%
H
12.9
15.8
|
L
 -35.3%
H
10.8
21.4
|
L
 -23.4%
H
7.9
21.7
|
L
 74.4%
H
5.5
21.7
|
L
 4.7%
H
5.5
21.7
|
Nautilus Biotechnology Inc |
|
140.0
|
1.1
|
L
 4.7%
H
1.1
1.2
|
L
 -7.5%
H
1.1
1.3
|
L
 -35.1%
H
1.1
1.8
|
L
 -43.1%
H
1.1
2.1
|
L
 -56.6%
H
1.1
3.1
|
L
 -69.8%
H
1.1
5.1
|
L
H
1.1
25.9
|
L
H
1.1
25.9
|
Neurocrine Biosciences, Inc. |
|
11,042.2
|
110.8
|
L
 1.6%
H
108.0
111.3
|
L
 -2.0%
H
105.2
113.9
|
L
 -3.7%
H
105.2
122.4
|
L
 -12.6%
H
105.2
154.6
|
L
 -20.4%
H
105.2
158.0
|
L
 21.6%
H
75.3
158.0
|
L
 29.8%
H
71.9
158.0
|
L
 170.4%
H
31.3
158.0
|
Minerva Neurosciences Inc |
|
10.8
|
1.5
|
L
 -4.9%
H
1.5
1.7
|
L
 -6.1%
H
1.5
1.7
|
L
 -21.8%
H
1.4
2.1
|
L
 -26.7%
H
1.4
2.7
|
L
 -44.8%
H
1.4
3.7
|
L
 -71.3%
H
1.3
15.3
|
L
 -96.9%
H
1.3
121.7
|
L
 -96.3%
H
1.3
126.7
|
Neximmune Inc |
|
-
|
0
|
L
H
|
L
H
|
L
 -100%
H
0.1
|
L
 -100%
H
0.4
|
L
 -100%
H
7.1
|
L
 -100%
H
122.8
|
L
H
700
|
L
H
700
|
Nektar Therapeutics |
|
166.0
|
0.9
|
L
 9.8%
H
0.8
1.0
|
L
 2.3%
H
0.8
1.0
|
L
 -8.2%
H
0.8
1.1
|
L
 -10.9%
H
0.7
1.3
|
L
 4.7%
H
0.7
1.9
|
L
 -79.9%
H
0.4
6.4
|
L
 -94.6%
H
0.4
26.8
|
L
 -93.5%
H
0.4
111.4
|
Nkarta Inc |
|
117.1
|
1.7
|
L
 -3.5%
H
1.7
1.7
|
L
 -9.8%
H
1.7
1.9
|
L
 -24.9%
H
1.6
2.4
|
L
 -27.8%
H
1.6
2.7
|
L
 -86.4%
H
1.6
13.9
|
L
 -82.7%
H
1.3
20.4
|
L
H
1.3
79.2
|
L
H
1.3
79.2
|
NLS Pharmaceutics Ltd |
|
6.4
|
1.6
|
L
 3.3%
H
1.5
1.6
|
L
 -7.1%
H
1.5
1.8
|
L
 -30.1%
H
1.5
2.4
|
L
 -18.6%
H
1.5
3.4
|
L
 -87.2%
H
0.1
18.4
|
L
 -97.8%
H
0.1
75.2
|
L
H
0.1
294
|
L
H
0.1
294
|
MetaVia Inc. |
|
12.8
|
1.5
|
L
 -1.3%
H
1.5
1.5
|
L
 -4.5%
H
1.4
1.7
|
L
 -11.4%
H
1.3
1.8
|
L
 -32.4%
H
1.3
2.8
|
L
 -67.8%
H
1.3
5.3
|
L
 -93.6%
H
0.4
63.9
|
L
 -99.5%
H
0.4
891.3
|
L
H
0.4
16192.5
|
Nurix Therapeutics Inc |
|
1,031.3
|
13.6
|
L
 3.0%
H
13.1
13.6
|
L
 -2.0%
H
13.0
14.9
|
L
 -22.7%
H
13.0
18.1
|
L
 -32.7%
H
13.0
21.4
|
L
 3.9%
H
11.9
29.6
|
L
 1.1%
H
4.2
29.6
|
L
H
4.2
52.4
|
L
H
4.2
52.4
|
NeuroSense Therapeutics Ltd |
|
27.4
|
1.2
|
L
 5.4%
H
1.1
1.2
|
L
 4.4%
H
1.0
1.2
|
L
 1.7%
H
1.0
1.2
|
L
 26.9%
H
0.8
1.3
|
L
 -14.5%
H
0.5
2.3
|
L
 -15.7%
H
0.4
8.2
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
NRX Pharmaceuticals Inc |
|
39.8
|
2.4
|
L
 13.5%
H
2.1
2.4
|
L
 8.3%
H
2.0
2.4
|
L
 -17.5%
H
1.8
3.0
|
L
 95.8%
H
1.2
6.0
|
L
 -48.4%
H
1.1
54
|
L
 -92.4%
H
1.1
54
|
L
 -97.8%
H
1.1
769.9
|
L
H
1.1
769.9
|
Intellia Therapeutics Inc |
|
946.1
|
9.1
|
L
 -0.9%
H
9.0
9.6
|
L
 -11.7%
H
8.6
10.2
|
L
 -14.6%
H
8.3
12.8
|
L
 -29.2%
H
8.3
13.8
|
L
 -67.7%
H
8.3
28.5
|
L
 -84.3%
H
8.3
78.6
|
L
 -20.2%
H
8.3
202.7
|
L
H
8.3
202.7
|
Nuvalent Inc - Ordinary Sh... |
|
5,513.8
|
77.0
|
L
 3.4%
H
76
78.2
|
L
 8.4%
H
64.8
78.2
|
L
 -1.2%
H
64.8
83.6
|
L
 -11.3%
H
64.8
91.5
|
L
 -4.7%
H
61.8
113.5
|
L
 518.6%
H
7.1
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
Novavax, Inc. |
|
1,285.1
|
8.0
|
L
 -2.2%
H
8.0
8.5
|
L
 -4.2%
H
7.7
8.5
|
L
 -2.4%
H
7.0
8.6
|
L
 -12.3%
H
7.0
11.6
|
L
 51.0%
H
3.8
23.9
|
L
 -89.2%
H
3.5
85.6
|
L
 -5.0%
H
3.5
331.7
|
L
 -95.7%
H
3.5
331.7
|
Nuvectis Pharma Inc |
|
207.0
|
8.9
|
L
 6.0%
H
8.3
9.0
|
L
 27.7%
H
6.8
9.0
|
L
 13.5%
H
5.9
9.0
|
L
 88.3%
H
4.4
9.0
|
L
 -19.6%
H
4.4
11.9
|
L
 15.4%
H
4.4
20.9
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
Nextcure Inc |
|
19.3
|
0.7
|
L
 -4.2%
H
0.7
0.7
|
L
 -8%
H
0.7
0.8
|
L
 -9.2%
H
0.7
0.8
|
L
 -36.1%
H
0.7
1.1
|
L
 -52.4%
H
0.7
2.6
|
L
 -85.9%
H
0.7
5.4
|
L
 -97.9%
H
0.7
41.9
|
L
H
0.7
109
|
NuCana plc - ADR |
|
3.0
|
0.8
|
L
 -5%
H
0.8
0.8
|
L
 -14.6%
H
0.8
0.9
|
L
 -16.5%
H
0.8
1.1
|
L
 -40.2%
H
0.8
1.7
|
L
 -91.3%
H
0.2
10.8
|
L
 -96.4%
H
0.2
56
|
L
 -99.5%
H
0.2
195.8
|
L
H
0.2
800
|
Ocugen Inc |
|
157.7
|
0.5
|
L
H
0.5
0.6
|
L
 -11.5%
H
0.5
0.6
|
L
 -25%
H
0.5
0.8
|
L
 -37.2%
H
0.5
1
|
L
 -50%
H
0.5
2.1
|
L
 -80.1%
H
0.3
4.0
|
L
 74.2%
H
0.2
18.8
|
L
 -99.9%
H
0.2
659.4
|
Oculis Holding AG |
|
901.0
|
18.8
|
L
 0.4%
H
18.4
18.8
|
L
 -0.4%
H
17.5
19.3
|
L
 -13.1%
H
17.5
21.9
|
L
 9.8%
H
16.8
23.1
|
L
 65.1%
H
10.6
23.1
|
L
 93.1%
H
6.3
23.1
|
L
H
6.3
23.1
|
L
H
6.3
23.1
|
Ocular Therapeutix Inc |
|
1,227.7
|
7.7
|
L
 -2.0%
H
7.7
8.1
|
L
 2.4%
H
7.3
8.9
|
L
 6.0%
H
5.8
8.9
|
L
 -13.0%
H
5.8
9.2
|
L
 -18.4%
H
4.1
11.8
|
L
 50.8%
H
2
11.8
|
L
 62.9%
H
2
24.3
|
L
 -82.0%
H
2
44.2
|
Opus Genetics Inc. |
|
29.7
|
0.9
|
L
 1.1%
H
0.9
1.0
|
L
 -6%
H
0.9
1
|
L
 -16.8%
H
0.9
1.2
|
L
 -7.8%
H
0.9
1.5
|
L
 -50.5%
H
0.9
2.3
|
L
 -71.8%
H
0.9
6.6
|
L
 -85.5%
H
0.9
14.8
|
L
 -99.7%
H
0.9
390.2
|
Oncocyte Corporation |
|
107.0
|
3.7
|
L
 -3.4%
H
3.5
3.9
|
L
 -4.1%
H
3.3
4.8
|
L
 46.1%
H
2.3
4.8
|
L
 61.2%
H
1.9
4.8
|
L
 25.5%
H
1.9
4.8
|
L
 -83.7%
H
1.9
33.6
|
L
 -91.1%
H
1.9
131.4
|
L
H
1.9
204.8
|
OKYO Pharma Limited - Ordi... |
|
51.2
|
1.5
|
L
 1.3%
H
1.5
1.5
|
L
 5.6%
H
1.3
1.6
|
L
 37.3%
H
1.1
1.6
|
L
 42.5%
H
0.9
1.6
|
L
 2.0%
H
0.8
1.9
|
L
H
0.8
7
|
L
H
0.8
7
|
L
H
0.8
7
|
Olema Pharmaceuticals Inc |
|
327.4
|
4.4
|
L
 0.9%
H
4.4
4.6
|
L
 -4.3%
H
4.0
4.6
|
L
 -11.3%
H
4.0
5.3
|
L
 -29.9%
H
4.0
6.9
|
L
 -61.8%
H
4.0
16.6
|
L
 13.4%
H
2
17.8
|
L
H
2
60.3
|
L
H
2
60.3
|
Omeros Corporation |
|
487.9
|
8.4
|
L
 7.1%
H
7.9
8.5
|
L
 9.9%
H
7.0
8.5
|
L
 -8.3%
H
7.0
10.0
|
L
 10.4%
H
7.0
13.6
|
L
 130.7%
H
2.6
13.6
|
L
 44.9%
H
0.9
13.6
|
L
 -31.0%
H
0.9
25.5
|
L
 -66.6%
H
0.9
30.2
|
Omega Therapeutics Inc |
|
1.1
|
0.0
|
L
H
0.0
0.0
|
L
 100%
H
0.0
0.0
|
L
 -91.3%
H
0.0
0.3
|
L
 -97.9%
H
0.0
1.0
|
L
 -99.5%
H
0.0
3.8
|
L
 -99.8%
H
0.0
12.0
|
L
H
0.0
31.4
|
L
H
0.0
31.4
|
Oncternal Therapeutics Inc |
|
1.6
|
0.5
|
L
H
0.5
0.5
|
L
H
0.5
0.5
|
L
H
0.5
0.5
|
L
H
0.5
0.5
|
L
 -93.4%
H
0.5
9.9
|
L
 -62.7%
H
0.3
10.6
|
L
 -83.5%
H
0.3
10.6
|
L
 -99.0%
H
0.3
179.2
|
Oncolytics Biotech, Inc. |
|
53.6
|
0.6
|
L
H
0.6
0.6
|
L
 -10.1%
H
0.6
0.7
|
L
 -19.5%
H
0.6
0.8
|
L
 -23.5%
H
0.6
1.1
|
L
 -37.4%
H
0.6
1.5
|
L
 -59.2%
H
0.6
3.4
|
L
 -55.4%
H
0.6
4.8
|
L
 -91.7%
H
0.4
8.8
|
Traws Pharma Inc. |
|
10.0
|
2.7
|
L
 -0.7%
H
2.7
2.8
|
L
 -3.2%
H
2.6
3.0
|
L
 -55.9%
H
2.0
6.7
|
L
 -41.1%
H
2.0
19.4
|
L
 -86.8%
H
2.0
27.5
|
L
 -92.7%
H
2.0
51
|
L
 -97.7%
H
2.0
723.8
|
L
 -100.0%
H
2.0
225000
|
Organovo Holdings Inc |
|
8.6
|
0.4
|
L
 5%
H
0.4
0.4
|
L
 -6.7%
H
0.4
0.5
|
L
 7.7%
H
0.4
1.8
|
L
 5%
H
0.3
1.8
|
L
 -60%
H
0.3
1.8
|
L
 -89.0%
H
0.3
4.1
|
L
 -91.3%
H
0.3
23.9
|
L
 -99.6%
H
0.3
116.4
|
OptiNose Inc |
|
53.9
|
5.4
|
L
 -0.2%
H
5.3
5.5
|
L
 1.5%
H
5.3
5.6
|
L
 -10.7%
H
5.1
6.5
|
L
 -24.1%
H
0.4
7.4
|
L
 -81.0%
H
0.4
31.5
|
L
 -83.0%
H
0.4
64.5
|
L
 -92.7%
H
0.4
150
|
L
H
0.4
450
|
Orgenesis Inc |
|
17.9
|
3.5
|
L
 0.3%
H
3.0
3.6
|
L
 -15.6%
H
2.8
4.2
|
L
 124.7%
H
1.5
5.9
|
L
 239.2%
H
0.9
5.9
|
L
 -56.2%
H
0.4
10.8
|
L
 -87.9%
H
0.4
40.4
|
L
 -90%
H
0.4
83
|
L
 -95.5%
H
0.4
168
|
ORIC Pharmaceuticals Inc |
|
553.3
|
7.8
|
L
 1.2%
H
7.7
8.0
|
L
 -2.6%
H
7.2
8.1
|
L
 -6.8%
H
7.2
9.5
|
L
 -3.8%
H
7.2
14.7
|
L
 -48.4%
H
6.3
15.4
|
L
 27.3%
H
2.4
16.7
|
L
H
2.4
40.8
|
L
H
2.4
40.8
|
Oramed Pharmaceuticals, Inc |
|
96.3
|
2.4
|
L
H
2.4
2.4
|
L
 -7%
H
2.3
2.7
|
L
 -0.4%
H
2.0
2.7
|
L
 -3.2%
H
2.0
3.1
|
L
 -18.2%
H
2.0
3.1
|
L
 -73.1%
H
1.7
13.7
|
L
 -21.9%
H
1.7
31.5
|
L
 -45.6%
H
1.7
31.5
|
Outlook Therapeutics Inc |
|
50.3
|
1.6
|
L
 6.1%
H
1.5
1.6
|
L
 5.4%
H
1.4
1.6
|
L
 -16.0%
H
1.3
1.9
|
L
 6.1%
H
1.3
2.6
|
L
 -81.0%
H
0.9
12.9
|
L
 -99.8%
H
0.9
848
|
L
 -99.4%
H
0.9
1704
|
L
H
0.9
17568
|
Ovid Therapeutics Inc |
|
30.6
|
0.4
|
L
 -2.3%
H
0.4
0.5
|
L
 -17.3%
H
0.4
0.6
|
L
 -32.8%
H
0.4
0.7
|
L
 -58.3%
H
0.4
1.1
|
L
 -84.2%
H
0.4
3.5
|
L
 -86.3%
H
0.4
4.1
|
L
 -80.9%
H
0.4
9.4
|
L
H
0.4
15.9
|
Opthea Limited - ADR |
|
489.4
|
3.2
|
L
 3.6%
H
3.0
3.5
|
L
 -9.4%
H
3.0
3.5
|
L
 -39.0%
H
3.0
5.5
|
L
 -2.2%
H
3.0
6.3
|
L
 -7.8%
H
1.8
6.3
|
L
 -37.6%
H
1.6
8.5
|
L
 -83.5%
H
1.6
18.1
|
L
 116.3%
H
1.6
21.2
|
Phibro Animal Health Corp.... |
|
860.7
|
21.3
|
L
 3.7%
H
20.8
21.4
|
L
 -10.1%
H
20.3
23.6
|
L
 -17.5%
H
20.3
26.6
|
L
 -6.3%
H
19.7
26.6
|
L
 72.2%
H
12.1
26.6
|
L
 6.3%
H
9.4
26.6
|
L
 -4.0%
H
9.4
31
|
L
 -40.9%
H
9.4
54.6
|
Palisade Bio Inc |
|
3.0
|
1
|
L
 8.7%
H
1.0
1.1
|
L
 17.7%
H
0.8
1.1
|
L
 -3.9%
H
0.8
1.1
|
L
 -43.5%
H
0.8
2.6
|
L
 -81.5%
H
0.4
9.7
|
L
 -99.9%
H
0.4
1147.5
|
L
 -100.0%
H
0.4
12015
|
L
 -100.0%
H
0.4
3276000
|
Passage Bio Inc |
|
24.2
|
0.4
|
L
H
0.4
0.4
|
L
 -15.2%
H
0.4
0.5
|
L
 -30.4%
H
0.4
0.6
|
L
 -48.7%
H
0.4
1.0
|
L
 -74%
H
0.4
1.7
|
L
 -86.3%
H
0.4
3.6
|
L
 -97.5%
H
0.4
38.2
|
L
H
0.4
38.2
|
Paranovus Entertainment Te... |
|
93.6
|
1.4
|
L
 -0.7%
H
1.4
1.4
|
L
 -2.1%
H
1.4
1.4
|
L
 0.7%
H
1.3
1.5
|
L
 24.1%
H
1.0
1.5
|
L
 -25.3%
H
0.3
2.0
|
L
 -74.7%
H
0.3
7.4
|
L
 -98.1%
H
0.3
93
|
L
H
0.3
122
|
Panbela Therapeutics Inc. |
|
1.8
|
0.4
|
L
 -7.5%
H
0.4
0.4
|
L
 2.8%
H
0.4
0.4
|
L
 8.8%
H
0.3
0.5
|
L
 15.6%
H
0.3
0.5
|
L
 -38.3%
H
0.3
0.7
|
L
 -100.0%
H
0.3
52560
|
L
 -100.0%
H
0.3
240000
|
L
 -100.0%
H
0.3
384000
|
Puma Biotechnology Inc |
|
164.7
|
3.3
|
L
 -0.6%
H
3.3
3.5
|
L
 -5.4%
H
3.3
3.6
|
L
 16.1%
H
2.7
3.8
|
L
 15.3%
H
2.7
4.1
|
L
 -33.6%
H
2.2
6.1
|
L
 22.1%
H
1.6
7.7
|
L
 -56.4%
H
1.6
14.1
|
L
 -98.6%
H
1.6
252.9
|
Pacira BioSciences Inc |
|
1,058.3
|
22.9
|
L
 0.8%
H
22.2
23.0
|
L
 -2.1%
H
21.8
23.5
|
L
 -10.1%
H
21.8
26.9
|
L
 15.2%
H
18.2
27.6
|
L
 -22.2%
H
11.2
31.7
|
L
 -67.6%
H
11.2
82.2
|
L
 -34.8%
H
11.2
82.2
|
L
 -75.4%
H
11.2
99.5
|
Processa Pharmaceuticals Inc |
|
2.1
|
0.5
|
L
H
0.4
0.5
|
L
 -6.3%
H
0.4
0.5
|
L
 -25%
H
0.4
0.6
|
L
 -59.5%
H
0.4
1.1
|
L
 -79.5%
H
0.4
3.3
|
L
 -87.0%
H
0.2
5.9
|
L
 -95.4%
H
0.2
14.2
|
L
 -99.5%
H
0.2
83.3
|
Vaxcyte Inc |
|
9,576.0
|
74.4
|
L
 1.9%
H
72.9
75.0
|
L
 4.5%
H
67.2
76.5
|
L
 -11.5%
H
67.2
85.2
|
L
 -14.7%
H
67.2
93.8
|
L
 6.7%
H
58.1
121.1
|
L
 198.8%
H
17.4
121.1
|
L
H
15.5
121.1
|
L
H
15.5
121.1
|
PDS Biotechnology Corporation |
|
54.8
|
1.2
|
L
 -2.4%
H
1.2
1.3
|
L
H
1.2
1.3
|
L
 -21.2%
H
1.1
2.2
|
L
 -33.2%
H
1.1
2.2
|
L
 -74.9%
H
1.1
5
|
L
 -77.5%
H
1.1
13.7
|
L
 38.2%
H
0.6
17.9
|
L
H
0.6
517.4
|
PepGen Inc |
|
78.5
|
2.4
|
L
 6.7%
H
2.2
2.4
|
L
 4.4%
H
2.0
2.7
|
L
 89.0%
H
1.3
4.5
|
L
 -48.7%
H
1.2
4.7
|
L
 -84.5%
H
1.2
19.3
|
L
H
1.2
20
|
L
H
1.2
20
|
L
H
1.2
20
|
Precigen Inc |
|
527.2
|
1.8
|
L
 3.5%
H
1.7
1.8
|
L
 -3.2%
H
1.7
1.9
|
L
 -8.2%
H
1.6
2.2
|
L
 164.7%
H
0.7
2.2
|
L
 25.9%
H
0.7
2.2
|
L
 -7.2%
H
0.7
2.9
|
L
 -10.4%
H
0.7
11.1
|
L
 -96.1%
H
0.7
69.5
|
Phathom Pharmaceuticals Inc |
|
307.1
|
4.4
|
L
 4.5%
H
4.1
4.5
|
L
 -12.9%
H
4.1
5.3
|
L
 -23.6%
H
4.1
7.0
|
L
 -44.1%
H
4.1
8.6
|
L
 -48.1%
H
4.1
19.7
|
L
 -61.8%
H
4.1
19.7
|
L
 -85.9%
H
4.1
64.5
|
L
H
4.1
64.5
|
Phio Pharmaceuticals Corp |
|
6.2
|
1.3
|
L
 -3.0%
H
1.3
1.4
|
L
 -0.8%
H
1.2
1.4
|
L
 -28.7%
H
1.2
1.8
|
L
 -54.1%
H
1.2
9.8
|
L
 -84.9%
H
0.6
10.0
|
L
 -98.5%
H
0.6
261.4
|
L
 -99.4%
H
0.6
699.8
|
L
 -100.0%
H
0.6
754380
|
Pharvaris NV |
|
904.1
|
16.7
|
L
 -1.4%
H
16.3
17.2
|
L
 11.1%
H
14.5
18.0
|
L
 -3.5%
H
14.1
18.0
|
L
 -9.4%
H
14.1
19.9
|
L
 -28.6%
H
14.1
26.6
|
L
 -3.9%
H
1.8
33
|
L
H
1.8
42.9
|
L
H
1.8
42.9
|
Pliant Therapeutics Inc |
|
94.3
|
1.5
|
L
 1.3%
H
1.5
1.6
|
L
 -4.9%
H
1.4
1.7
|
L
 -49.3%
H
1.3
3.5
|
L
 -88.4%
H
1.3
15
|
L
 -89.9%
H
1.3
16.5
|
L
 -79.6%
H
1.3
36.6
|
L
H
1.3
43.9
|
L
H
1.3
43.9
|
Pluri Inc |
|
32.3
|
4.6
|
L
 -1.3%
H
4.5
4.6
|
L
 -2.3%
H
4.5
4.7
|
L
 -0.2%
H
4.3
5.0
|
L
 -2.3%
H
4.1
5.0
|
L
 -42.2%
H
0.7
8.4
|
L
 -69.8%
H
0.7
17.7
|
L
 -83.6%
H
0.7
106.3
|
L
 -98.1%
H
0.7
242.4
|
PharmaCyte Biotech Inc |
|
11.0
|
1.6
|
L
 -5.4%
H
1.5
1.7
|
L
 -11.2%
H
1.5
1.8
|
L
 -3.1%
H
1.5
1.9
|
L
 -8.1%
H
1.5
1.9
|
L
 -19.0%
H
1.4
2.6
|
L
 -24.0%
H
1.4
3.2
|
L
 -97.3%
H
1.4
75
|
L
 -99.0%
H
1.4
392.3
|
Praxis Precision Medicines... |
|
771.8
|
38.3
|
L
 2.7%
H
37.3
38.6
|
L
 -0.6%
H
34.9
39.4
|
L
 -57.8%
H
30.0
91.6
|
L
 -44.7%
H
30.0
91.8
|
L
 -30.6%
H
30.0
91.8
|
L
 -75.8%
H
11.9
200.0
|
L
H
11.9
914.3
|
L
H
11.9
914.3
|
PainReform Ltd |
|
2.4
|
2.8
|
L
 5.3%
H
2.7
3.0
|
L
 -8.8%
H
2.7
3.1
|
L
 -1.1%
H
2.7
5.5
|
L
 -8.2%
H
2.2
16.6
|
L
 -74.7%
H
0.2
16.6
|
L
 -95.8%
H
0.2
158.5
|
L
H
0.2
471
|
L
H
0.2
471
|
Prelude Therapeutics Inc |
|
40.8
|
0.7
|
L
 4.2%
H
0.7
0.8
|
L
H
0.7
0.9
|
L
 -23.7%
H
0.7
1.0
|
L
 -14.0%
H
0.7
1.6
|
L
 -84.4%
H
0.7
6.8
|
L
 -89.7%
H
0.7
8.9
|
L
H
0.7
95.4
|
L
H
0.7
95.4
|
Prime Medicine Inc |
|
234.8
|
1.8
|
L
 4.1%
H
1.7
1.8
|
L
 -25.4%
H
1.7
2.4
|
L
 -37.0%
H
1.7
3.4
|
L
 -37.2%
H
1.7
3.5
|
L
 -75%
H
1.7
8.3
|
L
H
1.7
21.7
|
L
H
1.7
21.7
|
L
H
1.7
21.7
|
Procaps Group S.A |
|
85.7
|
0.8
|
L
H
0.8
0.8
|
L
 -16.5%
H
0.8
1.0
|
L
 -49.3%
H
0.8
1.3
|
L
 -68.5%
H
0.8
3.7
|
L
 -75.8%
H
0.5
3.7
|
L
 -90.9%
H
0.5
9.5
|
L
 -92.2%
H
0.5
12.0
|
L
H
0.5
12.0
|
ProKidney Corp - Ordinary ... |
|
125.4
|
1.0
|
L
 3.2%
H
0.9
1.1
|
L
 -6.7%
H
0.9
1.1
|
L
 -39.1%
H
0.9
1.6
|
L
 -45.6%
H
0.9
2.0
|
L
 -30.5%
H
0.9
4.4
|
L
H
0.9
14.2
|
L
H
0.9
14.2
|
L
H
0.9
14.2
|
ProPhase Labs Inc |
|
11.8
|
0.4
|
L
 -9.3%
H
0.4
0.4
|
L
 -7.1%
H
0.3
0.5
|
L
 21.9%
H
0.3
0.8
|
L
 -40%
H
0.2
0.9
|
L
 -92.3%
H
0.2
7.5
|
L
 -93.9%
H
0.2
15.3
|
L
 -79.9%
H
0.2
16.0
|
L
 -70.9%
H
0.2
16.0
|
ProQR Therapeutics N.V |
|
179.0
|
1.7
|
L
 -2.9%
H
1.7
1.8
|
L
 -11.5%
H
1.7
2.0
|
L
 -30.2%
H
1.7
2.7
|
L
 -40.3%
H
1.7
3.0
|
L
 -34.0%
H
1.6
4.6
|
L
 81.7%
H
0.5
4.6
|
L
 -71.2%
H
0.5
9.5
|
L
 -93.2%
H
0.5
27.6
|
Prothena Corporation plc |
|
739.6
|
13.7
|
L
 -2.4%
H
13.5
14.3
|
L
 -10.0%
H
13.4
15.1
|
L
 -3.0%
H
13.4
16.7
|
L
 7.4%
H
11.7
17.7
|
L
 -47.3%
H
11.7
26.8
|
L
 -58.8%
H
11.7
79.7
|
L
 37.4%
H
7.1
79.8
|
L
 -52.1%
H
6.7
79.8
|
Portage Biotech Inc |
|
6.9
|
4.2
|
L
 4.2%
H
4.0
4.5
|
L
 -5.4%
H
3.9
4.5
|
L
 -10.4%
H
3.9
5
|
L
 40.3%
H
3.2
12.9
|
L
 -61.7%
H
2.1
23.0
|
L
 -97.2%
H
2.1
239.8
|
L
 -98.3%
H
2.1
899.5
|
L
 -98.1%
H
0.2
1310
|
Plus Therapeutics Inc |
|
4.0
|
0.7
|
L
 -9.3%
H
0.6
0.7
|
L
 -56.7%
H
0.6
1.9
|
L
 -45.2%
H
0.2
2.3
|
L
 -46.5%
H
0.2
2.3
|
L
 -60.7%
H
0.2
2.7
|
L
 -95.3%
H
0.2
18
|
L
 -96.2%
H
0.2
81.3
|
L
 -100.0%
H
0.2
163125
|
PTC Therapeutics Inc |
|
4,298.4
|
54.5
|
L
 3.3%
H
53.1
55.7
|
L
 3.6%
H
50.7
55.7
|
L
 5.2%
H
44.3
55.7
|
L
 17.5%
H
41.7
55.7
|
L
 84.4%
H
24
55.7
|
L
 59.3%
H
17.5
59.8
|
L
 24.0%
H
17.5
70.8
|
L
 -25.6%
H
4.0
78.7
|
Protagonist Therapeutics Inc |
|
3,362.6
|
54.8
|
L
 -0.2%
H
53.5
55.4
|
L
 42.8%
H
48.5
60.6
|
L
 41.7%
H
33.7
60.6
|
L
 33.4%
H
33.7
60.6
|
L
 89.0%
H
24.2
60.6
|
L
 112.2%
H
6.9
60.6
|
L
 593.4%
H
5.3
60.6
|
L
H
4.5
60.6
|
Protagenic Therapeutics Inc |
|
1.9
|
0.3
|
L
 -7.1%
H
0.2
0.3
|
L
 -18.8%
H
0.2
0.3
|
L
 -3.7%
H
0.2
0.5
|
L
 -48%
H
0.2
0.8
|
L
 -77.4%
H
0.2
1.9
|
L
 -92%
H
0.2
4.2
|
L
 -96.0%
H
0.2
28
|
L
 -99.7%
H
0.2
154.6
|
Petros Pharmaceuticals Inc |
|
2.0
|
0.1
|
L
H
0.1
0.1
|
L
 -20%
H
0.1
0.1
|
L
 -72.4%
H
0.1
0.2
|
L
 -76.5%
H
0.1
0.7
|
L
 -94.7%
H
0.1
1.7
|
L
 -99.3%
H
0.1
28.8
|
L
H
0.1
59.6
|
L
H
0.1
59.6
|
Pulmatrix Inc |
|
30.9
|
8.5
|
L
 3.6%
H
8.2
8.7
|
L
 18.2%
H
6.4
8.7
|
L
 9.4%
H
6.4
10.4
|
L
 47.1%
H
5.7
10.4
|
L
 403.6%
H
1.6
10.4
|
L
 40.1%
H
1.6
10.4
|
L
 -64.2%
H
1.6
60.8
|
L
 -99.6%
H
1.6
2910
|
PaxMedica Inc |
|
-
|
0
|
L
H
|
L
H
|
L
 -100%
H
0.0
|
L
 -100%
H
0.1
|
L
 -100%
H
1.2
|
L
H
178.2
|
L
H
178.2
|
L
H
178.2
|
Polypid Ltd |
|
30.4
|
3.0
|
L
 1.4%
H
2.8
3.1
|
L
 3.8%
H
2.7
3.2
|
L
 1.0%
H
2.7
3.3
|
L
 14.2%
H
2.4
3.9
|
L
 -45.7%
H
2.4
5.5
|
L
 -97.8%
H
2.4
207
|
L
H
2.4
583.5
|
L
H
2.4
583.5
|
Pyxis Oncology Inc |
|
66.0
|
1.1
|
L
 3.7%
H
1.1
1.1
|
L
 -4.3%
H
1.0
1.2
|
L
 -15.9%
H
1.0
1.4
|
L
 -31.5%
H
1.0
1.8
|
L
 -78.3%
H
1.0
6.2
|
L
 -75.6%
H
1.0
6.9
|
L
H
1.0
19
|
L
H
1.0
19
|
Pharming Group N.V. - ADR |
|
607.1
|
9.0
|
L
 2.4%
H
8.6
9.0
|
L
 11.2%
H
7.7
9.2
|
L
 -2.7%
H
7.7
9.7
|
L
 -0.3%
H
7.7
11.1
|
L
 -22.1%
H
6.7
11.8
|
L
 9.1%
H
6.1
17.8
|
L
H
6.1
22.0
|
L
H
6.1
22.0
|
Purple Biotech Ltd - ADR |
|
7.2
|
2.7
|
L
 1.1%
H
2.7
2.8
|
L
 -2.9%
H
2.6
2.8
|
L
 -11.9%
H
2.6
3.5
|
L
 -26.8%
H
2.6
5.0
|
L
 -81.2%
H
2.4
20.6
|
L
 -94.9%
H
2.4
85.6
|
L
 -94.1%
H
2.4
288
|
L
H
2.4
1390
|
PureTech Health Plc - ADR |
|
418.9
|
17.4
|
L
 2.6%
H
17.4
17.5
|
L
 -2.8%
H
16.8
17.8
|
L
 -8.0%
H
16.8
19.5
|
L
 -14.3%
H
16.8
23.4
|
L
 -31.5%
H
16.8
34
|
L
 -35.3%
H
16.8
38.9
|
L
H
16.8
65.9
|
L
H
16.8
65.9
|
Qualigen Therapeutics Inc |
|
2.3
|
3.1
|
L
 -1.6%
H
3.0
3.1
|
L
 -1.9%
H
3.0
3.1
|
L
 -16.2%
H
3.0
3.8
|
L
 -20.9%
H
3.0
4.7
|
L
 -83.5%
H
0.1
29.4
|
L
 -98.9%
H
0.1
760
|
L
 -99.9%
H
0.1
9875
|
L
H
0.1
687487.5
|
Qilian International Holdi... |
|
933.3
|
9.6
|
L
 -2.0%
H
9.6
10.2
|
L
 -10.5%
H
9.5
11.2
|
L
 -5.5%
H
8.6
11.3
|
L
 11.6%
H
7.7
14.8
|
L
 217.9%
H
2.6
14.8
|
L
 22.3%
H
1.8
14.8
|
L
H
1
110
|
L
H
1
110
|
Quince Therapeutics Inc |
|
63.4
|
1.4
|
L
 2.1%
H
1.4
1.5
|
L
 -4.6%
H
1.3
1.5
|
L
 2.9%
H
1.3
1.6
|
L
 -29.1%
H
1.3
2.1
|
L
 24.1%
H
0.5
2.5
|
L
 -72.1%
H
0.5
6.8
|
L
 -95.7%
H
0.5
122.0
|
L
H
0.5
122.0
|
uniQure N.V. |
|
767.9
|
14.2
|
L
 3.1%
H
13.9
14.7
|
L
 16.1%
H
11.5
14.7
|
L
 0.1%
H
10.0
14.7
|
L
 -7.0%
H
10.0
19
|
L
 174.7%
H
3.7
19
|
L
 -5.8%
H
3.7
28.3
|
L
 -68.1%
H
3.7
71.5
|
L
 -43.8%
H
3.7
82.5
|